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Hepatitis C virus (HCV) and bovine viral diarrhea virus (BVDV) are 
closely related members of the family Flaviviridae and are important human 
and animal pathogens, respectively. In this work, I investigated how these 
viruses interact with and enter both naïve and previously infected cells, 
specifically, the mechanisms of superinfection exclusion, the phenomenon 
by which previous viral infection prevents reinfection of the same cell, and 
the pathways of entry into target cells for these viruses. BVDV-acutely 
infected cells establish two blocks to superinfection, at the levels of virus 
entry and RNA replication. The former is mediated by the BVDV E2 
protein, which was also identified as a transdominant inhibitor of BVDV 
entry in a screen of a random fragment BVDV cDNA library. The inhibitory 
region was further mapped to the E2 ectodomain and the block to entry was 
shown to occur downstream of CD46 receptor expression and BVDV 
binding, suggesting interference with a yet unidentified BVDV entry factor. 
In contrast to BVDV, HCV-infected and replicon-containing cells exhibit a 
post-entry block to superinfection, at one or more steps in viral replication. 
The entry pathways of both BVDV and HCV into target cells were also 
examined and found to be pH-dependent. In addition, these viruses were 
shown to be very acid-resistant, suggesting that they require an activation 
step to trigger pH-dependent entry. The role of the cellular 
receptors/coreceptors, CD81, scavenger receptor class B type 1 (SR-BI), and 
claudin-1 (CLDN1), in mediating HCV entry and their modulation during 
persistent HCV replication were also investigated. This work highlights 
common features shared between BVDV and HCV and provides insight into 
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1.1 Introduction to the family Flaviviridae 
The family Flaviviridae, including important human and animal 
pathogens, is comprised of small enveloped viruses with a single-stranded, 
positive-sense RNA genome (reviewed in 126). This family is currently 
divided into three genera, the classical flaviviruses, the pestiviruses, and the 
hepaciviruses. The life cycle of the Flaviviridae commences with receptor-
mediated endocytosis and low pH-mediated fusion (reviewed in 126) (Fig. 
1.1). Following uncoating, the viral RNA is translated into viral proteins to 
initiate intracellular RNA replication, which takes place entirely in the host 
cell cytoplasm in association with intracellular membranes. Virions are 
thought to assemble in and acquire their envelope by budding into an 
intracellular, most likely endoplasmic reticulum (ER)-derived compartment, 
and exit the cell through the host secretory pathway. Although the three 
genera have similar virion morphology, genome organization and replication 
strategies, more common features especially in terms of translation 
mechanism and sequence homology are shared among the hepaci- and 



















Fig. 1.1 The life cycle of the Flaviviridae. Virions enter the target cell by 
receptor-mediated endocytosis. Following uncoating, the viral genome is 
translated and the polyprotein processed into the individual viral proteins. 
RNA replication occurs in association with intracellular membranes and 
proceeds asymmetrically, favoring replication of positive-sense, genome-
length RNAs. Virions mature within intracellular vesicles and are thought to 
acquire their envelope by budding into these vesicles. Nascent virions are 
transported out of the cell through the host secretory pathway. Adapted from 
(126). 
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1.2 Features of bovine viral diarrhea virus 
Pestiviruses, including bovine viral diarrhea virus (BVDV), border 
disease virus (BDV) and classical swine fever virus (CSFV), cause 
economically important diseases in livestock leading to substantial financial 
losses within the industry each year (reviewed in 126). BVDV infection can 
result in a wide range of clinical symptoms from acute self-limiting disease 
to a sporadic, fatal mucosal disease (MD) (194). Transmission of BVDV in 
utero has a number of detrimental outcomes including fetal death, as well as 
immunotolerance in newborn calves leading to persistent life-long BVDV 
infection, which can progress to MD. Though vaccines are available for 
immunization against BVDV (149), there is a need to improve their safety 
and efficacy, especially to prevent transmission in utero. 
 
BVDV genome organization and encoded proteins 
BVDV harbors an RNA genome of approximately 12.5 kb, which 
contains a large open reading frame (ORF) flanked by both 5’ and 3’ non-
translated regions (NTRs) (Fig. 1.2) (reviewed in 126). Within the 5’NTR is 
an internal ribosome entry site (IRES), which drives cap-independent 
translation of the viral ORF, generating a polyprotein of approximately 4000 
amino acids. The polyprotein is co- and post- translationally processed into 
Fig. 1.2 Genome organization of pestiviruses and hepaciviruses. The
genomes of pestiviruses and the hepaciviruses contain a large open reading
frame (ORF), flanked by 5’ and 3’ nontranslated regions (NTR). The
5’NTR contains an IRES element that directs translation of the ORF
generating a polyprotein. The polyprotein is processed into structural
proteins (blue) and nonstrucutral (NS) proteins (green) by a combination of
viral and host-encoded proteases.




5’ C E1 E2 p7 NS2Npro Erns NS3 4A 4B 5A 5B 3’
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mature proteins by a combination of viral and host proteases to produce the 
viral proteins: Npro, C, Erns, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B.  
Within the virion, BVDV genomic RNA is complexed with multiple 
copies of capsid protein forming the viral nucleocapsid. The nucleocapsid is 
surrounded by a lipid envelope decorated with the three envelope 
glycoproteins, Erns, E1, and E2 (171, 195). Erns is both secreted from infected 
cells and present as disulfide-linked homodimers on the surface of virions 
(55, 116, 172, 202). The Erns glycoprotein exhibits ribonuclease activity, but 
the role of this activity although apparently important for BVDV infection 
and pathogenesis remains ambiguous (78, 177). E2 forms disulfide linked 
homo- and heterodimers with E1 and has been implicated in receptor 
binding as major neutralizing antibodies are directed against the E2 protein 
in an infected host (46, 159, 196). p7 is a small, hydrophobic protein that 
may function as an ion channel. Although p7 is not found within BVDV 
particles, it is essential for production of infectious virus (51, 73, 76). 
The remainder of the polyprotein is composed of non-structural (NS) 
proteins, which, likely partnered with cellular factors, are responsible for 
assembly or function of the viral replication complex. NS2 is an 
autoprotease responsible for cleavage at the NS2/3 junction (111). The 
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efficiency of cleavage between NS2-3 modulates levels of RNA replication 
and differs between BVDV biotypes (described below) (112). In addition, 
uncleaved NS2-3 protein is required for infectious virus production (2). NS3 
contains a serine protease motif at its N-terminus (17, 67) that cleaves 
between NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B (191, 
211, 215). NS4A functions as an NS3 protease cofactor for cleavage 
between NS4B/NS5A and NS5A/NS5B (191, 215). Additionally, NS3 
contains NTPase and helicase sequence motifs, and these enzymatic 
activities have been demonstrated in vitro (67, 71, 75, 190). NS5B is the 
viral RNA-dependent RNA polymerase (RdRp) (113, 222). Autonomous 
BVDV RNA replication in transfected cells does not require viral structural 
proteins (C, Erns, E1, E2), Npro, p7 or NS2 (18, 154, 192). 
 
BVDV entry and cellular entry factors 
 After interaction with one or more cellular receptors, BVDV enters 
the target cell by clathrin-mediated endocytosis in a pH-dependent manner 
(109, 118). CD46, a regulator of complement activation, has been identified 
as a cellular receptor for BVDV (137). CD46 contains four extracellular 
complement control protein (CCP) repeats (CCP1 to 4), an O-glycosylated 
STP region, a transmembrane domain, and a cytosolic tail (127, 128) (Fig. 
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1.3). The extent of glycosylation in the STP region (127) and the length of 
the cytosolic tail (137) is determined by differential splicing of CD46 
transcripts. The viral glycoprotein, which acts as a ligand for CD46, has not 
yet been determined, although it is likely E2 based on inhibition studies 
using CSFV recombinant E2 protein (86) and the observation that E2 
determines the cell culture tropism of BVDV (122, 169). BVDV binding has 
been mapped to CD46 CCP1, the domain most distal from the plasma 
membrane, and this region is necessary for BVDV infection (107). However, 
the requirement for additional BVDV entry factors is likely, given that 
BVDV enters cells by receptor-mediated endocytosis and CD46 is excluded 
from endosomes due to a sorting signal in its C-terminal tail. In addition, 
expression of CD46 cannot render certain cell types permissive for BVDV 
entry despite efficient virus binding (137). Interactions with highly sulfated 
heparin, mediated by the Erns protein, have also been shown to be important 
for entry of cell-culture adapted strains of BVDV (89). The increased 
affinity for heparin is due to a point mutation within the C terminus of Erns 
(90).  There has also been some evidence that low density lipoprotein 
receptor (LDL-R) has a role in BVDV entry (3), although a recent study 
















Fig. 1.3 Structure of CD46. Ovals = complement control protein (CCP) 
repeats. Small green ovals = STP (serine, threonine, proline-rich) motifs. 
Thin lines = O-glycosylation sites. Gray bar = plasma membrane. cyt1, cyt2 




BVDV pathogenesis and isogenic infectious clones 
Cows suffering from fatal MD harbor two BVDV biotypes, 
noncytopathic (ncp) and cytopathic (cp), as described by their respective 
effects on tissue culture cells (140, 146). In the infected animal, cp BVDV 
develops from mutation of the ncp BVDV parental strain and as a result the 
cp and ncp strains are genetically closely related. Further evidence for this 
hypothesis is that experimental superinfection of persistently infected 
animals with a closely related cp virus can result in MD (25, 148). Many of 
the cp BVDV variants that have been isolated contain genome 
rearrangements, point mutations or insertions leading to increased NS2-3 
autoprotease activity (reviewed in 194). In cell culture, this is manifested by 
the accumulation of free NS3 protein and increased RNA replication, both of 
which are associated with cytopathogenicity. Although the mechanism of the 
BVDV-induced cytopathic effect is still unclear, it appears that higher levels 
of RNA replication may activate cellular pathways leading to apoptosis (95).  
ncp BVDV NADLJiv90- and cp BVDV NADL are an isogenic pair of 
infectious viral cDNA clones, the former harboring a cellular insertion, 
Jiv90, upstream of the cleavage site between the NS2/3 proteins, which 
renders this virus cp (143).  Jiv90 is a 90 amino acid domain of Jiv (J-
domain protein interacting with viral protein), which is a cellular chaperone 
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for the NS2-3 autoprotease. Cis or trans over expression of Jiv during 
BVDV infection has been shown to increase cleavage at the NS2/3 site 
(112). Additional cp and ncp pairs with an insertion in NS2 have also been 
characterized including, strain CP7 which contains a smaller insertion of Jiv 
(193), and strain Osloss which has a ubiquitin sequence just upstream of 
NS3 (145).  
 
1.3 Features of hepatitis C virus 
Hepatitis C virus (HCV) is the type member of the Hepacivirus genus, 
which has recently been expanded to include GBV-B (reviewed in 126). 
First identified as the causative agent of non-A, non-B hepatitis in 1989, 
HCV is an important human pathogen establishing a chronic infection in 
approximately 70-80% of cases. Persistent HCV infection is associated with 
the development of severe liver disease, most notably, liver cirrhosis and 
hepatocellular carcinoma (135). A daunting 120 million people worldwide 
are infected with HCV and at present there is no HCV vaccine available. 
Moreover, antiviral therapy has limited efficacy, being successful in only 
about 50% of patients. HCV is currently the primary indication for liver 
transplantation in both the United States and Europe (29) and contributing to 
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public health concerns, extrahepatic disease associated with chronic HCV 
infection affects nearly 40% of patients (138). 
 
HCV genome organization and encoded proteins 
Similar to BVDV, the HCV genome is a single-stranded RNA 
molecule of approximately 9.6 kb, containing a large ORF flanked by 5’ and 
3’ NTRs (reviewed in 126) (Fig. 1.2). Translation of the viral ORF, driven 
by a cap-independent mechanism via an IRES element within the 5’NTR, 
generates a polyprotein of 3011 amino acids that is processed by host and 
viral encoded proteases into structural and nonstructural proteins: C, E1, E2, 
p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B. An additional protein, termed 
ARF or F for alternative reading frame or frameshift protein, respectively, 
resulting from ribosomal frameshifting within the core region, has also been 
described (26). However, a recent study suggests that the ARF/F-encoded 
protein is dispensable for replication and conservation of the ARF coding 
region is due to the presence of a functional RNA element (142). 
The structural proteins, core (C), E1, and E2, form the physical virion. 
The viral nucleocapsid, composed of C protein and genomic RNA, is 
encapsidated in a lipid envelope studded with non-covalently linked 
heterodimers of the E1 and E2 glycoproteins (156). Both E1 and E2 are type 
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I integral membrane proteins and have been shown to accumulate in the ER 
where particles are thought to assemble (156). The E2 glycoprotein likely 
mediates receptor binding of HCV to the host cell, given its ability to bind 
multiple putative HCV receptors (38, 82, 162, 166, 176). The role of E1 is 
less clearly defined, although it has been proposed to contain the putative 
fusion peptide (58). Analogous to the BVDV p7 protein, HCV p7 protein is 
essential for viral infectivity and can form ion channels (73, 160, 167, 174). 
Downstream from p7, NS2 encodes a C-terminal autoprotease, which 
cleaves at the junction between NS2/3 and requires the N-terminal domain 
of NS3 to function (70, 83, 132).  The remainder of the polyprotein encodes 
NS3-NS4A-NS4B-NS5A-NS5B that form the viral replication complex and 
are capable of autonomous HCV RNA replication (131). The catalytic 
activities of NS3, encoding protease, helicase, and RNA-stimulated NTPase 
activities, and NS5B, encoding the RdRp, explained above for BVDV are 
maintained in HCV. The NS4B protein is necessary and sufficient for 
membranous web formation, which has been observed in cells harboring 





Evolution of model systems for HCV research 
HCV research in the laboratory has been hampered by the absence of 
a small animal model and cell culture systems capable of supporting the 
complete viral life cycle (reviewed in 8, 126). The identification of the first 
full-length, infectious clone, H77, a genotype 1a isolate, which is infectious 
in chimpanzees, was a significant advance in the early study of HCV (105, 
216). Soon after, additional HCV genomes derived from various genotypes 
were also constructed (reviewed in 8, 10). Although infectious in vivo, all of 
these HCV genomes exhibited little to no replication in cell culture. This 
obstacle was overcome when it was reported that transfection of a 
subgenomic replicon, expressing the HCV NS3-NS5B coding region and a 
dominant selectable marker, neomycin phosphotransferase (neo), in the 
place of the viral structural proteins, allowed the selection of rare, successful 
HCV RNA replication events (131). It was later determined that the ability 
to replicate efficiently in cultured cells is due to the presence of adaptive 
mutations acquired in the viral genome (reviewed in 8, 10). The use of 
highly permissive cells, such as the Huh-7.5 human hepatoma cell line, 
allowed even more efficient RNA replication in culture (9). Building on 
these advances, full-length replicons were generated that replicated to high 
levels in cell culture. However, cells harboring these genome-length 
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replicons produced little to no infectious virus (23, 88, 165). Nevertheless, 
studies using HCV full-length and subgenomic replicons have established 
much of our current understanding of HCV translation and replication 
events, identified essential HCV-host factor interactions, and provided a 
system to screen possible antiviral agents. In the absence of an authentic 
infectious system, examination of HCV entry was based on retroviral 
pseudoparticles bearing HCV E1 and E2 glycoproteins (HCVpp) (13, 47, 
85), which provided the first insights into putative cellular receptors, as well 
as the pathway of virus entry (see below).  
A breakthrough in the study of HCV was the development of an HCV 
infectious cell culture system (HCVcc) based on the HCV genotype 2a JFH-
1 isolate from a patient in Japan suffering from fulminant hepatitis (101). 
JFH-1 is distinct from previously described genomes in its efficient 
replication in cell culture independent of adaptive mutations (100). 
Moreover, the full-length JFH-1 genome and a chimeric genome expressing 
the JFH-1 replicase in the context of the genotype 2a J6 isolate structural 
proteins (J6/JFH) are capable of producing viral particles in cell culture 
(123, 203, 221). These particles, termed HCV cell culture derived virus 
(HCVcc), are infectious both in vitro (123, 203, 221) and in vivo (123, 203). 
Recently, additional chimeric genomes capable of virus production, 
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harboring the genotype 1a, H77 isolate or the genotype 1b, Con1 isolate, 
have been generated (164). The HCVcc infectious system therefore enables 
study of the complete viral life cycle, including entry and assembly events, 
in the context of cell culture.  
  
HCV entry and cellular entry factors 
HCV entry is a multi-step process requiring specific interactions 
between the E1 and E2 glycoproteins and a number of cellular 
receptors/coreceptors. HCV enters cells by clathrin-mediated endocytosis 
(21). Productive infection requires a low pH compartment (13, 47, 85, 123, 
203, 221) and depends on the presence of cholesterol in the target cell 
membrane (97). Using the HCVpp and HCVcc systems, several cellular 
factors have been implicated in HCV entry, including CD81, SR-BI, 
CLDN1, and highly sulfated glycosoaminoglycans (GAGs) (Fig. 1.4). 
Although the list of candidate receptors is extensive, certain cell lines remain 
nonpermissive for HCV entry despite expression of all of these molecules, 
suggesting that they act in conjunction with an additional, as yet unidentified 
entry factor(s). It is also possible, however, that these cell lines are resistant 
to HCV entry due to a host restriction factor that acts downstream from the 



















Fig. 1.4 Cellular factors for HCV entry. HCV cell entry is thought to 
require interaction of the HCV glycoproteins E1 and E2 with cellular entry 
factors that likely include CD81, scavenger receptor class B type I (SR-BI), 










The tetraspanin CD81, first demonstrated to be an E2 binding protein, 
has now been clearly established as an essential HCV entry factor (15, 41, 
166, 220). CD81 has short N- and C-terminal cytoplasmic tails, four 
transmembrane domains, and small and large extracellular loops (120, 121). 
The CD81 large extracellular loop (LEL) confers interaction with E2 (57, 
166) and is a critical determinant of HCV entry (59, 220). CD81 LEL also 
contains two disulfide bonds important for the interaction with E2 (82, 102, 
162). HCVcc and HCVpp entry is inhibited by anti-CD81 antibodies (13, 85, 
123, 203, 221), RNAi targeting of CD81 (220), and protein fragments of 
CD81 (59, 123). In addition, the CD81-deficient, human hepatoma cell line 
HepG2 is HCV resistant, but becomes competent for HCV entry upon 
transduction with CD81 (15, 123, 220). CD81 is expressed on most cell 
types except platelets and red blood cells and is therefore unlikely to 
determine HCV’s liver tropism. Consistent with this idea, recent studies 
suggest that the role of CD81 in HCV entry is downstream from primary 
attachment (41, 53, 106).  
SR-BI also binds HCV E2 and is expressed highly on hepatocytes, 
where it mediates the selective uptake of cholesterol and cholesterol esters 
from high-density lipoprotein (HDL) particles (176). Although to a lesser 
extent than for CD81, HCV infection is inhibited by SR-BI antibodies and 
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RNAi targeting (15, 117). As further evidence supporting a role for SR-BI in 
productive HCV entry, the presence of HDL enhances HCVpp infectivity in 
an SR-BI dependent manner (14, 144, 155, 200) and infection is inhibited by 
the SR-BI ligand, oxidized LDL (201). It is also possible that SR-BII, a 
splice variant differing from SR-BI only in its C-terminal tail (205), may 
also have a role in HCV entry.  
CLDN1, an integral membrane protein and component of the tight 
junction, was recently identified as a required HCV entry factor by 
expression cloning of cDNAs derived from the highly permissive Huh-7.5 
cell line (53). 293T cells express CD81, as well as SR-BI, and become fully 
permissive for HCVpp and HCVcc infection upon CLDN1 transduction. 
CLDN1 is highly expressed in the liver and has four transmembrane 
domains and two extracellular loops (reviewed in 199). HCV entry requires 
residues within extracellular loop 1 and is unaffected by disruption of 
intracellular protein-protein interaction motifs in the CLDN1 C-terminal tail. 
HCVpp infection of 293T cells expressing CLDN1 remains CD81-
dependent, further supporting the model that no one factor is sufficient for 
HCV entry.  
The presence of highly sulfated glycosoaminoglycans (GAGs), such 
as heparin, on the target cell membrane has also been shown to contribute to 
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HCV entry (11, 106). HCV infection is inhibited in the presence of 
increasing amounts of soluble heparin, as well as by treatment of cells with 
heparinase I or III prior to infection (106). Although not certain, GAGs are 
thought to increase the efficiency of HCV entry possibly by facilitating 
primary attachment to the target cell. 
Other candidate receptors include the dendritic cell- and liver-specific 
intracellular adhesion molecule 3-grabbing nonintegrins (DC-SIGN and L-
SIGN) and LDL-R. DC- and L-SIGN do not appear to mediate productive 
HCV infection, but can bind HCVpp and transmit the virus to permissive 
cells in co-culture (40, 133). A similar mechanism may occur in vivo, where 
DC- and L-SIGN could pick up viral particles and transfer them onto 
hepatocytes, although this hypothesis has yet to be validated. LDL-R can 
bind plasma derived-HCV and appears to allow cellular uptake of HCV 
RNA (3, 150, 214). It is unclear, however, whether LDL-R can mediate 
productive HCV uptake, given that HCVpp do not require LDL-R in the 
target cell membrane (13, 85).  
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1.4 Objectives  
During my graduate studies I have explored two complementary 
subjects – the pathways of BVDV and HCV entry and the phenomenon of 
superinfection exclusion. My initial objective was to establish a screen for 
BVDV genome fragments that could act as transdominant inhibitors of 
BVDV replication. This work led to the identification of the E2 glycoprotein 
as a BVDV inhibitor and further study demonstrated that E2 expression 
acted to prevent BVDV entry into MDBK cells. We connected these 
observations with previous studies of BVDV superinfection exclusion and 
hypothesized that the E2 protein was mediating a superinfection block at the 
level of BVDV entry. I also sought to determine if superinfection exclusion 
was established in HCV-infected and replicon-containing cells. Like BVDV, 
HCV superinfection was inhibited, but the main mechanism of exclusion 
was downstream from virus entry. With the advent of the HCV infectious 
system, I attempted to further define the HCV entry pathway using cell-
culture derived virus. I also pursued similar studies with BVDV, finding that 
both HCV and BVDV require an activation step to trigger pH-dependent 
entry. My hope is that this body of work will provide insights into the basic 
virology of HCV and BVDV and the control and effective treatment of these 












Chapter 2. Materials and methods 
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Cells 
Huh-7.5 (24) and 293T cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS) and 100 nM nonessential amino acids. Gamma-
irradiated FBS was used for 293T cells when packaging the BVDV cDNA 
library. Huh-7.5 cells harboring HCV replicons were maintained DMEM 
with 10% FBS, 100 nM nonessential amino acids, and 0.5 mg/ml G418. 
Vero cells were grown in DMEM with 10% FBS. MDBK cells were 
maintained in DMEM with 10% heat-inactivated horse serum. CHO cells 
were maintained in DMEM/F-12 with 10% FBS. BHK-J cells were 
maintained in minimal essential medium (MEM) with 7.5% FBS. Media and 
reagents for cell culture were purchased from Gibco-BRL, Life 
Technologies Ltd.  
 
Chemicals 
Bafilomycin A1 (stock solution is 50 µM in DMSO), concanamycin A  
(stock solution is 25 µM in ethanol), and CA-074 (stock solution is 10 mM 
in DMSO) were purchased from Sigma (St. Louis). FYdmk (Z-Phe-Tyr-
(tBu)-diazomethylketone) (stock solution is 10mM in DMSO) was 
purchased from Calbiochem (San Diego). BILN 2061 (114) and 2’-C-
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methyladenosine (31) were resuspended at a concentration of 10 mM in 
DMSO. 
 
BVDV RNA transcription, transfection, and virus stocks 
For in vitro transcription, pBAC/NADL, pACNR/NADLJiv90-, and 
pACNR/NADLJiv90-/5’ubi-luc plasmids were linearized by digestion with 
SbfI (Promega) and blunt-ended using a combination of T4 DNA 
polymerase and Klenow. After phenol extraction and precipitation with 
ethanol, 1-2  µg of template was transcribed using the T7 Megascript kit 
(Ambion), according to the manufacturers instructions. RNA was purified 
using an RNeasy Mini column (Qiagen) or by precipitation with 1/2 vol of 
7.5 M NH4Ac and analyzed by 1% agarose gel electrophoresis.  
To generate stocks of BVDV strains NADL, NADLJiv90-, and 
NADLJiv90-luc, MDBK cells were trypsinized, harvested by centrifugation 
(500 x g, 5 min), washed twice and resuspended in ice-cold phosphate 
buffered saline (PBS) (Accugene) at 2.0 x 107 cells/ml. 5-10 µg of NADL, 
NADLJiv90-, or NADLJiv90-luc RNA was mixed with 0.4 ml of cells in a 
0.2-cm gap cuvette and immediately pulsed using a BTX 
ElectroSquarePorator (900 V, 5 pulses, 99 µs/pulse) (143). Electroporated 
cells were allowed to recover for 10 min at room temperature prior to the 
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addition of complete media and then plated in a 100-mm diameter cell 
culture dish. Supernatants were harvested after 24-48 h. Virus stocks were 
aliquoted and stored at –80 oC until use. 
 
HCV replicons and cells harboring HCV replicons  
pSGR-JFH1 has been described (100) and cells harboring this 
replicon (see below) will be referred to as JFH-SGneo cells. Con1-FLneo (I) 
and Con1-SGneo (I) are full-length and subgenomic genotype 1b (Con1 
isolate) constructs, respectively, containing an S2204I mutation in NS5A 
that have been described (22, 24), and will be referred to here as Con1-
FLneo and Con1-SGneo. H-FLneo and H-SGneo, are HCV genotype 1a 
(H77 isolate) full-length and subgenomic replicons, respectively, that 
contain the adaptive mutations P1496L, V1880A, A1940V, C1968R 
allowing for persistent replication of the H77 genome in Huh-7.5 cells. 
These adaptive mutations were identified after transfection of Huh-7.5 cells 
with H-SGneo (L) (23) and selection with G418 and subsequently 
reengineered into the H-SGneo (L) or H-FLneo (L) backbone (J. Fan and C. 
M. Rice, unpublished data).  
J6/JFH-FLneo, JFH-SGneo, Con1-FLneo, Con1-SGneo, H-FLneo, 
and H-SGneo replicon cell populations were generated by electroporation of 
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Huh-7.5 cells with 1 µg of the corresponding in vitro transcribed RNA [see 
below and (123)]. Replicon-containing cells were selected and maintained 
with 0.5 mg/ml G418.  
 
HCV RNA transcription, transfection, and virus stocks 
For in vitro transcription, pFL-J6/JFH, pFL-J6/JFH-5’C19Rluc2AUbi, 
pJ6/JFH-FLneo, and pSGR-JFH1 plasmids were linearized by digestion with 
XbaI. pCon1-FLneo and pCon1-SGneo were linearized with ScaI and pH-
FLneo and pH-SGneo plasmids were linearized with HpaI. 1-2  µg of 
linearized template DNA was transcribed using the T7 Megascript kit 
(Ambion) according to the manufacturer’s instructions, followed by 
purification using the RNeasy Mini Kit (Qiagen) with on column DNase 
treatment. The quality of the RNA was assessed using 1% agarose gel 
electrophoresis. 
To generate stocks of J6/JFH and FL-J6/JFH-5’C19Rluc2AUbi 
(HCVcc-Rluc), Huh-7.5 cells were trypsinized, harvested by centrifugation 
(500 x g, 5 min), washed twice and resuspended in ice-cold PBS (Accugene) 
at 1.5 x 107 cells/ml. 1-2 µg of J6/JFH or FL-J6/JFH-5’C19Rluc2AUbi RNA 
was mixed with 0.4 ml of cells in a 0.2-cm gap cuvette and immediately 
pulsed using a BTX ElectroSquarePorator (820 V, 5 pulses, 99 µs/pulse) 
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(123). Electroporated cells were allowed to recover for 10 min at room 
temperature prior to the addition of complete media and plated in a 150-mm 
diameter cell culture dish. After 72 h, electroporated cells were trypsinized 
and replated in complete media. Virus containing supernatant from replated 
cells was then harvested after an additional 3-4 d post electroporation. Virus 
stocks were aliquoted and stored at –80 oC until use.  
For HCVcc-Rluc infections, cells were incubated with undiluted virus 
[multiplicity of infection (MOI) ~0.01, 200  µl/well for 24-well plate] for 1-
3 h at 37 oC or 2 h at 4 oC where indicated. Cells were washed twice with 
media, incubated for the indicated time (usually 24 h) at 37 oC, and 
harvested for luciferase assays. All infections of G418-resistant cell 
populations were performed in the absence of G418. For infections including 
2’-C-methyladenosine, drug (1.35 µM) was added to the media at the time of 
infection and maintained during the 24 h incubation. At each time point, 
cells (untreated or treated with inhibitor) were harvested from triplicate 
wells for luciferase assays, and cells from duplicate wells were analyzed for 
HCV RNA levels.  
 
 28 
Generation of HCVpp stocks and HCVpp infection 
HCV pseudoparticles expressing firefly luciferase (HCVpp-Luc), and 
VSVGpp-Luc and no envelope control viruses were generated in 293T cells 
as described (85) by co-transfection of an envelope-deficient HIV genome 
(pNL4-3.Luc.R-.E-) and a plasmid expressing HCV H77 (56) or J6 (141) 
viral glycoproteins E1 and E2, vesicular stomatitis virus G protein (VSV G), 
or an empty vector (no envelope). For infection, Huh-7.5 cells, seeded in a 
96-well plate (1 x 104/well), were incubated with HCVpp, VSVGpp, or no 
envelope pp in the presence of polybrene (4 µg/ml) for 6-12 h at 37 oC.  
Luciferase activity was determined at 72 h postinfection (h.p.i.). HCVpp 
RLU values were normalized to VSVGpp values for each sample. Infections 
of G418-resistant cell populations were performed in the absence of G418. 
To generate HCVpp expressing a GFP reporter (HCVpp-GFP) and control 
VSVGpp-GFP, 293T cells were co-transfected as above with the CSGW 
HIV provirus encoding only GFP (44), a plasmid expressing the HIV gag-
pol genes, and either an HCV H77 E1 and E2 or the VSV G-protein 
expression plasmid. Infections were performed as above and cells were 
harvested for flow cytometry at 48 h.p.i. (see below). 
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Vesicular stomatitis virus, Sindbis virus, and herpes simplex virus-1 stocks   
Vesicular stomatitis virus (VSV), San Juan strain, stocks were 
generated by infection (MOI 0.01) of BHK-J cells (125), and collection of 
cell supernatants at approximately 17 h.p.i. For plaque assays, cells were 
seeded in 6-well plates and infected in duplicate with dilutions of virus. 
Cells were overlaid with 0.6% SeaKem LE agarose (Cambrex) in MEM 
containing 2.5% FBS, and incubated for 16 h when they were fixed with 7% 
formaldehyde and stained with crystal violet (1.25% crystal violet in 20% 
ethanol). Plaques were enumerated and titers were expressed as plaque 
forming units/ml (pfu/ml).  
Stocks of Toto1101/Luc (20), a Sindbis virus (SIN) expressing firefly 
luciferase, were generated by electroporation of in vitro transcribed RNA 
into BHK-J cells. For in vitro transcription, pToto1101/Luc was linearized 
with XhoI and transcribed using the SP6 Megascript Kit (Ambion) in the 
presence of cap analog.  
Stocks of KOSdluxoriL (188), herpes simplex virus-1 (HSV-1) 
expressing firefly luciferase, were generated by infection of Vero cells at an 
MOI of 0.01. After infected cells had detached from the plate (~48-72 
h.p.i.), culture media (containing detached cells) was harvested and clarified 
by centrifugation (5 k rpm, 15 min). The supernatant was transferred to a 
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new bottle and centrifuged at 9 k rpm for 1 h (A). The pellet from the first 
centrifugation was resuspended in medium, freeze-thawed 1x, and sonicated 
2x (30 s/cycle) (B). B was then used to resuspend the pellet from A. The 
solution was sonicated (45 s) and centrifuged at 1.5 k rpm for 10 min. The 
supernatant was aliquoted and stored at –80 oC until use.  
 
BVDV plaque and focus forming assays 
MDBK cells, seeded in 6-well dishes, were infected with 10-fold 
dilutions of virus for 1 h at 37 oC. The cells were overlaid with 1% SeaKem 
LE agarose in MEM containing 5% horse serum and penicillin/streptomycin 
and incubated at 37 oC for 3 d.  Monolayers were fixed with 7% 
formaldehyde and the agarose overlays were removed. For plaque assays, 
the monolayer was stained with crystal violet as previously described (143). 
For focus-forming assays, the monolayer was permeabilized with 0.25% 
Triton X-100 in PBS and stained with anti-BVDV polyclonal antibody B224 
(diluted 1:500 in PBS/0.25% Triton X-100) (kindly provided by Kenny 
Brock, Auburn University) and peroxidase-conjugated anti-bovine IgG 
(diluted 1:1000 in PBS/0.25% Triton X-100) (Sigma) (168). BVDV positive 
foci were visualized using the DAB peroxidase substrate (Vector 
Laboratories).  
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Construction of random BVDV cDNA library 
The random BVDV cDNA library was generated by Matthew Evans 
(Rockefeller University). To prepare BVDV random cDNA fragments, 10-
20 µg of pBAC/NADL in 1 ml TM buffer (50 mM Tris pH 8, 15 mM 
MgCl2) was nebulized in a chamber (Invitrogen) by application of 40 psi N2 
gas for 3 min.  The fragments were cleaned using a QIAquick PCR 
purification kit (Qiagen) and eluted in 50 µl TM buffer. To create blunt 
ends, the fragments were incubated with 9 U T4 DNA polymerase and 10 U 
Klenow in the presence of dNTPs for 15 min at room temperature. The 
enzymes were heat inactivated at 75 oC for 10 min. The fragments were then 
phosphorylated using 10 U T4 polynucleotide kinase for 10 min at 37 oC. 
The fragments were run on a 0.7% agarose gel and size fractionated into two 
groups containing 100-500 bp or 500-2000 bp fragments. Each group of 
fragments was gel purification using the Qiaquick gel purification kit 
(Qiagen).  
pBabeHAZSrfcI is an Moloney murine leukemia virus (MLV) 
expression vector which is derived from pBabeHAZ (63) and modified to 
contain a unique SrfI restriction site for cloning blunt-ended inserts. Inserts 
are expressed from a simian virus 40 (SV40) promoter, as fusion proteins 
with an influenza hemagglutinin (HA) epitope tag (YPYDVPDYA) at the N 
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terminus and a zeocin resistance protein (Zeo) at the C terminus. In this 
vector, Zeo is out of frame with the start site of the HA tag and is not 
expressed unless there is a stop codon-free insert in the cloning site.  
To prepare the vector for insertion of the BVDV fragments, 1  µg 
pBabeHAZSrfcI was digested to completion with SrfI and gel purified to 
remove any contaminating uncut vector. Linearized vector was eluted in 100 
µl shrimp alkaline phosphatase (SAP) buffer and phosphatased by two 
rounds of treatment with 10 U SAP. For library construction, 20 ng SrfI-
digested pBabeHAZSrfcI vector was ligated with 60 ng BVDV cDNA 
fragments in a total volume of 30 µl. Ligation products were purified using 
the Qiaquick PCR purification kit and eluted in 10 µl H2O. 5 µl of the 
purified ligation was added to 60 µl DH10B ElectroMAX cells (Gibco BRL) 
and divided equally into two cuvettes. Cells were electroporated using a 
BioRad Gene Pulser 2 and plated on Luria Bertani (LB) agar plates 
supplemented with 100 µg/ml ampicillin (Amp). Colonies were scraped into 
LB broth containing Amp and grown for 5 h at 37 oC.  Plasmid DNA was 





Packaging and screening of the random BVDV library 
For packaging of the BVDV library, 293T cells, grown in gamma-
irradiated serum to eliminate contaminating BVDV, were seeded in 100-mm 
plates (2 x 106 cells/plate) and incubated overnight. 1.5 µg of BVDV library 
in pBabeHAZSrfcI was mixed with 1 µg MLV-gagpol and 1 µg VSV G 
envelope expression plasmids (63) in a total of 15 µl TE (10 mM Tris, 1 mM 
EDTA). The mixture was added to a tube containing 18 µl Fugene-6 
(Roche) in 200 µl OptiMEM (Gibco). Complexes were allowed to form for 
15 min at room temperature and then added to 293T cells in fresh medium. 
At 48 h post transfection, supernatants were harvested and filtered through a 
0.45-µm syringe filter. For transduction, media from MDBK cells, seeded in 
a 6-well plate (5x105/well), was replaced with the retrovirus containing 
supernatant, and the cells were spun in a centrifuge (1150 x g) for 30 min at 
room temperature. The plates were transferred to a 37 oC incubator for an 
additional 1.5 h, after which the inoculum was removed and culture media 
was added.  At 48 h post transduction, selective media containing 400 µg/ml 
zeocin was added to each well. Cells were maintained in selective media for 
the duration of the experiments. A control cell population was also created 
by transduction with pBabeHAZ vector (63), where HA and Zeo are in 
frame, followed by zeocin selection. Zeo resistant cells expressing the 
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BVDV library or the empty vector, pBabeHAZ, were expanded and infected 
with BVDV NADL at an MOI of 5. Colonies that developed after infection 
were expanded and reinfected with NADL. Colonies that survived secondary 
infection were further analyzed.  
 
Analysis of resistant MDBK clones 
The genomic DNA from 2.5x106 cells of each resistant clone was 
harvested using the DNeasy Tissue Kit (Qiagen), based on the 
manufacturer’s protocol, and eluted in 200 µl elution buffer. 10 µl of the 
isolated genomic DNA was mixed with the primers 5’-gcttatccatatgatgtt 
ccagatt-3’ and 5’-gcaccggaacggcactggtcaactt-3’. The viral insert was 
amplified with the Expand High Fidelity PCR system (Roche) using 10 
cycles of 94 oC for 15 s, 60 oC for 30 s, 72 oC for 1.5 min and 20 cycles of 94 
oC for 15 s, 60 oC for 30 s, and 72 oC for 1 min (adding 5 s/cycle).  PCR 
products were gel purified and sequenced. To test if the library inserts could 
provide resistance to naïve cells, the PCR products were cloned into 
pBabeHAZSrfcI using EcoRI and NotI restriction sites. The pBabeHAZSrfcI 





Construction of pLenti6-EGFP, pLenti6-E1*E2p7*, pLenti6-Sig-E2, and 
pLenti6-Sig-E2*  
 
 pLenti6-EGFP is a derivative of pLenti6/GW-V5/LacZ (Invitrogen). 
The EGFP sequence was amplified from pEGFP (Invitrogen) using the 
EGFP-specific primers, 5’-cgggatccaccaccatggggcgcgccggcggaagcggcgg 
aagcatggtgagcaagggcgaggagctgttcac-3’ and 5’-ggctcgagttacttgtacagctcgtc 
catgccgagagtgatc-3’, which added BamHI and XhoI restriction sites, to the 5’ 
and 3’ ends of the EGFP sequence, respectively. The BamHI-EGFP-XhoI 
cassette was cloned into pLenti6/GW-V5/LacZ, which had been digested 
with BamHI and XhoI. To generate pLenti6-E1*E2p7*, nucleotides 2312-
3598 from the BVDV NADL genome were PCR amplified. The forward 
primer added a BamHI restriction site, a Kozack consensus sequence, and an 
ATG nucleotide sequence (5’-ggggatccgccaccatggtgaagttagtgttgagggcac-3’). 
The reverse primer added a stop codon followed by a XhoI restriction site 
(5’-ggggctcgagttatgatccatactgaatccctaa-3’). The BamHI- E1*E2p7*-XhoI 
cassette was inserted into the pLenti6 backbone that had been digested with 
BamHI and XhoI. To generate pLenti6-Sig-E2, the full-length E2 sequence 
(nucleotides 2462-3583) was amplified using the forward primer 5’-cgggatc 
cgccaccatgaagactatcattgctttgagctacattttctgtctggttctcg-3’ that added a BamHI 
restriction site, a Kozack consensus sequence and ATG, followed by the HA 
signal sequence (MKTIIALSYIFCLVLG), and a short linker region 
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containing unique NheI and AscI restriction sites. The reverse primer, 5’- 
ctcgagttaccctaaggcctt-3’, added a stop codon and XhoI restriction site. The 
BamHI-Sig-E2-XhoI cassette was inserted into the pLenti6 backbone that 
had been digested with BamHI and XhoI. For pLenti6-Sig-E2*, nucleotides 
3148-3490 were PCR amplified using 5’-gaacgagactggttacaggcta-3’ and 5’-
ggctcgagttaggact cagcgaagtaatcccg-3’. The reverse primer added a stop 
codon and XhoI restriction site. The PCR product was digested with BsrGI 
and XhoI and cloned into pLenti6-Sig-E2 that had been digested with BsrGI 
and XhoI.  
 For packaging, 1.5 µg lentiviral vector was packaged by cotransfection 
of 293T cells with 1 µg HIV-gagpol and 1 µg VSV G expression constructs 
(Invitrogen) using Fugene-6. MDBK cells were transduced as described 
above for the BVDV library. Transduced MDBK cells were selected with 
blasticidin (4 µg/ml) for 3 d, and infected with NADLJiv90-luc.  
 
BVDV Binding Assay 
MDBK-E1*E2p7* and pBabe cells, seeded in 12-well plates (2.5 x 
105/well), were cooled on ice for 5 min and triplicate wells were infected 
with BVDV NADLJiv90- (MOI 10) for 1 h at 4 oC. Cell monolayers were 
washed 7x with cold culture media, freeze-thawed 3x, and mixed with 450 
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µl TRIzol to extract RNA for real-time quantitative RT-PCR (qRT-PCR). 
BVDV RNA levels were quantified by qRT-PCR (see below) and the 
average amount of BVDV bound to MDBK-pBabe cells over three 
independent experiments was set at 100%.  
For antibody blocking experiments, cells were preincubated with 
hybridoma supernatant from a mixture of monoclonal antibodies (MAb) 
(BVD/CA 17, 26, and 27, kindly provided by Till Rümenapf, Justus-Liebig 
University) for 2 h at 37 oC. Cells were chilled on ice and infected in the 
presence of antibody with BVDV NADLJiv90- at 4 oC as above. After 
infection, monolayers were washed and RNA extracted using the RNeasy 




To detect the BVDV E2 protein in MDBK cells, cells were lysed in 
SDS lysis buffer (0.5% SDS, 50 mM Tris-Cl, pH 7.5, 1mM EDTA). Proteins 
were separated by 8% SDS-PAGE, transferred to a nitrocellulose membrane, 
and detected using α-E2 MAb 214 (Veterinary Laboratories Agency, 
Weybridge, United Kingdom) and a horseradish peroxidase (HRP)-
conjugated α-mouse secondary antibody (Sigma). Detection was performed 
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with the SuperSignal West Femto Maximum Sensitivity Substrate (Pierce), 
according to the manufacturer’s instructions.  
To detect CD46 protein in MDBK cells, cells were lysed as above in 
SDS lysis buffer. Proteins were separated by 10% SDS-PAGE, transferred to 
a nitrocellulose membrane, and detected using CD46 polyclonal antiserum 
(diluted 1:200 in Tris buffered saline with 10% horse serum, kindly provided 
by Till Rümenapf, Justus-Liebig University) and horseradish peroxidase 
(HRP)-conjugated α-rabbit secondary antibody (Sigma). Detection was 
performed with the SuperSignal West Pico chemiluminescent substrate 
(Pierce). 
To detect CD81 from Huh-7.5 cell lysates, cells were lysed in SDS 
loading buffer (2% SDS, 100 mM Tris-Cl pH 6.8, 20% glycerol). Proteins 
were separated by 12% SDS-PAGE under nonreducing conditions, 
transferred to a nitrocellulose membrane, and detected using α-CD81 MAb 
JS-81 (BD Pharmingen), followed by HRP-conjugated α-mouse secondary 
antibody (Pierce). β-actin was detected with MAb AC-15 (Sigma) and an α-
mouse secondary as above. Detection was performed with the SuperSignal 
West Pico chemiluminescent substrate (Pierce). 
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Immunostaining and flow cytometry 
For live cell surface staining of CD46, cells were detached with PBS-
0.5 mM EDTA and resuspended in 5% goat serum, 0.1% sodium azide in 
DPBS. Cells were incubated with primary antibody, α-CD46 (kindly 
provided by Till Rümenapf, Justus-Liebig University) diluted in 0.5% BSA, 
0.1% sodium azide (SB), washed with SB, then incubated with Alexa Fluor 
488 or 633 goat α-mouse IgG secondary antibody (Molecular Probes, 
Eugene, OR). Cells were washed with SB, fixed with 2% paraformaldehyde, 
and analyzed by flow cytometry on a FACSCalibur (Becton Dickinson), 
counting 104 cells. 
For live cell surface staining of CD81, cells were detached by a brief 
treatment with trypsin and resuspended in 3% FBS-0.05% sodium azide in 
PBS (WB1). Cells were incubated with α-CD81 1.3.3.22 (Santa Cruz 
Biotechnology, Santa Cruz, CA) or purified mouse IgG1 (BD Pharmingen, 
Franklin Lakes, NJ) primary antibodies, washed with WB1, then incubated 
with Alexa Fluor 488 goat α-mouse IgG secondary antibody (Molecular 
Probes, Carlsbad, CA). Alternatively, cells were incubated with 
phycoerythrin-conjugated CD81 antibody (MAb JS-81, BD Pharmingen). 
Cells were washed with WB1, fixed in 0.5% paraformaldehyde, and 
analyzed by flow cytometry as above. For total cell staining, cells were 
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detached, fixed in 0.5% paraformaldehyde, and permeabilized with 0.5% 
FBS-0.1% saponin in PBS (WB2). Fixed cells were then incubated with 
CD81 or isotype control primary antibody, followed by Alexa Fluor 488 
goat α-mouse IgG secondary antibody, and analyzed by flow cytometry.  
For CD81/NS5A co-staining, live cells were detached and stained 
with phycoerythrin-conjugated CD81 antibody (MAb JS-81, BD 
Pharmingen) as described above, fixed with 0.5% paraformaldehyde, 
permeabilized with WB2, and stained for NS5A, using α-NS5A primary 
antibody (MAb 9E10) (123), followed by Alexa Fluor 647 goat α-mouse 




For Renilla (HCVcc-Rluc) and firefly luciferase assays (BVDV 
NADLJiv90-luc, KOSdluxoriL, Toto1101/Luc, HCVpp-Luc, VSVGpp-
Luc), cells were washed 1x with DPBS and lysed with Renilla or Cell 
Culture lysis buffer (Promega), respectively (100 µl/well for 24-well plate, 
50 µl/well for 96-well plate). Lysates were harvested by scraping and mixed 
with 50-100 µl Luciferase Assay Substrate (Promega), as suggested by the 
manufacturer. Luciferase activity was measured using a Lumat LB9507 or a 
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Centro LB960 luminometer (Berthold Technologies, Bad Wildbad, 
Germany).  
For HCVcc-Rluc infections in the HCV superinfection exclusion 
study, relative luciferase units (RLU) values were normalized for the number 
of viable cells in each sample by quantifying total cellular ATP levels using 
the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to 
the manufacturer’s instructions. The normalization step was performed to 
control for differences in cell size or viability that might exist among the 
various cell populations used in the HCV superinfection exclusion study.  
 
Real-time quantitative reverse transcription PCR (qRT-PCR) 
For BVDV qRT-PCR, total RNA was extracted from cells using 
either TRIzol reagent (Invitrogen) or the RNeasy Mini Kit (Qiagen). RNA 
was mixed with primers and probe specific for the BVDV 5’NTR as well as 
for bovine β-actin to normalize total RNA levels. BVDV-specific RNA and 
bovine β-actin RNA were amplified using the Platinum Quantitative RT-
PCR ThermoScript One-Step System (Invitrogen) and detected using the 
ABI Prism 7700 sequence detection system (PE Applied Biosystems, Foster 
City, Calif.). BVDV and bovine β-actin cDNAs were generated by reverse 
transcription at 60 oC for 30 min, followed by inactivation of the RT at 95 oC 
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for 10 min. cDNAs were then amplified with 40 cycles of 95 oC for 15 s and 
60 oC for 1 min. The BVDV forward and reverse primers are 5’-ggt 
gactgcaggtcgggtag-3’ and 5’-ggtaaaatagtggccctggctt-3’, respectively. The 
probe sequence is 5’-6FAM-cagaggacctgtgagcgggatctacct-TAMRA-3’ (Eli 
Lilly and Co.). The forward and reverse primers for bovine β-actin are 5’-
atgtggatcagcaagcaggagta-3’ and 5’-aagcatttgcggtggacaa-3’ respectively. The 
probe sequence is 5’-VIC-cgagtctggcccctc-MGBNFQ-3’ (Applied 
Biosystems). BVDV RNA levels were normalized to levels of bovine β-
actin RNA.  
To amplify CD81 RNA, total RNA was harvested using the RNeasy 
Mini Kit (Qiagen). 50-150 ng of total cellular RNA was mixed with primers 
and probe specific for CD81 or glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) RNA. The CD81-specific primers and FAM-labeled probe were 
purchased from Applied Biosystems using a TaqMan inventoried gene 
expression assay for CD81 (Assay ID: Hs00174717_m1). GAPDH-specific 
primers and VIC-labeled probe were purchased from Applied Biosystems 
(Catalog # 4326317E). RNAs were amplified using the Platinum 
Quantitative reverse-transcription PCR ThermoScript One-Step System 
(Invitrogen) and detected with the ABI Prism 7700 sequence detection 
system (PE Applied Biosystems, Foster City, Calif.). cDNAs were generated 
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by reverse transcription at 50 oC for 30 min, followed by inactivation of the 
reverse transcriptase at 95 oC for 5 min. cDNAs were amplified with 40 
cycles of 95 oC for 15 s and 60 oC for 1 min. CD81 RNA levels were 
normalized to levels of GAPDH RNA.  
HCV RNA was amplified from 50 ng of total RNA using the 3’NTR 
MultiCode RT-qPCR System (EraGen) and detected as above with the ABI 
Prism 7700. cDNA was generated by reverse transcription at 45-60 oC, for 
15 min, 1 min per degree, and amplified with 40 cycles of 95 oC for 20 s, 60 
oC for 30 s, and 72 oC for 30 s. The sequence of the forward primer, labeled 
with 5’ 6FAM-isoC (2’-deoxy-5-methyl-isocytidine), was 5’-
ggctccatcttagccctagtc-3’ and the sequence of the reverse primer was 5’-
agtatcggcactctctctgcagt-3’ (Biosearch Technologies, Inc.). 
 
Bafilomycin A1, concanamycin A, and NH4Cl inhibitor experiments 
Huh-7.5 cells were seeded in a 24-well plate (5 x 104/well). Cells were 
pretreated with drug (bafilomycin A1, concanamycin A, or NH4Cl) diluted 
in medium for 1 h at 37 oC. The cells were then chilled on ice for 5 min and 
infected with HCV (FL-J6/JFH-5’C19Rluc2AUbi), SIN (Toto1101/Luc), or 
HSV-1 (KOSdluxoriL) for 2 h at 4 o C. Once added to a particular well, the 
drug was present for the duration of the experiment. After binding, the cells 
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were washed twice with cold DPBS and then warm media with or without 
drug was added. For postinfection drug addition, the drug was added directly 
to the media in the well. SIN and HSV-1 samples were harvested at 12 h.p.i. 
HCV samples were harvested at 24 h.p.i.  
 
Low pH treatment 
HCV or SIN stocks, in media containing 20 mM HEPES,  (4-1-
piperazine ethanesulfonic acid) were diluted 1:5 in a citric acid buffer at pH 
4.1 or 7.0 (15 mM citric acid, 150 mM NaCl). The final pHs of the solutions 
were pH 5.0 or 7.0 ± 0.1. For experiments with reducing agent, 10 mM 
dithiothreitol (DTT) was included in the citric acid buffer. The buffers 
containing the diluted virus were incubated in a 37 oC water bath for 10 min. 
After incubation, to neutralize the pH, a tenth volume of DMEM containing 
150 mM HEPES was added. Each sample was then diluted 1:10 in medium 
containing 20 mM HEPES. Huh-7.5 cells, seeded in a 24-well plate, were 
infected with 200 µl of the diluted HCV or SIN sample per well for 2 h at 37 
oC. The monolayers were washed twice with DPBS and fresh media was 
added. SIN samples were harvested at 24 h.p.i. and HCV samples at 48 h.p.i.  
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HCV, BVDV, and SIN entry at the plasma membrane 
Huh-7.5 (HCV, SIN) or MDBK (BVDV) cells were treated with 
bafilomycin A1 (25 nM) diluted in media for 1 h at 37 oC. The cells were 
infected with HCV, BVDV or SIN in the presence of bafilomycin A1 for 1 h 
(BVDV) or 2 h (HCV, SIN) at 4 o C. After incubation, cells were 
sequentially washed with cold DPBS, warm citric acid buffer (pH 7.0 or 
5.0), and medium. Medium containing bafilomycin A1 was replaced and 
cells were incubated at 37 oC. Samples were harvested at 24 h.p.i. For 
experiments with reducing agent, 10 mM DTT was included in the citric 
acid buffer. For HCV-infected cells that were shifted to 37 oC prior to the 
low pH wash, after 1 h at 37 oC, cells were removed from the incubator, 
washed as indicated above with DPBS, citric acid buffer (pH 7.0 or 5.0), and 
medium. Medium containing bafilomycin A1 was replaced and cells were 
incubated at 37 oC. Samples were harvested at 24 h.p.i.  
 
Cathepsin B/L inhibitor experiments 
Huh-7.5 cells, seeded in a 24-well plate (5 x 104/well), were pretreated 
with CA-074 (100 µM) or FYdmk (0.1 µM) for 3.5 h at 37 oC. Cells were 
infected for 2 h at 37 oC with HCV, HIV expressing firefly luciferase 
pseudotyped with VSV G (HIV-VSVG), or VSV expressing GFP 
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pseudotyped with Ebola virus glycoprotein (VSV-EboV GP) (35) (a 
generous gift from James Cunningham, Harvard University). Cells were 
washed and incubated for 24 h at 37 oC. Drug was present in treated wells 
for the duration of the experiment. At 24 h.p.i., cells were harvested for 
luciferase assays (HCV/HIV-VSV-G) or flow cytometry (VSV-EboV GP). 
Flow cytometry was performed on a FACSCalibur (Becton Dickinson), 
counting 104 cells.  
 
Transduction of J6/JFH-FLneo cells with TRIP-CD81 or TRIP-CD9 
The lentiviral vector expressing wild-type human CD81 (TRIP-CD81) 
or CD9 (TRIP-CD9) protein has been described (220). For transduction, 
J6/JFH-FLneo cells were incubated overnight with undiluted TRIP-CD81 or 
TRIP-CD9 lentivirus in the presence of polybrene (4 µg/ml). 48 h post 
transduction, CD81 surface expression was confirmed by immunostaining 
and flow cytometry as above, and cells were infected with HCVpp-Luc 
(H77). 
 
Treatment of HCV replicon-containing cells with BILN 2061 
HCV subgenomic replicon cell populations containing H-SGneo, 
Con1-SGneo, and JFH-SGneo replicons were treated with 40 nM (H-SGneo 
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and Con1-SGneo cells) or 5 µM BILN 2061 (JFH-SGneo cells) in DMSO, 
10 or 20x the EC50 determined in (123), respectively, in the absence of 
G418. The media was changed every 2-3 d. HCV RNA levels were 
determined in BILN 2061- or DMSO-treated cells at 4 and 9 d post 
treatment at which point the cells were challenged with HCVcc-Rluc. The 
RLU values from each cell population on day 4 or 9 were expressed as the 
percentage of the DMSO-treated Huh-7.5 RLU on day 4 or 9, respectively. 
J6/JFH-FLneo replicon cells were treated with 5 µM BILN 2061 or DMSO 
for 9 d, after which the concentration of drug was raised to 20 µM. HCV 
RNA levels were determined at 4, 9, and 23 d post treatment when they were 
analyzed for CD81 surface expression and HCV RNA levels, and challenged 
with HCVpp-Luc (H77).  
 
Construction of VEE-AP180c-GFP and inhibition of clathrin-mediated 
endocytosis 
 
  The GFP-AP180c sequence was amplified from pGFP-AP180c (a 
generous gift from Ian Mills, Cambridge Research Institute) using a GFP-
specific forward primer (5’-ggaacccctgcaggatggtgagcaagggcgagga-3’) and 
an AP180c-specific reverse primer (5’-ggaacccctgcaggttacaagaaatccttgatgt 
taaga-3’). Both primers added an SbfI site to the 5’ and 3’ end of PCR 
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product, generating an SbfI-GFP-AP180c-SbfI cassette, which was cloned 
into a likewise digested VEE-SapI-puro plasmid. VEE-SapI-puro is a 
derivative of VEE-GFP-puro (163) in which the GFP sequence was deleted 
and replaced with an insertion flanked by SapI restriction sites, generating a 
unique SbfI restriction site (C. T. Jones, in preparation).   
 For in vitro transcription of VEE-AP180c-GFP and VEE-GFP-puro, 
plasmids were linearized with MluI and 1 µg of template was transcribed in 
the presence of cap analog using the SP6 Megascript Kit (Ambion), DNase-
treated and purified using the RNeasy Mini Kit (Qiagen). 2.5 µg of VEE-
AP180c-GFP or VEE-GFP-puro RNA was electroporated into Huh-7.5 cells 
using a BTX ElectroSquarePorator (820 V, 5 pulses, 99 µs/pulse) as 
described above. Cells were seeded into a 24-well plate and incubated for 24 
h, when they were infected with HCVcc-Rluc or HSV-1 (KOSdluxoriL) for 
2 h at 37 oC. Infected cells were harvested for luciferase assays at 24 h.p.i. 
 
HCVcc binding assay 
To create the CHO cell populations for the HCVcc binding 
experiment, cells were mock transduced or incubated overnight with TRIP 
lentiviral vectors expressing human CD81, CLDN, or SR-BI in the presence 
of polybrene (4 µg/ml). Expression was confirmed by immunostaining for 
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the appropriate receptors and flow cytometry. These CHO cell populations 
were created by Thomas von Hahn (Rockefeller University). 
CHO cells, mock transduced, or transduced with human CD81, 
CLDN1, or SR-BI, seeded in triplicate wells, were preincubated with α-SR-
BI (C167) or α-human IgG antibodies (1 µg/ml) for 1 h at 37 oC, then 
incubated with J6/JFH HCVcc (MOI ~0.5) in the presence of antibody for 2 
h at 37 oC. After binding, the cells were washed extensively with DPBS and 
total RNA was harvested using the RNeasy Mini kit (Qiagen). HCV RNA 
was amplified from 100 ng total RNA using the LightCycler RNA 
Amplification kit (Roche) and detected using a LightCycler 480 (Roche). 
The forward and reverse primer sequences are 5’-cttcacgcagaaagcgtcta-3’ 
and 5’-caagcaccctatcaggcagt-3’, respectively (Applied Biosystems). The 
probe sequence is 5’-6FAM-tatgagtgtcgtgcagcctc-MGBNFQ-3’ (Applied 
Biosystems). 
 
HCV glycoprotein-mediated cell fusion assay 
The cell fusion assay was performed as described (53). Briefly, to 
create acceptor cells capable of responding to fusion with a HIV-1 
transactivator of transcription (Tat) expressing cell, 293T cells were 
transduced with V1dTat-GFP VSVGpp. From this population, cell clones 
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were isolated that had little to no GFP expression in the absence of Tat, but 
had a high reporter signal when infected with V1 VSVGpp, which expresses 
Tat. GFP expression was quantified by FACS as described above. To test the 
effects of CLDN1 in this assay, the acceptor cell clones were transduced 
with TRIP-mCherryCLDN1 VSVGpp, which renders 293T cells susceptible 
to HCVpp-Luc (53). 
To create donor cell populations, 293T cells were seeded in 6-well 
plates (8 x 105/well) that had been coated with poly-L-lysine (100 µg/ml, 
Sigma), to prevent cells from detaching. The cells were transfected with 
either 1.5 µg of mock protein, V1 vector, to provide Tat expression, a 
glycoprotein expression vector, either H77 HCV E1E2 or VSV G (1.5 µg), 
or V1 vector plus glycoprotein (0.75 µg each) using Fugene-6. Briefly, the 
DNA in TE buffer, was added to 200 µl OptiMEM containing 18 µl Fugene-
6. The mixture was incubated and added to the 293T cells in fresh media. 
The culture media was changed approximately 6-12 h post transfection. At 
36 h post transfection, combinations of donor and acceptor cells were co-
seeded (1.5x106 cells each/well) in poly-L-lysine-coated 2-well chamber 
slides (BD Falcon). 12 h later, cells were washed with citric acid buffer at 
either pH 5.0 or pH 7.0 (15 mM citric acid, 150 mM NaCl), followed by 
media to neutralize the pH, and incubated for an additional 48 h. Cells were 
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fixed with 2% paraformaldehyde and mounted with 80% glycerol. The total 
number of green foci on the slide for each co-culture was enumerated by eye 















Chapter 3. A transdominant screen of bovine viral diarrhea virus 





Viruses are obligate parasites and hence host factor interactions, in 
addition to those between viral proteins and RNA, are essential to the BVDV 
life cycle. One caveat of certain biochemical techniques that use the viral 
protein of interest as bait is that interacting factors are pulled out with little 
hint to their function or relevance. Alternatively, functional genomics is a 
powerful approach to identify virus-virus and virus-cell factor interactions. 
One technique is based on the isolation of genetic suppressor elements, 
sequences derived from a gene or genome of interest that can act as 
transdominant inhibitors of a particular biological function, for example by 
binding to and blocking an essential interaction surface (48, 84). This type of 
approach allows selective inhibition of specific RNA or protein interactions 
and identifies a probe to further study the targeted process. Libraries of 
sequences derived from viral genomes have been used to study various 
processes, including the phage lambda life cycle (84) and HIV-1 latency 
(48). Cellular processes have also been examined by screening for cellular 
cDNA fragments that inhibit mammalian cell growth or provide resistance to 
cytotoxic drugs (134, 161, 210).  
In this study, using a random fragment BVDV cDNA library, I 
identified a fragment of the BVDV genome, the C-terminus of E1, E2, and 
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the N-terminus of p7, that acts as a transdominant inhibitor of BVDV 
replication. MDBK cells expressing the fragment, called MDBK-E1*E2p7* 
cells, were defective at the level of BVDV entry, although CD46 receptor 
expression and binding of BVDV to the cells were normal. Analysis of the 
MDBK-E1*E2p7* cell population has application for defining the molecules 
required for BVDV entry into MDBK cells. 
 
3.2 BVDV E2 as a transdominant inhibitor of BVDV entry 
A functional genomics approach to identify essential interactions in the 
BVDV life cycle 
 
Throughout the life cycle of an RNA virus, viral RNAs and proteins 
are closely associated and presumably interact intimately with cellular 
factors. To identify interactions required for BVDV replication, a random 
cDNA library of the BVDV genome was constructed. A plasmid encoding 
the BVDV NADL genome was sheared into fragments, which were cloned 
into the retroviral vector pBabeHAZSrfcI. Inserts were flanked by the 
coding sequence for an HA epitope prefaced by a start codon and by a 
zeocin resistance gene, 5’and 3’ to the fragments respectively (Fig. 3.1A). 
The final library encoded approximately 40,000 BVDV clones, with inserts 










Fig. 3.1 Scheme for BVDV library screening. (A) Schematic illustration of 
the library expression cassette within the pBabeHAZSrfcI retroviral vector. 
An SV40 promoter (gray) drives expression of the BVDV cDNA library 
fragment (red) fused to an HA tag (light green) at the N terminus and a 
zeocin selectable marker (green) at the C terminus. (B) To package the 
library, 293T cells were transfected with the BVDV library in 
pBabeHAZSrfcI, as well as Gag-pol and VSV G-protein expression 
constructs, and supernatants were harvested. MDBK cells were transduced 
with the packaged library and selected with zeocin. To screen the library, 
Zeo-resistant (Zeor) MDBK cells were infected with cp BVDV NADL. 
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To screen the library for transdominant inhibitors of BVDV  
replication, Zeo-resistant MDBK cells expressing the BVDV library or the 
empty vector, pBabeHAZ, were infected with cp BVDV NADL to isolate 
cells able to survive BVDV-induced cytopathic effect (CPE) (Fig. 3.1B). Of 
the 20 resistant colonies that survived BVDV challenge, 11 survived 
expansion, and only three remained resistant after reinfection with BVDV 
NADL. To determine the identity of the library inserts contained in the 
resistant clones, I harvested genomic DNA from these cells and amplified 
the retroviral insertion by PCR. Two of the three clones contained an 
insertion of approximately 1.2 kb, which encoded 150 bases of BVDV E1, 
the entire E2 gene, and 15 bases of p7, and was named E1*E2p7* (Fig. 3.2). 
In one of these cell clones, a 0.7-kb library fragment, derived from the 
BVDV NS5A gene, but cloned into pBabeHAZSrfcI in the reverse 
orientation with respect to the BVDV genome, was found in addition to the 
E1*E2p7* fragment, likely a result of coinfection with two library clones. 
The same 0.7-kb insertion was also found in the third resistant clone. This 
sequence, however, could not protect naïve cells from BVDV infection (data 






















Fig. 3.2 A genetic screen identifies the BVDV E1*E2p7* sequence as a 
transdominant inhibitor of BVDV replication. Sequence alignment of the 
E1*E2p7* library insertion with the BVDV genome. The brackets 
descending from the pictured BVDV genome highlight the BVDV sequence 
present in the resistant clones. The amino acid and its position relative to the 
BVDV NADL polyprotein are indicated. 
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Naïve cells expressing E1*E2p7* are resistant to homologous BVDV 
infection 
 
To test if E1*E2p7* could provide resistance to naïve cells, the 
sequence was re-cloned into pBabeHAZSrfcI, packaged into 
pseudoparticles, and used to transduce naïve MDBK cells. After selection 
with zeocin, the resulting cell population was called MDBK-E1*E2p7*. As 
a control, an MDBK-pBabe population, transduced with the empty vector 
pBabeHAZ, was generated. 
MDBK-E1*E2p7* and pBabe cells were infected with BVDV NADL 
and cell supernatants were harvested at various time points to determine 
viral titer. Over time, the BVDV titers obtained from MDBK-E1*E2p7* 
cells were 10-1000-fold lower than from pBabe control cells (Fig. 3.3A). In 
addition, while total CPE was observed in the pBabe cells, there was 
minimal CPE in the E1*E2p7* cells (data not shown). A similar 1000-fold 
difference in infectivity between the control and E1*E2p7* cells was 
observed with noncytopathic (ncp) BVDV NADLJiv90- (Fig. 3.3B). Even a 
high MOI infection (MOI 10) could not overcome the inhibition to BVDV 
replication in the E1*E2p7* cells (Fig. 3.3C). These data demonstrate that 
the E1*E2p7* insert was responsible for the resistance observed in the 














Fig. 3.3 Cells expressing BVDV E1*E2p7* are resistant to homologous 
BVDV infection. (A) Cells transduced with a retroviral vector expressing 
the E1*E2p7* sequence, MDBK-E1*E2p7* cells (triangles), and MDBK-
pBabe control (squares) cells were infected with BVDV NADL. Each point 
represents the mean titer of virus present in the supernatants of duplicate 
wells at the indicated time point p.i. This graph is representative data from at 
least 2 independent experiments.  Error bars show the standard errors of the 
means. (B, C) MDBK-E1*E2p7* (triangles) and pBabe (squares) cells were 
infected with ncp BVDV NADLJiv90- at an MOI of 1 (B) or 10 (C) and 
supernatants were harvested as above. Titers were determined by focus 
forming assays in duplicate. Error bars show the standard errors of the 
means. (D) MDBK-E1*E2p7* cells are permissive for heterologous VSV 
infection. MDBK-E1*E2p7*(triangles) and pBabe (squares) cells were 
infected with VSV and supernatants were harvested as above and titered in 
duplicate by plaque assay. Error bars show the standard errors of the means. 
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To determine if the phenotype observed in the MDBK-E1*E2p7* 
cells was a BVDV-specific effect or a general virus inhibition, the 
E1*E2p7* and pBabe cells were infected with the interferon-sensitive 
rhabdovirus, vesicular stomatitis virus (VSV). VSV was equally able to 
grow and form plaques on the E1*E2p7* and pBabe cells (Fig. 3.3D and 
data not shown). Therefore, the resistance in the MDBK-E1*E2p7* cells 
was not due to a general antiviral mechanism.  
A small amount of virus could be detected in the supernatants of 
MDBK-E1*E2p7* cells after infection with either cp or ncp BVDV (Fig. 
3.3A, B, C). This could be due to a low level of virus infection in all of the 
E1*E2p7* cells or to infection of a subset of permissive cells in the 
population. To examine this further, I infected the E1*E2p7* and pBabe 
cells with NADLJiv90-GFP, an ncp BVDV that expresses GFP, and 
harvested the cells for flow cytometry. At 48 h.p.i., only 4-5% of E1*E2p7* 
cells were GFP positive compared to more than 70% of pBabe cells (Fig. 
3.4A). This result indicates that the majority of cells in the MDBK-
E1*E2p7* cell population cannot support BVDV replication. Moreover, 
BVDV NADL could not form plaques on E1*E2p7* cell monolayers (Fig. 
3.4B), suggesting that although some cells were infected, virus spread was 



















Fig. 3.4 The MDBK-E1*E2p7* cell population contains a small subset of 
permissive cells. (A) MDBK-E1*E2p7* and pBabe cells were infected with 
NADLJiv90-GFP. At 24 and 48 h.p.i., cells were harvested for FACS 
analysis to determine the number of GFP positive cells. Values are the 
average of duplicate samples; error bars show the standard errors of the 
means. (B) Serial dilutions of BVDV NADL were used to infect monolayers 
of MDBK-E1*E2p7* or pBabe cells. The cells were then overlayed with 




BVDV E2 is a heavily glycosylated, ER-resident, integral membrane 
protein, which is cleaved from the BVDV polyprotein by host signal 
peptidase (76, 206) (Fig. 3.5). To further characterize the MDBK-E1*E2p7* 
cells, I compared E2 protein expression in MDBK-E1*E2p7* cells to that 
from BVDV-infected MDBK cells by western blotting with an α-E2 
antibody. BVDV-infected cell lysates displayed a dominant band between 
50 and 60 kDa, corresponding to the molecular weight of the mature E2 
protein, and a minor species migrating slightly slower, most likely due to the 
stable E2-p7 product in BVDV infected cells (76) (Fig. 3.6). Two bands 
were also detected from MDBK-E1*E2p7* cell lysates, although the major 
band detected in these cells was of a greater molecular weight compared to 
BVDV-infected cell lysates (Fig. 3.6), and is likely an E2p7*-Zeo fusion 
protein. The presence of a minor species in MDBK-E1*E2p7* cells, 
migrating similarly to the molecular weight of the dominant band within the 
infected cell lysates, suggests that there is some processing of E2 at its C-
terminus from the E1*E2p7* protein (Fig. 3.6). In addition, the localization 
of E2 protein in E1*E2p7* cells was analogous to E2 expressed after BVDV 
infection, as judged by indirect immunofluoresence using an α-E2 antibody 
and sensitivity of immunoprecipitated E2 to Endoglycosidase H or PNGase 
















Fig. 3.5 Putative membrane topology of BVDV E2. The E2 glycoprotein 
is an ER-resident protein with a C-terminal transmembrane anchor (orange) 
and a short C-terminal tail (green). Arrows indicate sites of cleavage by host 





















Fig. 3.6 E2 expression in MDBK-E1*E2p7* cells. Lysates from MDBK-
E1*E2p7* and BVDV NADL infected-MDBK cells were assayed by 
western blot using an antibody against BVDV E2 (MAb 214). Lysates from 
mock-infected MDBK cells and pBabe cells were used as negative controls. 
Arrows indicate the expected identity of the protein in each band based on 
molecular weight. 
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Expression of the BVDV E2 ectodomain is sufficient for BVDV inhibition 
I sought to determine if E2 expression alone, in the absence of the E1* 
and p7* flanking sequences present in the MDBK-E1*E2p7* cells, was 
sufficient for BVDV inhibition. MDBK cells were infected with a packaged 
lentivirus expressing either the original construct, E1*E2p7* (pLenti6-
E1*E2p7*), or the E2 coding region alone, preceded by the signal sequence 
from influenza HA to direct E2 into the ER lumen and followed by a stop 
codon (pLenti6-Sig-E2) (Fig. 3.7). MDBK cells transduced with a lentivirus 
expressing EGFP (pLenti6-EGFP) were used as a control. Transduced 
MDBK cells were infected with NADLJiv90-luc (119), a bicistronic ncp 
BVDV that expresses a luciferase reporter gene driven by the BVDV IRES 
and the BVDV polyprotein via the EMCV IRES (Fig. 3.8A). The ubiquitin 
gene (ubi) was inserted upstream of the luc gene, to create the correct N 
terminus of Luc upon cleavage of Ubi. After infection with NADLJiv90-luc, 
cells expressing E1*E2p7* or E2 alone had a similar reduction in luciferase 
activity compared to the EGFP control cells (Fig. 3.8B). These results 
indicate that the flanking E1* and p7* sequences did not contribute to the 
BVDV inhibition observed using the original E1*E2p7* construct.  
To determine if the E2 ectodomain alone was responsible for BVDV 




















Fig. 3.7 E2 expression constructs. (A) Organization of the E2 protein. 
Numbers indicate the amino acid number within E2 corresponding to the 
start of a particular domain (104). (B) E2 expression constructs cloned into 
the pLenti6 lentiviral vector. The light blue fragments correspond to the E1* 
and p7* sequence of E1*E2p7*. Red, orange and green boxes represent 
domains of the E2 protein as indicated in A. The dark blue box in Sig-E2 
and Sig-E2* corresponds to the HA signal sequence inserted upstream of the 
































Fig. 3.8 The E2 ectodomain is sufficient for BVDV inhibition. (A) 
Schematic diagram of ncp NADLJiv90-luc viral RNA. (B) 
MDBK cells were transduced with packaged lentiviral vectors expressing 
EGFP, E1*E2p7*, Sig-E2, or Sig-E2*. After blasticidin selection, each cell 
population was infected with NADLJiv90-luc. At 48 h.p.i., cells from 
triplicate wells were harvested for luciferase assays. The graph shows the 
average of the 2 independent experiments done in triplicate; error bars show 




transmembrane or C terminal domain, was constructed (Fig. 3.7). MDBK 
cells were infected with packaged pLenti6-Sig-E2* lentivirus and challenged 
with NADLJiv90-luc. Luciferase activity from the Sig-E2* cells was similar 
to that from E1*E2p7* and Sig-E2 cells and more than 1 log lower than 
from the negative control-EGFP expressing cells (Fig. 3.8B).  
Immunofluorescence staining for E2 within the Sig-E2* cells showed a 
significant amount of E2 within the cell, possibly in the ER and secretory 
pathway (data not shown). Although, it is not clear whether ER retention 
provided by the E2 transmembrane domain is required for BVDV inhibition, 
this data demonstrates that the E2 ectodomain is sufficient to obtain the 
BVDV inhibition observed from E1*E2p7*.  
 
BVDV is blocked prior to translation in MDBK-E1*E2p7* cells 
To examine the block to BVDV infection in the original MDBK-
E1*E2p7* cells, I again used NADLJiv90-luc, which provided a sensitive 
assay to monitor BVDV translation and replication. Similar to the above 
titration experiments, a 100-1000-fold decrease in luciferase activity was 
observed after NADLJiv90-luc infection of MDBK-E1*E2p7* cells 
compared to pBabe cells (data not shown).  
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I examined translation of the incoming NADLJiv90-luc genome in the 
absence of viral RNA replication using a BVDV-specific polymerase 
inhibitor (6). After infection with NADLJiv90-luc, the luciferase activity 
within the pBabe cells peaked at 6 h and steadily decreased as expected due 
to the polymerase inhibitor. At the 6 h time point, the luciferase activity on 
the E1*E2p7* cells was approximately 10-fold less than on pBabe cells (Fig. 
3.9A), which could be due a defect in translation or in the ability of BVDV 
to enter the cells and deliver its genome to the cytoplasm. To distinguish 
between these options, I tested whether bypassing the virus entry steps by 
transfection could overcome the block to BVDV replication in E1*E2p7* 
cells. Virus titer in the supernatants of MDBK-E1*E2p7* and pBabe cells 
was examined after electroporation of in vitro transcribed BVDV NADL 
RNA. Over a 48 h period there was no difference in the titer of BVDV from 
MDBK-E1*E2p7* compared to the pBabe control cells (Fig. 3.9B). Because 
BVDV could be efficiently translated and replicated if allowed to bypass the 
entry steps into MDBK-E1*E2p7* cells, the block to BVDV replication is 





















Fig. 3.9 MDBK-E1*E2p7* cells have a defect at the level of BVDV 
entry. (A) MDBK-E1*E2p7* and pBabe cells were infected with 
NADLJiv90-luc in the presence of a BVDV polymerase inhibitor (6). At 
each time point, cells were harvested for luciferase assays. Each bar 
represents the mean value of duplicate wells; error bars show the standard 
errors of the means. The dashed line indicates the background level of the 
assay from naïve MDBK cells. (B) MDBK-E1*E2p7* and pBabe cells were 
electroporated with in vitro transcribed BVDV NADLJiv90-luc RNA. At 
each time point, supernatants from electroporated cells were harvested and 
titered on MDBK cells. Each point represents the mean titer of duplicate 
wells; error bars show the standard errors of the means. 
Time post electroporation (h) 
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CD46 expression and BVDV binding on MDBK-E1*E2p7* cells is similar to 
control cells 
I hypothesized that the resistance to BVDV entry in MDBK-
E1*E2p7* cells may be at the level of the viral receptor, CD46 (137). 
MDBK-E1*E2p7* and pBabe cells were analyzed for CD46 expression 
using flow cytometry and found to have similar levels on their surfaces (Fig. 
3.10A). Western blot of total cell lysates also revealed comparable levels of 
total CD46 in the two cell types (Fig. 3.10B). Taken together, these results 
suggest that down regulation of CD46 from the cell surface is not 
responsible for the BVDV inhibition seen in cells expressing the E1*E2p7* 
insertion.  
Although surface levels of CD46 were apparently similar between 
MDBK-pBabe and E1*E2p7* cells, it remained possible that E1*E2p7* 
cells could have a functional defect in cell surface binding of BVDV. To 
investigate this possibility, cells were chilled to 4 oC and infected with ncp 
BVDV NADLJiv90- at an MOI of 10. Cell-associated BVDV RNA was 
quantified by real-time quantitative RT-PCR analysis. The assay revealed 
similar levels of BVDV binding on the surface of both MDBK-pBabe and 
E1*E2p7* cells (Fig. 3.11A). Preincubation with an α-CD46 antibody 
reduced cell associated BVDV RNA levels in both cell types by 
















Fig. 3.10 CD46 expression on MDBK-E1*E2p7* cells is similar to 
control pBabe cells. (A) To analyze CD46 expression on the cell surface, 
cells were detached and stained with a polyclonal antibody against bovine 
CD46. Cells were stained in the absence of detergent to selectively stain 
only the surface of the cells. CD46 expression on MDBK-E1*E2p7* (thick, 
orange line) and pBabe cells (tinted, blue curve) was analyzed by FACS 
after gating on live cells. Cells stained with preimmune sera are indicated as 
thin solid lines. (B) To examine total CD46 expression, lysates from 
MDBK-E1*E2p7* and pBabe cells were western blotted with an antibody 
against bovine CD46 (α-CD46) or actin (α-actin). The presence of multiple 














































Fig. 3.11 BVDV binding to MDBK-E1*E2p7* cells is similar to control 
pBabe cells. (A) Cells were incubated for 1 h at 4 oC with BVDV 
NADLJiv90- at an MOI of 10. Cells were washed extensively and RNA was 
harvested for quantitative RT-PCR to determine cell associated BVDV RNA 
levels. Values are expressed as the percent of MDBK-pBabe BVDV 
binding. Each bar is the average value of 3 independent experiments done in 
triplicate; error bars show the standard errors of the means. (B) Cells were 
treated with an α-CD46 antibody prior to infection with BVDV as described 
above. RNA was harvested for quantitative RT-PCR to determine cell 
associated BVDV RNA levels. Values are expressed as the percent of 
untreated MDBK-pBabe BVDV binding and are the average of at least 




binding was dependent on CD46. These results indicate that the block to 
BVDV infection in MDBK-E1*E2p7* cells lies downstream of BVDV 
binding to the cell surface.  
 
3.3 Discussion 
To identify essential interactions in the BVDV life cycle, I took a 
functional genomics approach using a random genomic cDNA library of the 
BVDV genome and screening it for genome fragments that could act as 
transdominant inhibitors of viral replication. Two unique BVDV sequences 
were identified within resistant colonies that developed after cp BVDV 
infection – one aligning with the E2 protein in the BVDV structural region 
and another within the NS5A protein. Only the former insertion, which 
expressed the C-terminal end of E1, E2, and the N terminus of p7 
(E1*E2p7*), could provide resistance to naïve cells. Further experiments 
demonstrated that BVDV was blocked at the level of entry in the MDBK-
E1*E2p7* cells. However, if allowed to bypass the entry block, BVDV 
replication was unaffected by expression of the E1*E2p7* insertion.   
The role of the BVDV structural proteins in preventing BVDV 
infection is supported by previously published data. A cell line expressing 
the BVDV C through E2 proteins was shown to be non-permissive for 
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BVDV replication (170). Additionally, Harada et al. described an MDBK 
cell line expressing BVDV E2 and p7 separated by an IRES that was 
similarly inhibited in BVDV infection (76). My work described here, further 
maps the BVDV structural region necessary for BVDV inhibition to the 
ectodomain of the E2 protein and suggests that this inhibition is CD46-
independent. Sig-E2*-expressing cells, encoding the signal sequence of the 
HA protein, and the E2 ectodomain followed by a stop codon, were as 
resistant to BVDV entry as those expressing the original E1*E2p7* 
construct. Therefore, the E1 and p7 flanking sequences, as well as the E2 
transmembrane and C terminal domains are not required for BVDV 
inhibition. Moreover, the signal sequence for E2, normally provided by E1, 
acting to direct the E2 ectodomain into the ER lumen, could be replaced by a 
heterologous signal sequence to provide similar inhibition as the original 
insertion. Hence, the ectodomain of E2, independent from the 
transmembrane and C-terminal domain, can act as a transdominant inhibitor 
of BVDV entry. 
BVDV inhibition provided by the E1*E2p7* insertion may be due to 
a number of possible mechanisms. BVDV entry could be inhibited as a 
result of E2 interfering directly with the activity of a particular BVDV entry 
factor, or indirectly by antagonizing a host signaling pathway required for 
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virus uptake. Expression of BVDV E2 may prevent BVDV from entering 
the cell by a similar mechanism as superinfection exclusion observed in 
acutely infected cells (119). We and others have examined the phenomenon 
of BVDV superinfection exclusion in MDBK cells and shown that 
superinfecting BVDV encounters superinfection blocks both at the levels of 
entry and replication [Sections 4.2, 4.3 and (119, 147)]. For the entry block, 
it was found that cells harboring a BVDV genome lacking the E2 gene fail 
to exclude superinfecting BVDV at the level of entry. In light of this data, it 
is possible that expression of E2 within MDBK cells may mimic the 
phenomenon of superinfection exclusion at the level of viral entry.    
Superinfection exclusion has been observed for a number of viruses 
including HIV (1, 42, 92, 186), alphaviruses (1, 93), and VSV (180, 209). 
Envelope protein-mediated receptor down regulation and interference with 
the activity of a cellular receptor are well-documented mechanisms of viral 
superinfection exclusion. For example, the down regulation of CD4 from the 
surface of HIV infected cells by the viral envelope precursor gp160 (42, 92, 
186) or the removal of sialic acid by influenza neuraminidase from the 
glycoproteins within the secretory pathway and the surface of infected cells 
(4, 115, 158) prevents superinfection of these viruses. Additionally, the Env 
protein of the retrovirus foamy virus (FV) was shown to be sufficient for 
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mediating superinfection exclusion in FV-infected cells (19). Interference 
with a cellular receptor has also been observed for mouse 
gammaretroviruses. Mouse cells harboring certain integrated proviruses, 
ecotropic Fv4 or polytropic Rmcf or Rmcf2, which express murine leukemia 
virus (MLV)-envelope genes, are resistant to exogenous ecotropic or 
polytropic MLV infection, respectively (16, 77, 87, 213).  
The entry pathway for BVDV is CD46-dependent (137), although I 
found that CD46 expression in MDBK-E1*E2p7* cells did not differ from 
pBabe control cells. Consistent with this result, BVDV binding, which is 
mediated by CD46 (109, 137), was also equivalent between MDBK-
E1*E2p7* and the control cells. It remains possible that E2 could be 
interfering with a specific molecular form or localization of CD46 that is 
expressed on the cell surface and required for BVDV to be internalized into 
MDBK cells, yet our experiments suggest that the block to BVDV entry lies 
downstream of the CD46-dependent step. 
Screening a random genomic library to identify transdominant 
inhibitors has a number of advantages over simply screening ORFs from the 
BVDV genome. First, a random approach is inherently unbiased and thus 
allows the identification of functional domains or regions that may not be 
tested by a rationally designed approach. In addition, simply based on the 
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number of different sequences being screened, a library approach increases 
the likelihood of identifying functional interactions required for viral 
replication. Moreover, because the random library represents the entire 
BVDV genome, there is the potential to characterize interactions, which may 
occur between sequences that lie distal from each other within the viral 
genome.  
Functional genomics is a powerful approach to examine essential 
interactions between individual viral components, as well as between viral 
and cellular factors. Viral protein or RNA components associate and recruit 
cellular cofactors for processes such as viral translation and replication, and 
for host defense evasion and pathogenesis. Screening of a random fragment 
library derived from the HIV-1 genome identified inhibitors of productive 
HIV-1 infection and latency, which aligned with 7 regions of the virus 
genome (48). In our study, screening of a random fragment library of the 
BVDV genome identified a viral sequence capable of preventing BVDV 
entry into MDBK cells. The advantage of this approach over other in vitro 
techniques is that the BVDV inhibitor was identified in a functional context 
where it prevented viral infection, directly demonstrating the relevance of an 
E2-mediated interaction in BVDV replication. Notably, only one cDNA, 
spanning the full-length E2 gene, out the 40,000 cDNA clones included in 
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the random BVDV library, was pulled out of our screen and conferred 
resistance to naïve cells. This suggests that expression of the E1*E2p7* 
insertion in MDBK cells provides a strong, inhibitory mechanism against 
BVDV. Although the minimal region required for BVDV inhibition was the 
E2 ectodomain, the larger insertion could have provided some advantage in 
stability or expression level during screening in MDBK cells. In future 
studies, I may consider less stringent screening methods compared to cell 
death, which could allow selection for cDNA insertions offering 
intermediate levels of BVDV resistance to MDBK cells. This approach has 
potential to further identify essential interactions that occur with components 


































Superinfection exclusion, or homologous interference, is the ability of 
an established virus infection to interfere with secondary virus infection. 
Multiple mechanisms that contribute to superinfection exclusion have been 
demonstrated for various viruses, including interference with receptor-
mediated attachment (27, 28, 184, 185) and penetration into cells (180, 181, 
209), as well as downstream replication events (1, 66, 99). In this Chapter, 
superinfection exclusion in BVDV and HCV infected cells was examined. 
Superinfection exclusion has been described for pestiviruses (147), 
but the molecular mechanisms responsible for this phenomenon remain 
unclear. It was found that MDBK cells acutely infected with ncp BVDV are 
protected from cytopathic effect (CPE) following superinfection with cp 
BVDV, but not with an unrelated cp virus, VSV. Dual mechanisms of 
BVDV superinfection exclusion were observed; one occurred at the level of 
viral entry and another at the level of viral replication. It was determined that 
superinfecting BVDV fails to enter acutely infected cells and that the 
structural protein E2 was responsible for this block. If the viral entry steps 
were bypassed by transfection of the viral RNA, the RNA could be 
translated but failed to replicate in cells acutely infected with BVDV. The 
second mechanism of superinfection exclusion at viral RNA replication was 
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dependent on the level of primary RNA replication and was not influenced 
by expression of the viral structural proteins (C, Erns, E1, and E2).  
The recent development of an HCV infectious system that permits the 
growth of virus in cell culture (HCVcc) has enabled study of the complete 
virus lifecycle (123, 203, 221). In this study, I observed that cells acutely 
infected with genotype 2a HCV chimeric strain J6/JFH and cells harboring 
HCV RNAs from a range of genotypes were resistant to HCVcc 
superinfection. Further analysis revealed that superinfection was blocked 
downstream of viral entry. Unlike cells acutely infected with J6/JFH and 
cells supporting Con1 and H77 full-length, and Con1, H77, and JFH 
subgenomic replicons, cells containing a persistent, full-length J6/JFH 
replicon were nonpermissive for HCVpp. Study of this HCVpp-resistant, 
stable J6/JFH replicon population suggested that J6/JFH replication/infection 
applies a strong negative selection for CD81-expressing cells. This 
observation could be mimicked at later time points after infection with 
J6/JFH HCVcc.  
 
4.2 Background information for BVDV superinfection exclusion 
 Sections 4.2 and 4.3 encompass a comprehensive study of BVDV 
superinfection exclusion. This section (4.2) explains previous results 
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obtained by Young-Min Lee (Washington University). The following 
section (4.3) describes an additional set of experiments to further analyze the 
observations that BVDV superinfection exclusion is lost upon passaging and 
that the level of exclusion correlates with the level of primary RNA 
replication. All of these data have been reported in reference (119). 
 
MDBK cells acutely infected with ncp BVDV are protected from CPE when 
superinfected with cp BVDV, but not with VSV 
 
To examine whether ncp BVDV-infected MDBK cells are protected 
from subsequent BVDV infection, MDBK cells were infected with ncp 
NADLJiv90- at an MOI of 10 and challenged at 12 h.p.i. with cp NADL. As 
a control, naïve MDBK cells were infected in parallel with cp BVDV. CPE 
caused by cp BVDV replication was monitored quantitatively by plaque 
assay or qualitatively by incubating infected monolayers in liquid medium.  
 Plaques were formed on cell monolayers in plaque assays and no 
viable cells were observed for cultures incubated in liquid medium following 
infection of naïve MDBK cells with cp BVDV (Fig. 4.1A, plates 4 and 8). In 
contrast, neither plaques nor recognizable CPE resulted from superinfection 
of acutely ncp BVDV-infected cells with cp BVDV (Fig. 4.1A, plates 3 and 

















Fig. 4.1 MDBK cells acutely infected with ncp BVDV are protected from 
CPE when superinfected with homologous cp BVDV, but not with VSV. 
(A and B) Naïve MDBK cells were first mock-infected, or infected with ncp 
NADLJiv90- BVDV. At 12 h.p.i, ncp NADLJiv90--infected cells were 
washed three times with media, and either mock-superinfected or 
superinfected with cp NADL BVDV or cp VSV for 1 h. + or – above each 
column of plates indicates infection or mock-infection, respectively, with the 
particular virus shown at the top left. The cells were overlaid with agarose 
(A and B, plates 1-4) or incubated in liquid culture media (A and B, plates 5-
8). The cells were fixed and stained with crystal violet to visualize live cells 






overgrowth. Primary ncp BVDV-infected cells did not show any signs of 
CPE (Fig. 4.1A, plates 2 and 6). In addition to ncp NADLJiv90- virus, 
MDBK cells infected with a heterologous ncp strain of BVDV, SD-1 (45), 
were also protected from CPE upon superinfection with cp NADL (data not 
shown). 
  Next it was determined if ncp BVDV-infected MDBK cells are 
generally protected from virus-induced CPE, including that induced by a 
heterologous virus. To do so, VSV, a negative-sense interferon-sensitive 
rhabdovirus, was used to challenge the ncp BVDV-infected MDBK cells. 
CPE induced by VSV infection of BVDV-infected cells was 
indistinguishable from that of VSV-infected naïve MDBK cells as 
determined by plaque assays (Fig. 4.1B, compare plates 3 and 4) and 
observing infected monolayers overlaid with liquid media (Fig. 4.1B, 
compare plates 7 and 8). Thus, MDBK cells infected with ncp BVDV, either 
ncp NADLJiv90- or ncp SD-1 BVDV, were protected from CPE when 
superinfected with homologous cp BVDV, but not with heterologous cp 
VSV.  This suggests that the block may be virus-specific and not mediated 
by a general cellular antiviral defense pathway such as interferon or a block 
in the ability of the cells to undergo virus-induced cell death.  
 87 
To address whether the lack of CPE was due to a block in the ability 
of superinfecting virus to replicate in acutely infected cells, MDBK cells 
acutely infected with ncp NADLJiv90- were superinfected with ncp 
NADLJiv90-pac, which expresses a dominant selectable marker, the 
puromycin N-acetyltransferase (pac) gene (see Fig. 4.3A).  After selection 
with puromycin, neither foci nor surviving cells were observed in 
superinfected monolayers whereas naïve MDBK cells infected with ncp 
NADLJiv90-pac were transduced to puromycin resistance with high 
efficiency (data not shown). These results indicate that the lack of CPE 
observed in the first experiments was likely due to the failure of the 
superinfecting cp BVDV to replicate efficiently in cells acutely infected with 
ncp BVDV (rather than inhibition of CPE despite replication of the cp 
virus). 
 
Superinfection exclusion is established rapidly 
 To determine the kinetics with which superinfection exclusion is 
established, we infected with ncp NADLJiv90-luc (Fig. 3.8A). The level of 
luciferase activity from ncp NADLJiv90-luc after superinfection of ncp 
NADLJiv90- -infected cells was used as a measure of the degree of 
superinfection exclusion.  
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Naïve MDBK cells were infected with ncp NADLJiv90- virus for 0, 
0.25, 0.50, 1, 2, 4, 8, or 12 h prior to superinfection with ncp NADLJiv90-
luc. At 24 h post superinfection, the luciferase activity was determined. Cells 
preincubated with ncp NADLJiv90- for at least 30-60 min prior to 
superinfection with ncp NADLJiv90-luc had dramatically reduced luciferase 
activity compared to cells simultaneously coinfected with the two viruses 
(Fig. 4.2). Beyond 4 h preincubation, little luciferase activity was detected. 
Thus, superinfection exclusion of BVDV is efficiently established within 30-
60 min after primary BVDV infection.  
 
BVDV persistently infected cells lose the ability to exclude superinfecting 
virus  
 
To determine if superinfection exclusion is maintained during 
persistent infection, individual persistently infected cells were examined. 
Cells were infected with ncp NADLJiv90-pac and maintained under 
puromycin selection (Fig. 4.3A).  At 1, 2, 3, 4, and 5 d after acute infection, 
cells were superinfected with cp NADL. Two days later, supernatants were 
harvested and titered by plaque assay to measure the yield of cp NADL. 
Over the 5 d period, the decrease in virus production from the puromycin 
selected cells directly correlated with the increase in cp NADL titer from 

















Fig. 4.2 Superinfection exclusion is established within 30-60 minutes of 
primary BVDV infection. Naïve MDBK cells were infected with ncp 
NADLJiv90- for 0.25, 0.5, 1, 2, 4, 8, or 12 h prior to superinfection. The 
cells were then superinfected with ncp NADLJiv90-luc virus. In parallel, 
naïve MDBK cells were coinfected with ncp NADLJiv90- and ncp 
NADLJiv90-luc viruses, indicated as time point 0. After 24 h incubation, the 

















Fig. 4.3 Superinfection exclusion is transient and lost upon passaging. 
(A) Schematic diagram of ncp NADLJiv90-pac viral RNA. (B) MDBK cells 
were infected with ncp NADLJiv90-pac and maintained under puromycin 
selection.  At 1, 2, 3, 4, and 5 d after acute infection, supernatants were 
harvested from the infected cells to determine ncp NADLJiv90-pac titer by 
focus forming assay and also superinfected with cp NADL. Two days later, 
supernatants were harvested and titered by plaque assay to measure the yield 
of cp NADL. Plaque and focus forming assays were incubated for 3 d under 
overlaid agarose and then fixed and stained with crystal violet or α-BVDV 
antibody respectively. The titers of ncp NADLJiv90-pac and cp NADL are 
expressed as focus forming units per ml (ffu/ml) or pfu/ml, respectively.  




puromycin selection throughout the course of the experiment ensured that 
cells superinfected with cp BVDV harbored replicating ncp BVDV, albeit at 
decreasing titers.  These experiments strongly suggest that the loss of 
superinfection exclusion over time seen in persistently infected cells is due 
to an alteration occurring in the cells that remained persistently infected with 
BVDV rather than to a subpopulation of uninfected cells. Additional 
experiments regarding this point are shown below in Section 4.3. 
 
Superinfecting BVDV is blocked at the level of viral entry 
The lack of BVDV replication could be due to the inability of 
superinfecting BVDV particles to efficiently enter a BVDV-infected cell 
and/or the inability of the superinfecting viral genome to be translated and 
replicated after entry. To examine these two options, ncp NADLJiv90--
infected cells were challenged with NADLJiv90-luc. To assay primary 
translation of incoming genome RNA, luciferase activity was measured at 6 
h.p.i. with ncp NADLJiv90-luc. The 6 h time point was chosen by two 
criteria. First, infection with NADLJiv90-luc in the absence or presence of a 
potent BVDV-specific RdRp inhibitor (6), resulted in luciferase activities 
differing by approximately 2.5-fold at 6 h, as compared to a greater than 
500-fold difference by 15 h due to replication in the absence of the inhibitor 
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(data not shown). Second, transfection experiments showed no significant 
difference in luciferase levels between replication competent and replication 
defective BVDV replicons at the 6 h time point (see below).  
Superinfection of ncp NADLJiv90--infected cells with ncp 
NADLJiv90-luc virus resulted in luciferase activity almost 100-fold lower 
than that from naïve MDBK cells infected with ncp NADLJiv90-luc (Fig. 
4.4A, Infection). Transfection of this construct into ncp NADLJiv90- 
infected cells showed that the superinfecting genome could be efficiently 
translated (Fig. 4.4A, Transfection; and below). Therefore, superinfecting 
ncp NADLJiv90-luc was unable to deliver its translation competent RNA 
genome into ncp NADLJiv90--infected MDBK cells, indicating a block at 
the level of entry. Entry is loosely defined here to encompass all of the pre-
translation steps. 
To investigate the importance of the BVDV structural proteins, an 
MDBK cell line expressing only the BVDV nonstructural proteins was 
generated by transfection of a subgenomic ncp NADLJiv90-∆S-pac replicon 
and selection with puromycin (Fig. 4.4B). An MDBK cell line expressing all 
of the viral proteins was also generated using full-length ncp NADLJiv90-
pac RNA (Fig. 4.4B). Both puromycin-selected cell populations were 







Fig. 4.4 Homologous BVDV superinfecting particles are blocked at the 
level of viral entry. (A) Naïve (uninfected) or ncp NADLJiv90--infected 
(infected) cells were superinfected (Infection) or transfected (Transfection) 
with ncp NADLJiv90-luc. At 6 h post superinfection or transfection, the cells 
were lysed and luciferase activity determined. The dashed line represents the 
background level of the assay from naïve MDBK cells. (B) Schematic 
diagram of ncp NADLJiv90-pac and ncp NADLJiv90-ΔS-pac viral RNAs. 
(C) ncp NADLJiv90-pac (FL), ncp NADLJiv90-ΔS-pac (ΔS), and naïve (N) 
cells were superinfected with ncp NADLJiv90-luc. At 6 h.p.i., the cells were 
lysed and luciferase activity was determined. The dashed line represents the 
background level of the assay from naïve MDBK cells. (D) Naive (N), ncp 
NADLJiv90-pac (FL), ncp NADLJiv90-ΔC-pac (ΔC), ncp NADLJiv90-
ΔErns-pac (ΔErns), ncp NADLJiv90-ΔE1-pac (ΔE1), and ncp NADLJiv90-
ΔE2-pac (ΔE2) selected MDBK cells were infected with ncp NADLJiv90-






















determined at 6 h.p.i. In ncp NADLJiv90-pac selected cells (Fig. 4.4C, FL) 
the luciferase activity after superinfection was more than 50-fold less than in 
naïve cells (Fig. 4.4C, N). In contrast, the ncp NADLJiv90-∆S-pac selected 
cells, were as susceptible as naïve cells for delivery and early translation of 
luciferase-expressing virion RNA (Fig. 4.4C, ∆S). These results demonstrate 
that expression of one or more BVDV structural proteins was required for 
superinfection exclusion at the level of viral entry.  
To investigate which viral structural protein was responsible for 
exclusion during entry, four puromycin-selected MDBK cell lines were 
generated.  Each harbored a recombinant viral RNA containing an in-frame 
deletion of each viral structural gene, designated as NADLJiv90-∆C-pac, 
NADLJiv90-∆Erns-pac, NADLJiv90-∆E1-pac, and NADLJiv90-∆E2-pac. 
The selected cells appeared to express similar amounts of NS2-3 protein, 
measured by immunoblotting or radioimmunoprecipitation with an α-NS3 
specific antiserum (data not shown). The MDBK cell lines were infected 
with ncp NADLJiv90-luc viral particles and luciferase activity at 6 h.p.i. was 
determined. Luciferase activities obtained from ncp NADLJiv90-∆C-pac, 
ncp NADLJiv90-∆Erns-pac, and ncp NADLJiv90-∆E1-pac mutant cell lines 
upon superinfection with ncp NADLJiv90-luc virus (Fig. 4.4D, ∆C, ∆Erns, 
∆E1), were similar to cells expressing a full complement of structural 
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proteins (Fig. 4.4D, FL). These results suggest that the viral structural 
proteins C, Erns, and E1 do not play a major role in exclusion at the level of 
viral entry. In contrast, ncp NADLJiv90-luc infection of the ncp 
NADLJiv90-∆E2-pac selected cells resulted in similar luciferase activity 
(Fig. 4.4D, ∆E2) to that obtained from infection of naïve MDBK cells (Fig. 
4.4D, N). Hence, these findings show that deletion of viral glycoprotein E2 
was sufficient to abolish the exclusion at the level of viral entry. 
Interestingly, although ncp NADLJiv90-luc could be efficiently translated in 
the ncp NADLJiv90-∆E2-pac selected cells there was no amplification of 
this genome, suggesting a second, internal block to superinfection might 
exist.   
 
Transfection of BVDV RNA reveals a second block at replication, but not 
translation 
 
To determine if superinfecting viral RNA would be competent for 
replication if it were allowed to bypass the viral entry steps, MDBK cells 
acutely infected with ncp NADLJiv90- were transfected with ncp 
NADLJiv90-pac RNA. These cells did not survive puromycin selection (Fig. 
4.5, plate 8), indicating that the transfected ncp NADLJiv90-pac RNA had 
failed to replicate. Naïve MDBK cells transfected with ncp NADLJiv90-pac 

















Fig. 4.5 Transfected ncp NADLJiv90-pac RNA fails to replicate in ncp 
NADLJiv90- infected cells. Naïve MDBK cells were either mock-infected 
(plates 1-4) or acutely infected with ncp NADLJiv90- (plates 5-8). The cells 
were then mock-transfected or transfected with in vitro transcribed ncp 
NADLJiv90-pac RNA. + or – above each column of plates indicates 
transfection or mock-transfection with ncp NADLJiv90-pac RNA, 
respectively. Following transfection, the cells were incubated in culture 
media +/- 5 µg/ml of puromycin as indicated, and viable cells were fixed and 
stained with crystal violet after 5 d. 
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eventually became confluent (Fig. 4.5, plate 4). Whereas, MDBK cells 
infected with only ncp NADLJiv90- were unable to survive puromycin 
selection (Fig. 4.5, plate 6). Transfection of an alphavirus-based expression 
vector SINrep3-lacZ (61) indicated that there was no significant difference 
in transfection efficiency of naïve vs. BVDV-infected MDBK cells (data not 
shown). These findings demonstrate that the ncp NADLJiv90-pac RNA 
transfected into MDBK cells acutely infected with ncp NADLJiv90- was 
unable to replicate to a level required for puromycin selection, and suggests 
an additional post-entry block to superinfection.  
Since translation of the incoming genome is a prerequisite for RNA 
replication, additional experiments were performed (besides that described 
in Fig. 4.4A) to examine translation of BVDV RNA transfected into acutely 
BVDV-infected MDBK cells.  To more clearly distinguish between 
translation of input RNA versus signal due to productive replication, a 
subgenomic ncp BVDV replicon, ncp NADLJiv90-ΔS-luc, encoding the luc 
reporter with its isogenic replication-incompetent derivative, ncp 
NADLJiv90-∆S-luc-pol- (Fig. 4.6A), were compared. In naïve MDBK cells 
transfected with ncp NADLJiv90-∆S-luc RNA (Fig. 4.6B, solid circles), the 
luciferase activity at 6 h post transfection was similar to that observed with 






Fig. 4.6 ncp NADLJiv90-ΔS-luc viral RNA transfected into ncp 
NADLJiv90--infected MDBK cells is competent for translation, but not 
for replication. (A) Schematic diagram of ncp NADLJiv90-ΔS-luc and ncp 
NADLJiv90-ΔS-luc-pol- viral RNAs. (B) Either 8 x 106 naïve (closed circles) 
or ncp NADLJiv90--infected MDBK cells (closed squares) were 
electroporated with 5 µg of ncp NADLJiv90-ΔS-luc RNA. In parallel, 5 µg 
of ncp NADLJiv90-ΔS-luc-pol- RNA was electroporated into naïve (open 
circles) and ncp NADLJiv90--infected (open squares) cells. The luciferase 
activity was measured at the indicated time. The dashed line indicates the 
background level of the assay from naïve MDBK cells. (C) Naïve MDBK 
cells were transfected with ncp NADLJiv90-ΔS-pac or ncp NADLJiv90-pac 
RNA and then selected with 5 µg/ml of puromycin. Both ncp NADLJiv90-
ΔS-pac selected (closed and open triangles) and ncp NADLJiv90-pac 
selected cells (closed and open squares) were electroporated with either ncp 
NADLJiv90-ΔS-luc RNA (closed triangles and squares) or ncp NADLJiv90-
ΔS-luc-pol- RNA (open triangles and squares). Naïve cells (closed and open 
circles) were also electroporated with ncp NADLJiv90-ΔS-luc RNA (closed 
circles) or ncp NADLJiv90-ΔS-luc-pol- RNA (open circles). After incubation 























that detectable RNA replication had not taken place at this early time point. 
Transfection of either ncp replicon into ncp NADLJiv90--infected MDBK 
cells resulted in similar luciferase levels at the 6 h time point (Fig. 4.6B, 
closed and open squares). Therefore, in ncp NADLJiv90--infected MDBK 
cells, transfected ncp NADLJiv90-∆S-luc viral RNA can be translated as 
efficiently as in uninfected cells.  
After 6 h, the luciferase activity in naïve MDBK cells transfected with 
ncp NADLJiv90-∆S-luc-pol- RNA gradually decreased over time (Fig. 4.6B, 
open circles). In contrast, the luciferase activity from naïve cells transfected 
with ncp NADLJiv90-∆S-luc RNA dramatically increased at 16 h post 
transfection, and maintained this activity until the final time point at 120 h 
post transfection (Fig. 4.6B, solid circles). In contrast, in ncp NADLJiv90--
infected MDBK cells, both initial activities decreased over time similarly to 
naïve MDBK cells transfected with ncp NADLJiv90-∆S-luc-pol- RNA (Fig. 
4.6B, open circles). Therefore, in ncp NADLJiv90--infected MDBK cells 
viral RNA can be translated, but this RNA fails to replicate. These results 
demonstrate a second block at the level of BVDV RNA replication. The fact 
that there is no amplification of luciferase expression from the pol- genome 
after transfection of ncp NADLJiv90--infected cells indicated that lethal 
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mutations in the BVDV RdRp, NS5B, could not be trans-complemented, 
consistent with previous results (72). 
To examine if the BVDV structural proteins were required for 
superinfection exclusion at the level of RNA replication, subgenomic ncp 
NADLJiv90-∆S-pac and full-length ncp NADLJiv90-pac selected cells were 
transfected with NADLJiv90-∆S-luc (Fig. 4.6C, solid triangles) or 
NADLJiv90-∆S-luc-pol- (Fig. 4.6C, open triangles). In both cases, the 
luciferase activity decreased over time, and mirrored that of ncp 
NADLJiv90-pac selected cells transfected with the luc replicons (Fig. 4.6C, 
solid and open squares). These results show that expression of the BVDV 
structural proteins is not required for exclusion at the level of viral RNA 
replication. 
 
Level of RNA replication correlates with the extent of superinfection 
exclusion 
 
 A possible factor in the block at RNA replication could be the level of 
RNA replication in the infected cell. This hypothesis was supported by the 
observation that when puromycin-selected cells infected with ncp 
NADLJiv90-pac were superinfected with cp NADL at various time points 
post primary infection, the increase in cp NADL titer over time on the 
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persistently infected cells directly correlated with a decrease in the ncp 
NADLJiv90-pac titer (Fig. 4.3B).  
To further examine this possible correlation, MDBK cell lines 
supporting different levels of viral RNA replication were generated by 
transfecting puromycin selectable replicons lacking the structural region to 
exclude structural protein effects. Since RNA replication of cp NADL has 
been shown to be higher than that of ncp NADLJiv90- (143), both cp and 
ncp replicons were used. Naïve MDBK cells were transfected with either 
ncp NADLJiv90-ΔS-pac or cp NADLΔS-pac viral RNAs and yielded 
puromycin resistant colonies that were picked and expanded into cell lines. 
As might be expected from previous work (168), the replicons within clones 
Cl.2, Cl.11 and Cl.10 were sequenced and found to contain adaptive 
mutations in the NS4B-5A region allowing persistent ncp replication. Some 
of these mutations have been previously characterized (168); others are the 
subject of ongoing work (M. Paulson, personal communication).  Metabolic 
labeling of viral RNA using [32P] orthophosphate showed the relatively low 
level of viral RNA replication in Cl.2 (<5%), harboring the ncp NADLJiv90-
∆S-pac replicon, and higher levels in Cl.10 (50%), and Cl.11 (100%), 







Fig. 4.7 The level of primary viral RNA replication correlates with the 
degree of superinfection exclusion at viral RNA replication. (A) Cell 
clones harboring different levels of BVDV RNA replication were generated 
by transfection of naïve MDBK cells with ncp NADLJiv90-ΔS-pac or cp 
NADLΔS-pac RNAs and selection with puromycin. Cl.2 was derived from 
ncp NADLJiv90-ΔS-pac selected cells and Cl.10 and Cl.11 were derived 
from cp NADLΔS-pac selected cells. The three cell clones were 
metabolically labeled for 6 h with [32P] orthophosphate in the presence of 
dactinomycin. The viral RNAs were analyzed by gel electrophoresis and 
visualized by autoradiography. Labeled viral RNA was quantified by 
phosphoimage analysis. The relative levels of RNA replication are expressed 
in the bar graph as percent of replication in Cl.11, set at 100%. (B) Naïve 
MDBK cells (solid bar), Cl.2 (gray bar), Cl.10 (patterned bar), and Cl.11 
(open bar) were infected with cp NADL. At a given time point, culture 
supernatants were collected and used to determine the virus titer. The extent 
of CPE caused by cp NADL viral replication was estimated under light 
microscopy and indicated by +/-. ∗ represents the absence of attached viable 

























The cell clones were infected with cp NADL and observed for the 
extent of CPE and virus yield. At 24 h post transfection, maximum virus 
titer and clear CPE were observed in naïve MDBK cells (Fig. 4.7B, solid 
bar). In contrast, Cl.2 (Fig. 4.7B, gray bar) and Cl.10 (Fig. 4.7B, patterned 
bar) only displayed extensive CPE and reached maximum titer by 48 h post 
transfection. Cl.11, which had the highest level of ncp BVDV RNA 
replication, was protected from significant CPE until 72 h post transfection 
(Fig. 4.7B, open bar). Therefore, the level of ncp BVDV primary RNA 
replication strongly correlates with the extent of superinfection exclusion at 
the RNA replication level. An additional experiment supporting this 
hypothesis is described below (Section 4.3). 
 
4.3 Additional studies of BVDV superinfection exclusion 
BVDV superinfection exclusion is transient and lost upon passaging 
To further examine the observation that superinfection exclusion may 
be lost during persistent infection, naïve MDBK cells were infected with ncp 
NADLJiv90- and passaged every 2-3 d. At each passage, the ncp 
NADLJiv90--infected cells were superinfected with cp NADL and 
monitored for the ability to undergo CPE.  
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 At passage 0 neither CPE nor visible plaques (Fig. 4.8A and data not 
shown) were found in the ncp NADLJiv90--infected cells upon 
superinfection with cp NADL. In contrast, upon superinfection of passage 1 
cells, persistently infected for 3 d, major CPE and visible plaques were 
observed (Fig. 4.8A and data not shown). There was, however, an 
approximately 6-fold decrease in titer compared to cp NADL infection of 
naïve P1 cells (Fig. 4.8B). The extent of CPE and size of the plaques were 
also diminished compared to infection of the naïve P1 cells (Fig. 4.8A and 
data not shown). Superinfection of additional passages of persistently 
infected cells did not result in further changes to cp NADL titer, plaque size 
or the extent of CPE (Fig. 4.8B and data not shown). Thus, while 
persistently infected cells quickly lost the majority of the superinfection 
exclusion phenotype, their infectability was not fully restored even out to 
passage 20 and greater (data not shown). Nonetheless, the ability to 
efficiently exclude a superinfecting virus is primarily a transient phenotype 
associated with acutely infected cells.  
Although it had been shown that the loss of superinfection exclusion 
was most likely not due to a mixed population of cells with only some 
infected by ncp NADLJiv90- (Section 4.2), to rigorously rule out this 














Fig. 4.8 MDBK cells persistently infected with ncp NADLJiv90- are not 
protected from cp NADL-induced CPE. (A) MDBK cells were infected 
with ncp NADLJiv90-. At 0.5 and 3 d.p.i.  the cells were superinfected with 
cp NADL or mock-superinfected as indicated above each column of plates. 
Naïve cells were also infected or mock-infected for comparison. The cells 
were incubated in liquid media for 3 d at which time they were fixed and 
stained with crystal violet to visualize live cells surviving CPE. (B) ncp 
NADLJiv90--infected and uninfected cells were maintained by passaging for 
a period of 13 d. Every 2-3 d, the cells were superinfected with cp NADL. 
Naïve cells were maintained over the same time period and infected in 
parallel. After superinfection, the cells were grown under overlaid agarose 
for 3 d and then fixed and stained with crystal violet. Plaques were 
enumerated and cp NADL titer on naïve cells or ncp NADLJiv90- infected 
cells was expressed as pfu/ml.   
Time postinfection (d) 
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passage by flow cytometry using a BVDV α-NS3 antibody. Over a period of 
5 passages, the majority of cells, 75.1 ± 13.0%, remained positive for BVDV 
antigen, although the ability to exclude superinfecting cp NADL was lost 
after 3 d of infection (passage 1) when at least 91% of cells were NS3 
positive.  
I also examined whether cells persistently infected with ncp BVDV 
lose the ability to exclude superinfecting ncp BVDV as well as cp BVDV. 
Persistently infected MDBK cells were infected with ncp NADLJiv90-luc 
every 2-3 d over a period of 5 passages. At 24 h post superinfection, the cells 
were harvested to assay for luciferase activity. Although a small increase in 
luciferase activity was observed after superinfection of passage 2-5 
persistently infected cells, the average luciferase activity on the persistently 
infected cells was only 0.69 ± 1.2% of that on the naïve cells, and never rose 
to more than 3% of the naïve cell luciferase activity (data not shown). 
Therefore, cells persistently infected with ncp BVDV remain efficient at 








Decreased RNA levels during persistent ncp BVDV infection render cells 
susceptible to cp BVDV superinfection 
 
To complement the experiments described in Section 4.2 regarding 
the level of BVDV RNA replication and its correlation with the degree of 
exclusion, I also looked directly at RNA levels in persistently infected cells. 
As superinfection exclusion of cp BVDV disappeared in persistently 
infected cells by approximately 3 d.p.i., the appearance of high titers of cp 
NADL correlated with a 6-fold decrease in ncp NADLJiv90- RNA levels as 
quantified by real-time quantitative RT-PCR (Fig. 4.9).  In later passages the 
level of ncp NADLJiv90- RNA remained relatively constant, as did the titer 
of cp NADL on the persistently infected cell monolayers (Fig. 4.9). Hence, 
primary viral RNA levels decrease during persistent ncp BVDV infection 














Fig. 4.9 The loss of superinfection exclusion in BVDV persistently 
infected cells correlates with a decrease in primary viral RNA 
replication. ncp NADLJiv90--infected cells were maintained by passaging 
for a period of 13 d. Every 2-3 d, the cells were superinfected with cp NADL 
and titers were determined by plaque assay as indicated on the left y-axis. 
The ncp NADLJiv90--infected cells were also analyzed for levels of ncp 
NADLJiv90- RNA at each time point. Total cellular RNA was isolated and 
BVDV-specific RNA was quantified using real-time quantitative RT-PCR. 
The relative levels of ncp NADLJiv90- RNA, indicated on the right y-axis, 
are expressed as the ratio of copies of BVDV RNA to copies of bovine β-
actin RNA. 
Time postinfection (d) 
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4.4 HCV superinfection exclusion 
Superinfection exclusion in HCVcc-infected and replicon-containing Huh-
7.5 cells 
 
 To determine if previous infection with HCV renders cells resistant to 
secondary HCV infection, Huh-7.5 cells were infected with J6/JFH genotype 
2a chimeric virus (MOI 0.01) (123). At 4 d.p.i., when approximately 77% of 
cells stained positive for NS5A antigen (data not shown), the J6/JFH-acutely 
infected cells, in parallel with naïve Huh-7.5 cells, were challenged with the 
HCVcc Renilla luciferase reporter virus FL-J6/JFH-5’C19Rluc2AUbi 
(HCVcc-Rluc) (Fig. 4.10) (198). FL-J6/JFH-5’C19Rluc2AUbi encodes the 
first 19 residues of the HCV C protein fused to the N-terminus of Renilla 
luciferase (Rluc). The C-terminus of Rluc is fused to a 17-residue fragment 
from the self-cleaving foot and mouth disease virus 2A protein (2A), a 
ubiquitin monomer (Ubi) sequence, and finally the complete HCV 
polyprotein. Together, 2A and Ubi mediate removal of Rluc from the HCV 
polyprotein and generate the native N terminus of the HCV C protein.  
Luciferase activity resulting from HCVcc-Rluc superinfection of J6/JFH-
infected cells was <10% of the Huh-7.5 luciferase signal, suggesting that 














Fig. 4.10 Scheme for analysis of HCV superinfection exclusion. (A) 
Schematic of HCV and FL-J6/JFH-5’C19Rluc2AUbi (HCVcc-Rluc) 
genomes. The 5’ NTR contains an internal ribosome entry site (IRES), 
which allows translation of the HCV polyprotein containing structural (C, 
E1, E2) and nonstructural proteins (p7, NS2, NS4A, NS4B, NS5A, and 
NS5B). FL-J6/JFH-5’C19Rluc2AUbi is a full-length HCV genome encoding 
the Renilla luciferase (Rluc), a foot and mouth disease virus (FMDV) 2A 
sequence (2A), and a ubiquitin monomer sequence (Ubi).  The N-terminus 
of Rluc is fused to the first 19 residues of the HCV C protein. (B) Huh-7.5 
cells were infected with HCVcc. After 4 d, these cells were superinfected 






















Fig. 4.11 Cells harboring HCV do not support HCVcc superinfection. 
(A) Huh-7.5 cells were infected with J6/JFH HCVcc and maintained in 
parallel with naïve cells. At 4 d.p.i., when approximately 77% of cells were 
NS5A positive, J6/JFH-acutely infected and naïve cells were superinfected 
with HCVcc-Rluc. Each bar, expressed as the percentage of the Huh-7.5 
RLU, is the average value of triplicate wells; error bars show the standard 
deviations. RLU, relative light units. (B) Huh-7.5 and HCV full-length or 
subgenomic replicon-containing cells were infected with HCVcc-Rluc. 
Luciferase activity was measured at 24 h.p.i. Values, expressed as the 
percentage of Huh-7.5 RLU, are the combined data from two independent 
experiments done in triplicate; error bars represent the standard errors of the 
means. (C) Huh-7.5 and HCV replicon cells were infected with VSV and 
overlayed with agarose. After 16 h, cells were fixed with formaldehyde and 
stained with crystal violet to visualize plaques. Each bar is the mean titer 




 To determine if superinfection exclusion occurs across genotypes and 
in cells harboring long-term, persistent HCV replication, I generated HCV 
genotype 1a, 1b, and 2a full-length replicon-bearing cell populations. The 
bicistronic RNAs, H-FLneo (genotype 1a, H77), Con1-FLneo (genotype 1b, 
Con1), and J6/JFH-FLneo (genotype 2a, J6/JFH chimera), used to establish 
these replicon cells express the dominant selectable marker neomycin N-
acetyltransferase (neo), which provides resistance to the drug G418 and thus 
allows stable maintenance of cells harboring replicating HCV RNA. The 
expression of neo is driven by the HCV IRES, while the EMCV IRES drives 
translation of the HCV polyprotein in the downstream cistron. 
 Following challenge of H-FLneo, Con1-FLneo, and J6/JFH-FLneo 
cells, as well as Huh-7.5 parental cells with HCVcc-Rluc (MOI 0.01), all of 
the replicon-containing cells were able to efficiently exclude HCVcc, 
yielding <10% of the luciferase activity of infected Huh-7.5 cells (Fig. 
4.11B). This result indicates that cells harboring HCV genotypes 1a, 1b, or 
2a, exhibit superinfection exclusion against genotype 2a HCVcc, similar to 
that observed in cells acutely infected with J6/JFH (Fig. 4.11A). To rule out 
that resistance to HCV infection was due to expression of the neo resistance 
gene by the HCV replicons, I challenged Huh-7.5 cells, which had been 
transiently transfected with a plasmid expressing neo, with HCVcc-Rluc. 
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Luciferase activity from the transfected cells was >80% of naïve Huh-7.5 
cells, despite similar levels of NPTII expression compared to the HCV 
replicon-containing cells (data not shown). 
 To establish whether expression of the HCV structural-NS2 region 
was required for superinfection exclusion, I challenged Huh-7.5 cell 
populations selected for stable maintenance of H-SGneo, Con1-SGneo, or 
JFH-SGneo RNAs, the subgenomic counterparts of the full-length genomes 
described above. These genomes express neo and HCV NS3-NS5B via the 
HCV IRES and EMCV IRES, respectively. Similar to results observed with 
the full-length replicon cells, luciferase activity after infection of the HCV 
subgenomic replicon cell populations with HCVcc-Rluc was reduced to 
<15% compared to naïve Huh-7.5 cells (Fig. 4.11B).  
 Infection of replicon-containing cells with VSV yielded titers that 
were comparable to those observed on Huh-7.5 cells (Fig. 4.11C). This 
excludes the possibility that the observed HCVcc superinfection exclusion 
was due to the induction of a non-specific antiviral state.   
 
Treatment with BILN 2061 restores HCV permissiveness 
I treated the H-SGneo, Con1-SGneo, and JFH-SGneo replicon cells 
with the HCV-specific protease inhibitor BILN 2061 and subsequently 
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challenged with HCVcc-Rluc. At 4 d post treatment, HCVcc permissiveness 
was partially restored in H-SGneo, Con1-SGneo, and JFH-SGneo cells that 
had been treated with BILN 2061, as RLU values from these cells, and not 
from DMSO-treated cells, were at least 50% of Huh-7.5 control cells (Fig. 
4.12A). The increase in HCVcc permissiveness in BILN 2061-treated cells 
coincided with an approximate 100-fold decrease in HCV RNA levels, 
compared to the DMSO-treated cells (Fig. 4.12B). By 9 d of BILN 2061 
treatment, viral RNA levels had decreased further and the cells became fully 
permissive for HCVcc infection. A slight but unexpected decrease in 
luciferase activity was observed in BILN 2061-treated Huh-7.5 cells at the 
later time points. This was observed in several repetitions of the experiment 
(data not shown), suggesting that prolonged BILN 2061 treatment may 
create a cellular environment less favorable for HCV replication or select a 
subpopulation of less permissive cells. In any case, the dramatic increase in 
HCVcc permissiveness observed in BILN 2061-treated replicon cells 
indicates that superinfection exclusion requires the continuing presence of 
HCV RNA and/or proteins and is readily reversible by treatment with 





Fig. 4.12 HCV subgenomic replicon cells treated with an HCV-specific 
protease inhibitor become permissive for HCVcc infection. (A) Huh-7.5, 
JFH-SGneo, Con1-SGneo, and H-SGneo cells were treated with BILN 2061 
or DMSO in the absence of G418 for 4 or 9 d. BILN 2061 (white and gray 
bars) or DMSO (black bars) -treated cells were infected with HCVcc-Rluc, 
in the absence of inhibitor, and samples were harvested for luciferase assays 
at 24 h.p.i. Black bars (DMSO-treated cells) represent the average RLU 
value over days 4 and 9 for each DMSO-treated cell population, compared to 
Huh-7.5 cells. RLU values from BILN 2061-treated cells (Gray and white 
bars) on day 4 or 9 are expressed as the percentage of the DMSO-treated 
Huh-7.5 RLU on day 4 or 9, respectively. Each bar is the average value of 
triplicate wells; error bars show the standard deviations. The data shown is 
representative of at least 2 independent experiments. (B) HCV RNA levels 
in DMSO (black bars) or BILN 2061-treated JFH-SGneo, Con1-SGneo, and 
H-SGneo replicon-containing cells at 4 (gray bars) or 9 d (white bars) post 
treatment were determined by real-time quantitative RT-PCR. Black bars 
(DMSO-treated cells) represent the average RNA level over days 4 and 9 for 






















Superinfection exclusion occurs downstream of viral entry 
Given that superinfection exclusion occurs at both entry and 
replication for BVDV [(119) and Sections 4.2, 4.3], I used lentiviral 
pseudoparticles bearing HCV glycoproteins (HCVpp) to examine HCV 
entry in acutely infected or stable replicon cell populations (Fig. 4.13). HCV 
glycoprotein-mediated HCVpp entry was monitored via expression of 
luciferase from the encapsidated HIV RNA genome (HCVpp-Luc) (13, 85).  
J6/JFH-acutely infected cells (4 d.p.i., 77% HCV NS5A positive; Fig. 
4.11A) exhibited similar luciferase activity as naïve Huh-7.5 cells when 
infected with HCVpp-Luc bearing J6 glycoproteins (Fig. 4.14A). This 
suggested a block downstream of entry given the resistance of this cell 
population to HCVcc.  
 Full-length and subgenomic HCV replicon-containing cells were also 
challenged with HCVpp-Luc bearing J6 or H77 glycoproteins. With the 
exception of cells harboring the stable J6/JFH-FLneo replicon, all of the 
replicon-containing cells were fully permissive for HCVpp (Fig. 4.14B), 
suggesting that the dominant mechanism(s) of HCVcc exclusion in these 
selected cell populations was also post-entry.  
 Unexpectedly, HCVpp-expressed luciferase activity in the stable 













Fig. 4.13 The HCVpp system. 293T cells are cotransfected with an HIV-1 
provirus expressing a luciferase or GFP reporter, a Gag-pol expression 
construct, and an HCV E1-E2 expression construct. HCVpp, secreted into 
the supernatants of the transfected cells, harbor an HIV-1 nucleocapsid 
expressing the reporter gene and HCV E1-E2 glycoproteins on their surface. 
HCVpp can be used to infect target cells, such as Huh-7.5, and give rise to 






Fig. 4.14 J6/JFH-acutely infected cells, but not cells harboring a stable 
J6/JFH-FLneo replicon, are permissive for HCVpp infection. (A) Huh-
7.5 cells were infected with J6/JFH HCVcc and maintained in parallel with 
naïve cells. At 4 d.p.i., when approximately 77% of cells were NS5A 
positive, J6/JFH-acutely infected and naïve cells were superinfected with 
HCVpp-Luc bearing strain J6 glycoproteins. Each bar, expressed as the 
percentage of the Huh-7.5 RLU, is the average value of triplicate wells; error 
bars show the standard deviations. (B) Huh-7.5 and HCV full-length or 
subgenomic replicon-containing cells were infected with HCVpp-Luc 
bearing HCV genotype 1a, strain H77 (black bars) or genotype 2a, strain J6 
(white bars) glycoproteins or with VSVGpp-Luc. Luciferase activity was 
measured at 72 h.p.i. HCVpp-Luc RLU were normalized to VSVGpp-Luc 
RLU and expressed as the percentage of the Huh-7.5 cell RLU. Each bar is 
the combined data from at least two independent experiments done in 



















(H77 HCVpp) compared to control Huh-7.5 cells, in contrast to cells acutely 
infected with J6/JFH, which were fully permissive to HCVpp (Fig. 4.14A). 
These data suggest that in cells selected for long-term, persistent J6/JFH-
FLneo replication, there is an additional block at the level of entry. I address 
this surprising observation in more detail below.  
 
Examination of the post-entry superinfection block 
To further define the superinfection block, I determined whether 
translation of incoming HCV RNA was inhibited. To monitor translation in 
the absence of viral replication, JFH-SGneo replicon and parental Huh-7.5 
cells were infected with HCVcc-Rluc in the presence of 2’-C-
methyladenosine a nucleoside inhibitor of the NS5B RNA-dependent RNA 
polymerase (31). 2’-C-methyladenosine was used at a 50-fold excess over 
the EC50 reported for HCV genotype 2a (123) and I confirmed that HCV 
RNA levels in HCVcc-infected Huh-7.5 and JFH-SGneo cells declined over 
the 24 h time course (data not shown).  
 In the absence of 2’-C-methyladenosine, luciferase activity in 
HCVcc-infected Huh-7.5 cells steadily increased and by 24 h was more than 
10-fold greater than the level found in JFH-SGneo replicon cells (Fig. 
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4.15A). When 2’-C-methyladenosine was present during HCVcc-Rluc 
infection, luciferase activity was maximal at 6 h.p.i. and then decreased over 
24 h in both Huh-7.5 and JFH-SGneo cells (Fig. 4.15B). During this time, 
luciferase activity was equivalent and even slightly greater in JFH-SGneo 
cells compared to Huh-7.5 cells (Fig. 4.15B), suggesting that entry, 
uncoating and primary translation were unaffected by the presence of the 
HCV replicon. Similar levels of luciferase activity were also observed after 
transfection of JFH-SGneo cells and Huh-7.5 cells with a polymerase 
defective luciferase reporter HCV RNA (data not shown). In addition, I 
compared HCVcc-Rluc primary translation in BILN 2061-cured JFH-SGneo 
cells to untreated JFH-SGneo cells. Similar to what I had observed above in 
the presence of 2’-C-methyladenosine, the two cell types had similar HCV 
translation capacities (Fig. 4.15C). Moreover, I also found that the BILN 
2061-cured and untreated JFH-SGneo cells supported similar levels of 
translation after infection with a temperature-sensitive Sindbis mutant, 
Toto1101/Luc:ts110 (20), at the nonpermissive temperature, which allows 
translation, but is blocked for RNA replication (data not shown). Thus, these 
data indicate that the superinfection block in JFH-SGneo cells lies 















Fig. 4.15 JFH-SGneo cells exhibit a post-entry superinfection block. (A) 
Huh-7.5 and JFH-SGneo cells were infected with HCVcc-Rluc. At each time 
point, luciferase activity was determined from triplicate wells and 
normalized to the average cellular ATP content for each cell type at that time 
point. Each bar is the average value of triplicate wells; error bars show 
standard deviations. (B and C) Huh-7.5 (B) or BILN 2061-cured JFH-SGneo 
(C) and JFH-SGneo cells were infected with HCVcc-Rluc in the presence of 
2’C-methyladenosine. At each time point, luciferase activity was determined 
from triplicate wells and normalized to the average cellular ATP content for 
each cell type at that time point. Each bar is the average value of triplicate 
wells; error bars show standard deviations. 
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An additional defect in J6/JFH-FLneo selected cells 
 I further investigated the surprising observation that HCVpp entry was 
blocked in the J6/JFH-FLneo cell population (Fig. 4.14B). A possible 
mechanism for restriction at the level of entry is down regulation or 
interference with an essential viral receptor or coreceptor. The tetraspanin 
CD81, originally identified as an HCV E2 binding protein (166), is an 
essential HCV coreceptor required for entry of HCVpp and HCVcc 
(reviewed in 12, 38). I examined CD81 surface expression on J6/JFH-
FLneo, JFH-SGneo, and Huh-7.5 parental cell lines by flow cytometry. 
While JFH-SGneo and Huh-7.5 cells expressed similar levels of CD81 at the 
cell surface (Fig. 4.16A), levels were greatly reduced on the J6/JFH-FLneo 
cells (Fig. 4.16B). In addition, staining of permeabilized cells, western blot 
analysis of whole cell lysates, and real-time quantitative RT-PCR revealed 
that total cellular CD81 protein and RNA levels were also decreased in 
J6/JFH-FLneo cells compared to Huh-7.5 cells (Fig. 4.16C, D, E). In 
contrast, CD81 expression on the surface of HCV genotype 1a and 1b full-
length and subgenomic replicon cell populations, as well as on cells acutely 
infected with J6/JFH was also examined and found to be similar to parental 
Huh-7.5 cells (data not shown), in keeping with the previous observation 







Fig. 4.16 Stable J6/JFH-FLneo replicon cells have decreased CD81 
protein and RNA levels. (A and B) Huh-7.5 (tinted, blue curve), JFH-
SGneo (A, thick, red line), and J6/JFH-FLneo (B, thick, orange line) cells 
were surface stained for CD81 and analyzed by flow cytometry. (C) 
Permeabilized Huh-7.5 (tinted, blue curve) and J6/JFH-FLneo (thick, orange 
line) cells were stained for total cell CD81 protein expression and analyzed 
by flow cytometry. Thin lines indicate the IgG isotype controls. (D) Western 
blot for CD81 or actin protein expression in lysates from J6/JFH-FLneo, 
Huh-7.5, and JFH-SGneo cells. (E) CD81 RNA was amplified using real-
time quantitative RT-PCR from total RNA derived from Huh-7.5, J6/JFH-
FLneo, and JFH-SGneo cells. Values were normalized to GAPDH RNA 
levels for each sample and are expressed as relative levels compared to Huh-
7.5 cells. Values are the combined data from 3 independent experiments 




























































































Additionally, levels of scavenger receptor BI, another proposed HCV entry 
factor (15, 176), were similar to Huh-7.5 parental cells in all of the replicon 
cells tested, including cells harboring the stable J6/JFH-FLneo replicon and 
J6/JFH-acutely infected cells (data not shown). 
 I next determined if reduced CD81 on J6/JFH-FLneo-containing cells 
was responsible for the entry defect by restoring CD81 expression. 
Transduction of the J6/JFH-FLneo cells with the lentiviral vector TRIP-
CD81 (220) efficiently restored CD81 expression at the cell surface and 
permissiveness to HCVpp-Luc to a level of 150% of control Huh-7.5 cells 
(Fig. 4.17A and B, J6/JFH-FLneo-CD81). In contrast, J6/JFH-FLneo cells 
transduced with a lentivirus expressing the tetraspanin CD9 (TRIP-CD9), 
which does not bind E2 or support HCV entry, was less than 3% of Huh-7.5 
cells (Fig. 4.17B). Thus, over-expression of CD81 rescues infection by 
HCVpp, indicating that reduced CD81 surface expression is responsible for 
the entry defect observed in J6/JFH-FLneo cells.  
 It was unclear if RNA replication and HCV protein expression by the 
J6/JFH-FLneo replicon was somehow down regulating CD81 mRNA and 
protein or whether G418 selection of the replicon-containing population was 
favoring cells with low or absent CD81. I first examined whether J6/JFH-

















Fig. 4.17 Ectopic expression of CD81 renders stable J6/JFH-FLneo 
replicon cells permissive for HCVpp infection. (A) Transduction of 
J6/JFH-FLneo cells with TRIP-CD81 restores CD81 expression. J6/JFH-
FLneo (orange line), J6/JFH-FLneo-CD81 (green line), and Huh-7.5 (tinted 
curve) cells were surface stained for CD81 and analyzed by flow cytometry. 
Thin lines indicate the IgG isotype controls. (B) Huh-7.5, J6/JFH-FLneo, 
J6/JFH-FLneo-CD81, and J6/JFH-FLneo-CD9 cells, transduced with TRIP-
CD9, were infected with HCVpp-Luc (genotype 1a, strain H77) or 
VSVGpp-Luc and luciferase activity was measured at 72 h.p.i. HCVpp-Luc 
RLU were normalized to VSVGpp-Luc RLU. Each bar is the average value 

























treatment with BILN 2061. Cells were treated with BILN 2061 at 20-50x the 
reported EC50 (123) over a period of 23 d in the absence of G418. Cell 
surface expression of CD81 and HCVpp-Luc permissiveness were assessed 
after 4 d, 9 d and 23 d of treatment.  At 4 d, J6/JFH-FLneo cells remained 
resistant to HCVpp-Luc infection despite a 100-fold reduction in HCV RNA 
levels (Fig. 4.18A and data not shown).  By 9 d, when HCV RNA levels had 
fallen 1000-fold, a small increase in luciferase signal was observed. After 23 
d of BILN 2061 treatment, HCV RNA levels had fallen to background levels 
(< 0.005 RNAs/cell) and the cells became permissive for HCVpp-Luc 
infection with a concomitant increase in CD81 surface expression (Fig. 
4.18B).  These results indicate that permissive cells expressing CD81 can 
emerge after curing the population of replicating J6/JFH-FLneo. 
 I also examined this phenomenon during long-term J6/JFH infection 
of Huh-7.5 cells. Cells were infected at an MOI of approximately 0.3 
(infected population) and maintained in parallel with naïve cells (naïve 
population) (Fig. 4.19). Both populations were analyzed for CD81 surface 
expression, NS5A expression, and permissiveness to HCVpp-GFP or as a 
control, VSVGpp-GFP. Pseudoparticle-challenged cells were harvested at 48 
h.p.i., stained for NS5A, and analyzed by flow cytometry. The percentage of 
















Fig. 4.18 BILN 2061 treated J6/JFH-FLneo replicon cells have increased 
CD81 surface expression and are permissive for HCVpp infection. (A) 
J6/JFH-FLneo and Huh-7.5 parental cells were treated with BILN 2061 or 
DMSO for a period of 23d. At 4 (black bars), 9 (gray bars), and 23 d (white 
bars) post treatment, DMSO and BILN 2061-treated cells were challenged 
with HCVpp-Luc or VSVGpp-Luc. Luciferase activity was measured at 72 
h.p.i. and HCVpp-Luc RLU were normalized to VSVGpp-Luc RLU. Each 
bar, expressed as the percentage of DMSO-treated Huh-7.5 RLU, is the 
average value of triplicate wells; error bars show the standard deviations. (B) 
At 23 d post treatment BILN 2061 (red line) and DMSO (orange line)-
treated J6/JFH-FLneo and Huh-7.5 (tinted, blue curve) cells were 







































Fig. 4.19 Time course of superinfection with HCVpp. Huh-7.5 cells were 
infected (infected population) or mock-infected (naïve population) with 
HCVcc on day 0 and the populations were maintained in parallel. At 1, 2, 3, 
4, 6, and 8 d.p.i. the infected and naïve populations were superinfected with 
HCVpp expressing GFP (HCVpp-GFP). The percent of cells that had 
become HCVcc infected, HCVpp infected, or HCVcc-HCVpp coinfected 
was monitored by flow cytometry over the time course.  
HCVcc 
infection 
(low MOI) HCVpp-GFP infection 
Day: 0        1        2        3        4        6        8  
Monitor by flow cytometry: 
% HCVcc infected (NS5A+) 
% HCVpp infected (GFP+) 









NS5A negative, was normalized to the percentage of GFP positive cells 
from the VSVGpp-GFP infection. 
 After 1 d or 2 d, the infected population was fully permissive for 
HCVpp (Fig. 4.20A). Beginning at 3 d and continuing through 8 d, there 
was a decrease in the percentage of GFP positive cells compared to the naïve 
population, which correlated with increasing numbers of NS5A positive 
cells in the J6/JFH-infected population (Fig. 4.20A). However, the vast 
majority of the cells that were HCVpp-susceptible (greater than 80%), were 
also NS5A positive (Fig. 4.20B). This demonstrated that cells productively 
infected with J6/JFH were fully permissive for HCV entry. Regarding 
surface CD81 expression, NS5A positive and negative cells had CD81 
expression comparable to naïve cells early in infection (3 d and 4 d; Fig. 
4.20C). After 6 d, surface CD81 on NS5A positive cells remained 
comparable (70%) to naïve cells. However, CD81 expression on NS5A 
negative cells was greatly reduced (10% of the naïve cell intensity; Fig. 
4.20C). Interestingly, the appearance of this distinct CD81low NS5A negative 
population was coincident with an observed cytopathic effect in the infected 
population (data not shown) and a 65% reduction in HCVpp-GFP 
permissiveness in the infected population (Fig. 4.20A). At 6 d and 8 d, 





Fig. 4.20 J6/JFH-infection of Huh-7.5 cells promotes the emergence of a 
CD81low cell population. Huh-7.5 cells were infected with HCVcc (J6/JFH) 
at an MOI of 0.3 and maintained in parallel with naïve cells (as described in 
Fig. 4.19). (A) At 1, 2, 3, 4, 6, and 8 d.p.i. with J6/JFH, the infected and 
naïve populations were infected with HCVpp-GFP or VSVGpp-GFP. Cells 
were harvested at 48 h.p.i. Cells were stained for NS5A and analyzed by 
flow cytometry for GFP and NS5A expression. The total number of GFP 
positive cells resulting from HCVpp-GFP infection was normalized to the 
total number of GFP positive cells in the VSVGpp-GFP infected samples. 
Values are expressed as the percentage of naïve GFP positive cells. (B) The 
J6/JFH-infected population, which was infected with HCVpp-GFP and 
stained for NS5A in (A), was grouped into NS5A positive and NS5A 
negative cells. GFP expression in NS5A positive (black bars) and NS5A 
negative (white bars) cells was determined and plotted as the percentage of 
the total GFP positive cells. (C) The J6/JFH-infected and naïve populations 
were analyzed for CD81 surface expression and NS5A expression using 
immunostaining and flow cytometry at 3, 4, 6, 8, and 17 d.p.i. with J6/JFH. 
Cells were gated on NS5A positive (green line) or NS5A negative (blue line) 
cells and CD81 expression was compared to the naïve population (red line). 
The d.p.i. and percentage of NS5A positive cells at each time point are 









































































































































of the J6/JFH-infected cell population. However, this NS5A negative 
fraction persisted and increased in frequency to >70% by the final time 
point, day 17. Notably, the modest decrease in CD81 expression in NS5A 
positive cells at 6 d and 8 d was more apparent by 17 d (Fig. 4.20C). Unlike 
the J6/JFH-FLneo population, which had been selected with G418 and 
undergone multiple passages, I saw no decrease in CD81 RNA levels during 
the 17 d J6/JFH infection (data not shown). These data suggest that J6/JFH 
infection selects against cells expressing high levels of CD81, possibly due 
to a cytopathic effect or retarded growth kinetics, leaving CD81low, 
uninfected cells to emerge. This scenario may also explain the low levels of 
CD81 and HCVpp resistance that I observed in G418 selected cell 
populations harboring the J6/JFH-FLneo replicon. 
 
4.5 Discussion 
In this chapter, the mechanisms of BVDV and HCV superinfection 
exclusion were examined. The data presented demonstrate that cells acutely 
infected with BVDV are protected against superinfection with homologous 
BVDV. These cells, however, remain susceptible to a heterologous virus, 
VSV, suggesting a BVDV-specific exclusion. The ability to exclude 
superinfecting BVDV is established quickly, within 30-60 minutes after 
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primary infection, but is transient, as persistently infected, passaged cells are 
not efficiently protected from cp BVDV. The results of this study show that 
BVDV superinfection exclusion is mediated by dual mechanisms – one at 
the level of viral entry and a second at the level of viral RNA replication.  
I have also described and investigated the mechanisms of 
superinfection exclusion in human hepatoma cells infected with HCV [(197) 
and above]. Superinfection exclusion of HCVcc was observed in J6/JFH 
acutely infected cells and in cells containing full-length and subgenomic 
replicons derived from HCV genotypes 1a, 1b, or 2a genomes. Treatment 
with an HCV-specific antiviral agent restored permissiveness in these cells, 
indicating that the superinfection exclusion phenotype was fully reversible 
and that it required the presence of HCV RNA or proteins. I determined that 
the block to superinfection in cells harboring HCV replication was 
downstream from virus entry and translation of the incoming genome RNA, 
possibly at the level of RNA replication. An additional, unexpected defect at 
virus entry was observed in cells harboring a persistent full-length J6/JFH-
FLneo replicon. Further analyses revealed that this block to HCV entry was 
due to the loss of CD81high cells within selected or infected cell populations 
rather than to a classical superinfection exclusion mechanism.  
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The first mechanism of superinfection exclusion in cells acutely 
infected with BVDV is a block at the level of entry. This block was 
dependent upon expression of the BVDV structural proteins. The importance 
of the BVDV structural proteins in superinfection exclusion is supported by 
recent studies by Reimann et al., in which cells constitutively expressing the 
BVDV structural proteins C-E2 cannot be efficiently infected with BVDV 
(170). Our study indicates that expression of BVDV glycoprotein E2 appears 
to play an essential role in the entry block. The importance of E2 in 
superinfection exclusion is also consistent with the description of an MDBK 
cell line expressing E2, called MDBK-E2IRESp7, which was shown to be 
nonpermissive for BVDV infection (76). Moreover, I have demonstrated that 
expression of the E2 ectodomain alone is sufficient to prevent entry of 
superinfecting BVDV (Chapter 3). 
Exclusion at an early stage of viral infection has been shown for a 
variety of viruses. One well-characterized mechanism is down regulation of 
the cell surface receptor after primary viral infection (described above in 
Section 3.3). Exclusion of a homologous virus can also be due to 
interference with receptor-mediated surface binding as shown for respiratory 
syncytial virus (RSV) by using pseudotyped antigenically-related RSV (184, 
185). Furthermore, steps post-binding may be blocked. Multiple 
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mechanisms of VSV superinfection exclusion exist at the level of entry, 
including a reduced rate of endocytic vesicle formation, decreased 
internalization of bound ligands, and competition between virions for coated 
pits (180, 209). Based on our findings, it is possible that the block at BVDV 
entry might be due to a defect in receptor-mediated interactions on the 
plasma membrane, virion internalization, fusion or nucleocapsid uncoating. 
It seems likely, however, considering the data presented in Chapter 3, that 
the block to BVDV entry is downstream from CD46.  
We also demonstrate a second mechanism of BVDV superinfection 
exclusion at the level of viral RNA replication. Transfected viral RNAs, 
although fully competent for translation, were not able to replicate in the ncp 
NADLJiv90--infected MDBK cells. Exclusion of BVDV at the level of viral 
RNA replication did not require expression of the viral structural proteins. 
Instead, the degree of exclusion correlated with the level of primary viral 
RNA replication. For HCV, a block downstream from entry, uncoating, and 
translation of the incoming genome RNA, mediated by the viral 
nonstructural proteins, also exists, but in contrast to BVDV, our data 
indicate that this is the principle mechanism of superinfection exclusion in 
HCV-infected cells. Although it remains possible that a transient block at the 
level of primary translation may exist during acute HCV infection, our data 
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suggest that in JFH-SGneo replicon cells the superinfection block is due to a 
direct effect on a downstream event, most likely at one or more steps in 
RNA replication.   
 Interference at the level of RNA replication has been previously 
examined in the HCV replicon system. HCV replication efficiency was 
inversely correlated with the amount of replicon RNA transfected into Huh-
7 cells (130). This effect was dependent on the presence of the HCV NS3-
NS5B replicase proteins. In another study, replication capacity of a 
transfected replicon was reduced in cells that harbored an existing, 
replicating HCV genome (52). Similarly, in cells acutely infected with 
BVDV, the block to superinfecting virus at the level of replication was 
directly correlated to the level of the primary virus replication [(119) and 
above]. A superinfection block at replication is also consistent with previous 
observations in other viral systems. For example, Sindbis virus ts mutants in 
two different RNA-negative complementation groups failed to exclude 
superinfecting viruses at the nonpermissive temperature although 
complementation could be observed (1, 93), demonstrating that replication 
of the superinfecting virus was blocked after attachment, penetration, and 
translation of the superinfecting viral RNA. These observations suggest that 
viral replication can sequester host factors that are limiting and saturable in 
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the host cell, thereby interfering with superinfecting virus replication. There 
may also be competition for replication sites, which are in specialized 
membrane compartments similar to those observed during classical 
flavivirus RNA replication (33, 36, 37, 207, 208).  
 In the course of the HCV superinfection exclusion study I made the 
surprising observation that G418 selected cells harboring the J6/JFH-FLneo 
replicon have an additional defect in virus entry. J6/JFH-FLneo cells were 
resistant to HCVpp bearing glycoproteins from J6 or H77, whereas cells 
acutely infected with J6/JFH and cells harboring either genotype 1a or 1b 
replicons, and genotype 2a subgenomic replicon bearing cells were fully 
permissive. Given that the defect was specific to selected J6/JFH-FLneo, but 
not subgenomic replicon-containing cells suggested that the phenotype was 
dependent on J6 C-NS2 expression (or an RNA element harbored in this 
region). Further analyses revealed that CD81 down regulation was the 
mechanism responsible for this phenotype. Total and cell surface CD81 
protein and CD81 mRNA levels were dramatically reduced in J6/JFH-FLneo 
cells compared to parental cells. Furthermore, ectopic expression of CD81 
rendered J6/JFH-FLneo cells fully permissive for HCVpp infection.  
 Two possibilities, among others, might explain the low levels of 
CD81 mRNA in J6/JFH-FLneo cells: (1) HCV-dependent down regulation 
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of CD81 expression, (2) a selective advantage for cells with low or absent 
CD81 during G418 selection. Consistent with the latter possibility, 
prolonged J6/JFH infection yielded a cell population that was increasingly 
resistant to HCVpp infection, although NS5A positive cells were readily 
infected with HCVpp. When CD81 surface expression was examined, it 
became evident that a population of CD81low NS5A negative cells had 
emerged within the J6/JFH-infected cell culture, coincident with and 
subsequent to a virus-induced cytopathic effect. The pathway by which 
J6/JFH infection leads to cell death is unknown, but our data indicate that 
expression of CD81 and the HCV J6 C-NS2 region are involved. Although I 
did find some CD81low NS5A positive cells at later stages of J6/JFH 
infection, the absence of CD81 down regulation during acute infection 
suggests that this may be due to inefficient infection of cells with lower 
levels of CD81. Therefore, the main mechanism of this resistance could not 
be attributed to a classical superinfection exclusion block at the level of 
virus entry, where replicating HCV prevents a secondary HCV infection. 
Rather, selection occurs at the population level and resistance is due to an 
emerging population of CD81low cells that are less permissive for HCV 
infection. Recently, similar observations during persistent JFH-1 infection 
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were reported by Zhong et al. (221). Clearly, this phenomenon and its 





















Infection with an enveloped virus requires a fusion event between the 
viral and a cellular membrane.  This event can occur at the cell surface, as 
demonstrated by HIV and herpes simplex virus (HSV), where binding to one 
or more receptors induces conformational changes in the envelope 
glycoprotein allowing membrane fusion at neutral pH. Alternatively, the 
fusion event can occur within an endosomal compartment in the presence of 
low pH (reviewed in 183) as has been previously described for classical 
flaviviruses and alphaviruses (74, 79, 81, 109). 
Previous studies of HCV entry have been based on retroviral 
pseudotypes bearing HCV E1 and E2 glycoproteins (HCVpp) (15, 85). Such 
pseudotypes were shown to undergo pH-dependent entry into Huh-7 cells in 
a CD81-dependent manner and could be neutralized by certain α-E2 
monoclonal antibodies (85, 220). Additional receptors, including SR-BI and 
CLDN1 have also been suggested to have a role in HCV entry (15, 176). As 
described above, using the JFH genotype 2a strain of HCV, it has recently 
become possible to propagate infectious HCV particles in cell culture 
(HCVcc), allowing the study of the complete viral lifecycle, including virus 
entry and fusion events.  
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In this section, I demonstrate that the entry pathways of BVDV and 
HCVcc into their respective target cells, MDBK and Huh-7.5, are pH-
dependent, although both BVDV and HCV virions are acid-resistant, 
suggesting that these two viruses may have a similar mechanism of entry. 
The trigger(s) by which an acid-resistant virus becomes pH-sensitive during 
entry, as well as the role of putative cellular receptors/coreceptors were 
investigated.  
 
5.2 Mechanism of BVDV entry 
BVDV entry is pH-dependent 
To determine if the BVDV entry pathway requires a pH-dependent 
step, I inhibited the acidification of endosomal compartments in MDBK 
cells using bafilomycin A1, an inhibitor of vacuolar type H+-ATPase. As a 
negative control for this experiment, I utilized herpes simplex virus-1 (HSV-
1), a pH-independent virus, which fuses at the plasma membrane (183).  
MDBK cells were pre-treated with a range of concentrations of 
bafilomycin A1 and subsequently infected with ncp NADLJiv90-luc or 
HSV-1 [KOSdluxoriL, (188)]. At all concentrations tested, BVDV-



















Fig. 5.1 BVDV entry is pH-dependent. MDBK cells were pre-treated with 
0, 12, 25, 50 or 100 nM bafilomycin A1 and infected with BVDV 
NADLJiv90-luc or HSV-1 (KOSdluxoriL) in the presence of drug. At 24 
h.p.i. cells were harvested for luciferase assays. Each point is the mean value 






































A1 (Fig. 5.1). A 12 nM bafilomycin A1 treatment had an intermediate effect 
on BVDV infection, while increased concentrations reduced the luciferase 
activity to background levels. In contrast, HSV-1 luciferase activity was 
unaffected by the presence of the inhibitor (Fig. 5.1). These data suggest that 
BVDV entry requires a pH-dependent step.  
 
BVDV infectivity is unaffected by low pH treatment 
Enveloped viruses that are internalized by endocytosis are, in general, 
very sensitive to low pH treatment. Exposure to acidic pH induces a 
conformational change in the envelope glycoproteins, which prematurely 
exposes the fusion peptide and thereby diminishes the viral infectivity.  Such 
a scenario occurs in Sindbis (SIN) virions upon treatment with low pH. To 
determine if BVDV is sensitive to low pH treatment, I treated BVDV virions 
with a pH 5 or 7 buffer at 37 oC, neutralized the pH, and infected MDBK 
cells. Unlike SIN, which was used as a positive control, a pH 5 treatment 
had no effect on BVDV infectivity (Fig. 5.2). These data suggest that unlike 
SIN virions, which are primed to undergo fusion upon exposure to low pH, 
BVDV requires an additional trigger to become acid-sensitive. This 
















Fig. 5.2 BVDV infectivity is acid-resistant. BVDV or SIN was diluted in 
citric acid buffer (15 mM citric acid, 150 µM NaCl) at pH 7 (white bars) or 
pH 5 (black bars) for 10 min at 37 oC. Samples were then neutralized and 
titered on either MDBK (BVDV) or BHK-J (SIN) cells. Values, expressed at 
the percent of pH 7 RLU, are mean titers of duplicate samples titered in 

















































Fig. 5.3 Schematic illustration of entry in the presence of bafilomycin 
A1. Target cells are pretreated with bafilomycin A1 (+Baf) to block the 
normal route of virus entry. Virus is added to the cells at 4 oC to allow 
binding, but prevent virus internalization. After washing to remove unbound 
virus, cells are washed with low pH buffer, mimicking the environment of 
the endosome, to determine if the virus can enter the cell in presence of 
bafilomycin A1. After the pH of the media is neutralized, the infection is 
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Fig. 5.4 Bound BVDV virions cannot enter a bafilomycin A1 treated cell 
upon exposure to low pH. MDBK cells were treated with bafilomycin A1 
(25 nM), then were infected with BVDV at 4 oC for 1 h.  Cells were washed 
to remove unbound virus, then washed with citric acid buffer at pH 7 or 5. 
Cells were incubated in the presence of bafilomycin A1 for 24 h when they 
were harvested for luciferase assays. Luciferase activity from untreated cells 
(-Baf) was expressed as 100 percent. Values are the mean value of duplicate 
wells; error bars show the standard errors of the means. 
 

















not enter a bafilomycin A1-treated cell upon exposure to low pH (Figs. 5.3 
and 5.4). A recent report proposed a role for disulfide bond reshuffling in the 
activation of BVDV virions (109). Although, in our hands, the presence of 
reducing agent in the low pH wash did not enhance BVDV entry into cells 
treated with bafilomycin A1 (Fig. 5.4). 
 
5.3 Mechanism of HCV entry 
 
HCV entry is pH-dependent 
To examine the HCV entry pathway into Huh-7.5 cells, I utilized the 
HCV reporter virus HCVcc-Rluc (Fig. 5.5A). The expression of Rluc from 
HCVcc-Rluc serves as a highly sensitive assay for viral RNA replication 
after infection of permissive cells. To examine the replication kinetics of 
HCVcc-Rluc in Huh-7.5 cells, virus was bound to cells at 4 oC. The cells 
were then shifted to 37 oC for a 48 h period of infection. After a low MOI 
infection (~0.01), a small increase in signal was observed after 8-12 h, 
followed by a logarithmic rise in the luciferase activity between 12 and 24 
h.p.i. (Fig. 5.5B).  
To determine if HCV entry is dependent on a low pH step, I utilized 
bafilomycin A1, concanamycin A, and NH4Cl, agents that prevent 

















Fig. 5.5 Characterization of HCVcc-Rluc. (A) Schematic of HCV and FL-
J6/JFH-5’C19Rluc2AUbi (HCVcc-Rluc) genomes (described fully in Fig. 
4.10A). (B) Huh-7.5 cells were infected with HCVcc-Rluc for 0, 4, 6, 8, 10, 
12, 20, 24, 30, 36, or 48 h. At each time point, cells were harvested and 
luciferase activity determined. Each point is the average value of triplicate 
wells; error bars show the standard deviations. The dashed line indicates the 





I infected Huh-7.5 cells in parallel with SIN or HSV-1, which are well-
characterized, pH-dependent and independent viruses, respectively. SIN 
undergoes receptor-mediated endocytosis followed by fusion in the acidic 
environment of the endosome, while HSV-1 fuses at the plasma membrane 
at neutral pH.  
 Huh-7.5 cells were pretreated with various concentrations of 
bafilomycin A1, and then infected with HCV, SIN, or HSV-1. At all 
concentrations tested, a 3 h pretreatment with bafilomycin A1 reduced HCV 
expressed luciferase activity to nearly background levels (Fig. 5.6A, -3 h), 
while having no effect on HSV-1 infection (Fig. 5.6B, -3 h). SIN infection 
was inhibited in a similar manner to HCV by pretreatment of cells with 
bafilomycin A1 (data not shown). To confirm that the drug was acting at 
viral entry and not at subsequent replication steps, bafilomycin A1 was 
added at 3 h.p.i. with HCV, SIN, or HSV-1, with minimal effects on HCV or 
SIN luciferase activity (Fig. 5.6A, +3 h, and data not shown). As expected, 
HSV-1 was unaffected by the presence of bafilomycin A1 at the 3 h.p.i. time 
point (Fig. 5.6B, +3 h).  
 To determine the time point p.i. when HCV loses sensitivity to 
bafilomycin A1 treatment, I performed a time course of bafilomycin A1 












Fig. 5.6 HCV entry is sensitive to bafilomycin A1. (A) Huh-7.5 cells were 
incubated with bafilomycin A1 (0, 25, 50 or 100 nM) either prior to 
(squares) or at 3 h.p.i. (triangles) with HCVcc-Rluc. Samples were harvested 
for luciferase assays at 24 h.p.i. Each point is the average value of triplicate 
wells; error bars show the standard deviations. The dashed line indicates the 
background level of the assay from naïve Huh-7.5 cells. (B) Huh-7.5 cells 
were incubated with bafilomycin A1 (0, 25, 50 or 100 nM) either prior to 
(squares) or at 3 h.p.i. (triangles) with HSV-1. Samples were harvested for 
luciferase assays at 12 h.p.i. Each point is the average value of triplicate 
wells; error bars show the standard deviations.  (C) Huh-7.5 cells were 
untreated or incubated with bafilomycin A1 prior to (-3 h), at the time of 
infection (-2 h), or at 0, 1, 2, 3, 4, 5, 6 h.p.i. with HCVcc-Rluc. Samples 
were harvested for luciferase assays at 24 h.p.i. Values are expressed as the 
percent of untreated RLU and are the combined data from 2 independent 




to HCV infection (-3 h), at the time of infection at 4 oC (-2 h), after inoculum 
was removed and cells were shifted to 37 oC (0 h), or 1, 2, 3, 4, 5, or 6 h.p.i.  
(Fig. 5.6C). Drug addition at 1 h p.i. or after had little effect on HCV 
luciferase activity, while if bafilomycin A1 was present at time point -3, -2, 
or 0 h, the luciferase signal was nearly eliminated (Fig. 5.6C). These data 
suggest that soon after the temperature shift to 37 oC, bound HCV virions are 
able to enter Huh-7.5 cells, thereby becoming insensitive to bafilomycin A1 
treatment. 
To further confirm that HCV requires a pH-dependent entry step, I 
tested another inhibitor of vacuolar type H+-ATPase, concanamycin A. 
Concanamycin A inhibited HCV and SIN entry into Huh-7.5 cells, but had 
minimal effect on downstream replication events (Fig. 5.7A and data not 
shown). Pre- or post- infection treatment with concanamycin A had no effect 
on HSV-1 infection (Fig. 5.7B). Infection in the presence of NH4Cl, a 
lysosomotropic agent, was also tested for its ability to inhibit HCV entry. 
Pretreatment with 25 mM NH4Cl inhibited HCV (Fig. 5.7C), but similar 
inhibition was also observed when the drug was added at 3 h.p.i. (data not 
shown). This observation was unlike that for SIN, which was inhibited in a 
dose-dependent manner by pretreatment with NH4Cl, but the inhibition was 
















Fig. 5.7 HCV entry is sensitive to concanamycin A and NH4Cl. (A) Huh-
7.5 cells were incubated with concanamycin A (0, 12.5, 25 or 50 nM) prior 
to (squares) or at 3 h.p.i. (triangles) with HCVcc-Rluc. Samples were 
harvested for luciferase assays at 24 h.p.i. The dashed line indicates the 
background level of the assay from naïve Huh-7.5 cells. (B) Huh-7.5 cells 
were incubated with concanamycin A (0, 12.5, 25, or 50 nM) prior to 
(squares) or at 3 h.p.i. (triangles) with HSV-1. Samples were harvested for 
luciferase assays at 12 h.p.i. (C) Huh-7.5 cells were untreated (0 nM) or 
incubated with 25 mM NH4Cl prior to infection with HCVcc-Rluc (black 
bars) or HSV-1 (white bars). Samples were harvested for luciferase assays at 
24 h.p.i. In A, B, and C, each point or bar is the average value of triplicate 
wells; error bars show the standard deviations. 
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shown).  HSV-1 infection was unaffected by the presence of 25 mM NH4Cl, 
indicating that the decrease in HCV luciferase activity for the 3 h.p.i. 
treatment was not likely due to nonspecific or cytotoxic effects of NH4Cl on 
the Huh-7.5 cells (Fig. 5.7C). These data suggest that HCV may require an 
additional low pH step for downstream replication events that is inhibited by 
NH4Cl. Taken together, HCV sensitivity to bafilomycin A1, concanamycin 
A, and NH4Cl demonstrates that HCV entry requires a low pH step.  
 
HCV infectivity is unaffected by low pH treatment 
As stated above for BVDV, a common feature of viruses that enter 
cells by endocytosis is their sensitivity to low pH treatment. To determine if 
HCV infectivity is sensitive to acidic pH, I treated virions with pH 5 or 7 
buffers. After neutralization, the virus was used to infect Huh-7.5 cells. SIN 
virus was again used as a control, being a well-characterized acid-sensitive 
virus that is readily inactivated by low pH treatment. Treatment at pH 5 for 
10 min at 37 oC had minimal effect on HCV infectivity, but reduced SIN 
luciferase activity to less than 1% of the pH 7-value (Fig. 5.8A). The 
observed insensitivity of HCV to low pH treatment is reminiscent of the 
related pestivirus BVDV [(109) and above] and suggests that HCV, as well, 














Fig. 5.8 HCV infectivity is resistant to acidic pH. (A) HCV or SIN was 
diluted in citric acid buffer (15 mM citric acid, 150 mM NaCl) at pH 7 
(white bars) or pH 5 (black bars) for 10 min at 37 oC. Samples were then 
neutralized and used to infect Huh-7.5 cells. Samples were harvested at 24 h 
(SIN) or 48 h (HCV) for luciferase assays. Values, expressed as the percent 
of pH 7 RLU, are the combined data from 2 independent experiments done 
in triplicate; error bars represent the standard errors of the means. (B) Huh-
7.5 cells were treated with bafilomycin A1 (25 nM), then were infected with 
HCV (black bars) or SIN (white bars) at 4 oC for 2 h.  Cells were washed to 
remove unbound virus, then washed with citric acid buffer at pH 7 or 5. 
Cells were incubated in the presence of bafilomycin A1 for 24 h when they 
were harvested for luciferase assays. Luciferase activity from untreated cells 
washed with pH 7-buffer (-Baf/pH 7) was expressed as 100 percent. Values 
are the combined data from 2 independent experiments done in triplicate; 
error bars represent the standard errors of the means.  
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HCV fails to enter bafilomycin A1 treated cells when exposed to low pH  
Many viruses that utilize the acidic environment of the endosome to 
trigger glycoprotein-mediated fusion can be induced to fuse at the plasma 
membrane with a brief low pH treatment (Fig. 5.3). Whereas free virus is 
inactivated, cell bound virus can enter and initiate infection. Using SIN as a 
control, I tested whether HCV bound at the plasma membrane could enter 
when exposed to low pH. Huh-7.5 cells were pretreated with bafilomycin A1 
to prevent productive entry via endosomal acidification. Cells were then 
infected with HCV or SIN at 4 oC. After washing to remove unbound virus, 
the cells were washed with pre-warmed buffer at pH 5 or 7, then incubated 
in the presence of bafilomycin A1 at 37 oC. While there was no increase in 
HCV luciferase activity from samples washed with pH 5, SIN luciferase 
activity increased to nearly 50% of the untreated values in samples that had 
been washed with pH 5 buffer (Fig. 5.8B). Therefore, cell surface bound 
HCV is unable to enter at the plasma membrane under the same conditions 
as SIN. These results suggest that cell bound HCV remains acid-resistant 
and requires an additional trigger for low pH-induced infection.  
In the case of BVDV, the presence of reducing agent in addition to 
low pH has been reported to allow some, albeit inefficient, entry and 
replication (109). Therefore, I reproduced this experiment with HCV by 
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including 10 mM DTT in the pH 5 buffer. No enhancement of the luciferase 
signal was observed (data not shown). However, this experiment is difficult 
to interpret since treatment of HCV with DTT, either at pH 5 or pH 7, 
abrogated detectable HCV infection (data not shown). It is unclear if DTT is 
mediating this effect by destabilizing the HCV glycoproteins or cell surface 
receptors like CD81, which contains a disulfide bond in its large 
extracellular loop that is required for E2 binding (82, 162). 
 
HCV entry is not dependent on cathepsin B or L 
As observed above for HCV, Ebola virus (EboV) entry is sensitive to 
inhibitors of endosomal acidification (189, 212), but acid pH cannot induce 
glycoprotein (GP)-dependent membrane fusion (91). A recent study 
demonstrated that infection with VSV virions pseudotyped with EboV GP 
(VSV-EboV GP) depends on the action of pH-dependent endosomal 
proteases, cathepsin B (CatB) and cathepsin L (CatL) (35). I therefore tested 
if endosomal proteolysis by CatB or CatL is required for HCV entry.  
 Huh-7.5 cells pretreated with CA-074, an inhibitor of CatB, or with 
FYdmk, an inhibitor of both CatB and CatL, were infected with either HCV, 
HIV particles bearing the VSV-G protein on their surface (HIV-VSV-G), or 
VSV-EboV GP (35). Both HCV and HIV-VSV-G infections were 
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unaffected by CA-074 or FYdmk, although either inhibitor reduced the 
efficiency of VSV-EboV GP infection by approximately 80% compared to 
untreated cells (Fig. 5.9). This experiment demonstrates that HCV infection 
is not sensitive to inhibitors of CatB and CatL, suggesting that, in contrast to 
EboV, these endosomal proteases do not have a significant role in HCV 
entry.  
 
Evidence that additional post-binding steps are required to activate HCV for 
entry 
 
The inability of bound HCV to enter at the plasma membrane after 
exposure to low pH (Fig. 5.8B) suggested that an additional step(s) was 
required to activate the virus for pH-dependent entry. For some viruses like 
avian leukosis virus (151), and Semliki Forest virus and VSV in certain cell 
types (136), fusion in the presence of inhibited endosomal acidification 
requires incubation at 37 oC prior to acid treatment. I examined whether low 
pH could override the bafilomycin A1 block to HCV infection if the cells 
were shifted to 37 oC prior to the pH 5 wash (Fig. 5.10). After 1 h at 37 oC, 
the HCV-infected cells were washed with buffer at pH 5 or 7. In contrast to 
what I observed when the cells were washed immediately with low pH (Fig. 













Fig. 5.9 HCV is unaffected by inhibitors of CatB and CatL. Huh-7.5 cells 
were pretreated with CA-074 (100 mM), a CatB selective inhibitor, or 
FYdmk (0.1 mM), a CatB/CatL inhibitor, then infected with HCV (black 
bars), HIV-VSV-G (gray bars), or VSV-EboV GP (white bars) for 2 h at 37 
oC. Cells were incubated in the presence of inhibitor for 24 h. At 24 h.p.i., 
cells were harvested for luciferase assays (HCV, HIV-VSV-G) or FACS 
analysis (VSV-EboV GP). The luciferase activity or number of GFP positive 
cells from untreated cells is expressed as 100 percent. Each bar is the 

















Fig. 5.10 Schematic illustration of entry in the presence of bafilomycin 
A1 with prior incubation at 37 oC. Same procedure as that described in 
Fig. 5.3, but instead of washing with low pH immediately after the binding 
step (0 h.p.i.) the cells were shifted to 37 oC for 1 h. After which, the cells 
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Fig. 5.11 Incubation at 37 oC allows HCV to enter bafilomycin A1-
treated cells. Huh-7.5 cells were treated with bafilomycin A1 (25 nM), then 
infected with HCV at 4 oC for 2 h. Cells were washed to remove unbound 
virus, then washed with citric acid buffer at pH 7 (white bars) or 5 (black 
bars) immediately (0 h.p.i.) or after 1 h at 37 oC (1 h.p.i.). Cells were 
incubated in the presence of bafilomycin A1 for 24 h when they were 
harvested for luciferase assays. Luciferase activity from untreated cells 
washed with pH 7-buffer (white bar, -Baf) was expressed as 100 percent. 
Values are the combined data from 2 independent experiments done in 
triplicate; error bars represent the standard errors of the means. 
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prior to the low pH wash increased more than 10-fold, to approximately 15% 
of the untreated value (Fig. 5.11, 1 h.p.i.). Again, no increase in luciferase 
activity was observed from cells that had been washed with pH 7 (Fig. 5.11, 
1 h.p.i.). These results suggest that HCV requires an event that occurs within 
1 h.p.i., possibly at the cell surface or within a forming endosome, for low 
pH to trigger entry in the presence of bafilomycin A1.  
 
An inhibitor of clathrin-mediated endocytosis reduces the efficiency of HCV 
entry  
 
To determine if HCV requires clathrin for productive uptake, I 
utilized a dominant-negative inhibitor of clathrin-mediated endocytosis, 
AP180c. In addition to its role as an accessory protein in AP-2 mediated 
uptake, AP180 functions as an alternative endocytic adaptor between 
clathrin and cargo (152). Because AP180 can bind directly to clathrin via its 
C-terminal domain (AP180c), this domain can act as a dominant negative of 
both AP-2 dependent and independent clathrin-mediated endocytosis.  
AP180c was cloned into a Venezuelan equine encephalitis (VEE) replicon 
(163), which allowed high levels of expression in Huh-7.5 cells.  
Cells were electroporated with VEE-AP180c-GFP or VEE-GFP 
RNAs and monitored for GFP expression and susceptibility to HCVcc-Rluc 
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infection. HSV-1, which fuses at the plasma membrane and does not require 
clathrin, was used as a negative control. At 24 h post electroporation, when 
VEE-GFP and VEE-AP180c-GFP-transfected cells were 80-100% GFP-
positive, cells were infected with HCVcc-Rluc or HSV-1. After 24 h of 
infection, infected cells were harvested and luciferase activity was 
determined. In Huh-7.5 cells harboring the VEE-AP180c-GFP replicon, 
HCV luciferase values were reduced by 44% compared to cells transfected 
with VEE-GFP (Fig. 5.12). In contrast, HSV-1 infection was supported 
similarly in both the VEE-AP180c-GFP and VEE-GFP cells; only a modest 
16% decrease in HSV-1-driven luciferase activity was observed in the 
dominant-negative expressing cells.  These data suggest a role for clathrin-
mediated endocytosis in HCV entry. Further supporting this conclusion, 
HCV is inhibited by siRNAs which target clathrin heavy chain, as well as 




















Fig. 5.12 HCV entry is moderately inhibited by a dominant-negative 
inhibitor of clathrin-mediated endocytosis. Huh-7.5 cells were 
electroporated with VEE-GFP (black bars) or VEE-AP180c-GFP (white 
bars) RNA and infected with either HCVcc-Rluc or HSV-1. At 24 h post 
electroporation, cells were harvested for luciferase assays. Values are the 
mean value of triplicate wells; error bars show the standard errors of the 




















5.4 Role of HCV entry factors 
SR-BI enhances HCV binding to CHO cells 
To examine the role of HCV cellular entry factors in primary binding, 
CHO cell populations expressing human CD81, human SR-BI, or human 
CLDN1 were generated. CHO cells are nonpermissive for HCV entry, as 
demonstrated by their resistance to HCVpp (53), and therefore provide a 
means to isolate the initial interactions between HCV virions and molecules 
on the surface of the host cell.  
CHO cells, mock-transduced or transduced with CD81, SR-BI or 
CLDN1, were incubated with HCVcc (J6/JFH) (MOI ~0.5). Cells were 
washed extensively, and total RNA was harvested for real-time qRT-PCR. 
While CHO-CD81 and CHO-CLDN1 cells bound similar levels of HCV 
RNA as mock-transduced cells, HCV RNA bound to CHO-SR-BI cells was 
increased nearly three-fold over the background level (Fig. 5.13). To 
confirm that the enhancement of HCV RNA binding to CHO-SR-BI cells 
was SR-BI dependent, all of the CHO cell populations were incubated with 
α-SR-BI antibody prior to and during the incubation with HCVcc. The 
presence of α-SR-BI antibody had no effect on HCV RNA binding to CHO-
CD81 and CHO-CLDN1 cells, although it reduced the level of bound HCV 


















Fig. 5.13 HCVcc binds to CHO cells expressing SR-BI. CHO cells, mock 
transduced or transduced with CD81, CLDN1, or SR-BI, were preincubated 
with either anti-SR-BI or anti-human IgG antibodies, then incubated with 
J6/JFH HCVcc for 2 h at 37 oC. After washing, total RNA was isolated and 
HCV RNA was amplified by real-time quantitative RT-PCR. Values are the 










































suggest that the cellular receptor SR-BI may have a role in primary HCV 
binding to the host cell, whereas CD81 and CLDN1 may act downstream in 
the entry pathway.  
 
CLDN1 enhances HCV glycoprotein-mediated cell fusion 
CLDN1, an integral membrane protein that is a component of tight 
junctions, has been recently shown to be a required HCV entry factor (53). 
293T cells are rendered permissive for HCV entry by expression of CLDN1 
and were therefore used in a cell fusion assay to examine the role of CLDN1 
in HCV entry. For the fusion assay, 293T “Acceptor” cells expressing an 
HIV-1 transactivator of transcription (Tat)-inducible GFP reporter were co-
cultured with 293T “Donor” cells expressing Tat (Fig. 5.14). A fusion event 
between donor and acceptor cells will thereby result in GFP expression. 
When Donor cells expressing HCV E1/E2 were co-seeded with 
Acceptor cells harboring CLDN1, the number of GFP-positive foci 
increased by 7-fold compared to control cultures where Acceptor cells 
lacked CLDN1 (Fig. 5.15A). Although a pH 5 wash did not amplify the 
number of GFP foci compared to a pH 7 wash, it did enhance the size and 





















Fig. 5.14 Schematic illustration of cell fusion assay. Donor and Acceptor 
293T cells are co-cultured to determine if HCV glycoprotein-mediated cell 
fusion can occur. 
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Fig. 5.15 CLDN-1 enhances HCV glycoprotein-mediated fusion in 293T 
cells. (A) 293T Acceptor cells expressing Tat-inducible GFP, as well as 
mock (-CLDN1, white) or CLDN1 (+CLDN1, black), were co-cultured with 
293T Donor cells expressing mock (naïve), HIV-1 Tat, HCV E1E2, or both. 
Co-cultures were briefly treated with either pH 7 or 5, as indicated below 
each set of bars, at 24 h post seeding. The number of GFP foci per slide is 
the mean value from 3 experiments; error bars show the standard deviations. 
(B) Representative examples of typical GFP positive loci observed 48 h post 
pH treatment. For both VSV G and HCV E1/E2-mediated fusion, pH 5 
treatment enhanced syncytia formation, but did not increase the number of 


























































observation was made when Donor cells expressing VSV G on their surface 
were washed with low pH. These data and the data above suggest that 
CLDN1 acts downstream from the primary binding step and is required for 
efficient HCV-glycoprotein-mediated fusion. 
 
5.5 Discussion 
The sensitivity of BVDV and HCV to agents that inhibit endosomal 
acidification strongly suggests that these viruses require a low pH step to 
enter their respective target cells. Such a pH-dependent route of entry is a 
common feature among viruses of the Flaviviridae. Both BVDV and HCV 
are also acid-resistant and the inability of these viruses to infect a 
bafilomycin A1-treated cell after exposure to low pH, under the same 
conditions that could induce fusion of the alphavirus SIN, suggests that a 
post-binding maturation step is required to render the virus competent for 
low pH-triggered entry.  
The observation that HCV infectivity is resistant to acidic pH is 
surprising given its route of transmission through direct blood-to-blood 
exposure. In contrast, pestiviruses have long been known to be acid resistant, 
which fits with their need for protection against low pH as they travel 
through the ruminant digestive system. This shared characteristic of acid 
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resistance could be the result of a common evolutionary origin and may have 
been retained by HCV. Alternatively, production of acid-resistant virions 
may simply reflect a common strategy in the HCV and pestivirus lifecycles.  
Low pH induces conformational changes to the envelope 
glycoproteins of viruses that enter cells by endocytosis, allowing fusion 
between viral and cellular membranes. Two classes of viral fusion proteins, 
Class I and Class II, that mediate entry of enveloped viruses have been 
defined (80).  Influenza hemagglutinin (HA) is a prototype class I fusion 
protein (182). HA is primed for activation during assembly of influenza 
virions by proteolytic cleavage, which liberates an N-terminal fusion 
peptide. When exposed to low pH, HA undergoes a dramatic conformational 
change, which exposes the fusion peptide promoting interaction with 
membranes for fusion. Class II fusion proteins, found in alphaviruses and 
classical flaviviruses, are distinct from Class I in their structure, mechanism 
of action, and apparent evolutionary origin. Alphavirus and flavivirus 
glycoprotein precursors PE2 and prM, respectively, serve dual roles in virus 
maturation. As precursors, PE2 and prM act as chaperones to protect the 
viral fusogens E1 and E from exposure to the low pH environment of the 
trans-Golgi network, which would otherwise trigger exposure of the fusion 
peptide and premature fusion. During virion maturation, PE2 and prM are 
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cleaved by furin, releasing their N terminal fragments, and rendering the 
viral fusogens competent for pH-triggered fusion during entry (79, 80, 129). 
These fusion proteins have a well-defined dimer to trimer transition upon 
exposure to low pH (5, 103, 187).  With the exception of the G-proteins of 
the rhabdoviruses, VSV and rabies virus, the transition of Class I or Class II 
proteins to the fusogenic state is irreversible (64, 65).  
As mentioned above, the prM accessory protein of the classical 
flaviviruses provides protection during egress from the low pH environment 
of the cellular secretory pathway upon virion maturation; cleavage of this 
protein prior to release renders the virus competent for acid catalyzed fusion. 
For HCV and the pestiviruses, there is no evidence for such a proteolytic 
maturation event during assembly or release (157, 172, 195), suggesting that 
activation for subsequent low pH-requiring steps must occur during entry. 
Activation could theoretically occur at any of the multiple steps involved in 
the viral entry pathway, for example, binding to a receptor at the cell 
surface, sequential binding to a receptor and coreceptor, assembly of 
multiple factors at the cell surface, or within a forming or mature endosome.  
 In the case of BVDV, evidence exists for activation via disulfide bond 
reshuffling. The three pestiviral glycoproteins are stabilized by a 
combination of intra- and inter- molecular disulfide bonds. Treatment with 
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DTT was reported to decrease BVDV’s resistance to acidic pH and to 
enhance its ability to fuse at the plasma membrane in the presence of low pH 
(109). Although I was unable to reproduce these results, it has been 
suggested that DTT might act by mimicking the action of protein disulfide 
isomerases (PDIs) at the cell surface or within the endocytic pathway that 
are required to destabilize the BVDV glycoproteins and prime them for 
fusion upon exposure to low pH. The role of PDIs in the entry of other 
viruses such as HIV and Moloney murine leukemia virus has been 
demonstrated (173, 175, 204). In my experiments with HCV, the possible 
contribution of disulfide bond reshuffling to HCV entry could not be 
assessed since DTT, at either pH 5 or 7, eliminated detectable HCVcc 
infection.                                                                                                 
Another possibility I explored for HCV is proteolytic activation of the 
envelope glycoproteins by endosomal proteases. Similar to our observations 
for HCV, Ebola virus enters via a pH-dependent pathway, but these particles 
cannot fuse at the plasma membrane upon low pH exposure (91, 189, 212). 
Infection with VSV particles pseudotyped with EboV GP is inhibited when 
the activities of the CatB and CatL endosomal proteases are blocked by 
chemical inhibitors (35). This suggests that EboV entry requires a 
proteolytic cleavage, which triggers fusion in the endosome. Severe acute 
 181 
respiratory syndrome coronavirus infection was also shown to be dependent 
on CatL to cleave its spike glycoprotein within the endosome (179). 
Additionally, the non-enveloped reoviruses require CatB and CatL for 
efficient virus disassembly (34, 49). Although inhibitors of CatB/CatL had 
no effect on HCV infection, it is still possible that different endosomal 
proteases or other endosomal determinants are required to prime the HCV 
glycoproteins for fusion.  
Alternatively, HCV may be primed for low pH-induced entry by 
receptor binding or subsequent steps prior to the formation of mature 
endosomes. Simple binding of HCVcc to cells at 4 °C was not sufficient to 
activate the virus for low pH-triggered entry at the plasma membrane. One 
explanation is that HCV entry at the plasma membrane is non-productive for 
downstream events in the viral life cycle, as previously observed for Semliki 
Forest virus and VSV in CHO cells (136), and avian leukosis virus (151). 
However, the fact that low pH could override the bafilomycin A1 block to 
HCV infection after a shift to incubation at 37 °C, described in Fig. 5.11, 
suggests that HCV can undergo time- and temperature-dependent activation 
at the cell surface or in forming endosomes. Further study is necessary to 
delineate the nature of this event regarding the viral and cellular 











Chapter 6. Unanswered questions and future directions 
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6.1 Mechanism of E1*E2p7* inhibition of BVDV entry 
In this study, I successfully used a functional genomics approach to 
examine the BVDV life cycle and to identify E2 as a transdominant inhibitor 
of BVDV entry. Furthermore, the MDBK- E1*E2p7* cells characterized 
above will provide valuable insights into the molecules required for BVDV 
to productively enter a cell and the mechanism of BVDV superinfection 
exclusion at the level of entry.  
The observation that CD46 down regulation from the surface of 
MDBK-E1*E2p7* cells is not the mechanism of BVDV inhibition, suggests 
that CD46 may not be the only molecule required for BVDV entry. This 
hypothesis has been proposed previously by Maurer et al. (137). In this 
study, non-permissive cells transduced to express CD46 remained non-
permissive for BVDV infection. Moreover, BVDV enters cells by clathrin-
mediated endocytosis and CD46 is excluded from endosomes due to a 
sorting signal (74, 109, 137), suggesting that an additional factor may act 
downstream from CD46 to mediate subsequent internalization steps. 
Therefore, although CD46 expression and binding of BVDV to the MDBK-
E1*E2p7* cells is unaffected, the possibility of E2-mediated down 
regulation of an unidentified, essential coreceptor, required for BVDV 
internalization and fusion, still exists. The requirement for multiple cellular 
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entry factors is certainly true for HCV and may be likely for BVDV as well, 
considering that both of these viruses undergo an activation step, which 
occurs after primary binding (109, 198). MDBK-E1*E2p7* cells may then 
be resistant to BVDV entry due to the ability of E2 to sequester this 
additional entry factor away from the cell surface or from other BVDV entry 
factors.  
One may take a variety of approaches to examine BVDV E2-
interacting factors in MDBK-E1*E2p7* cells and to define the inhibitory 
mechanism within them. As a first attempt, E2-associated proteins can be 
immunoprecipitated from MDBK-E1*E2p7* cell lysates or cells expressing 
an epitope-tagged E2 protein. This approach will demonstrate if BVDV E2 
is associated with a particular cellular molecule and is thereby preventing its 
function in BVDV entry. Another method to identify the essential factor(s) 
absent or nonfunctional in these cells is to screen for cDNAs from wild-type 
MDBK cells that can render MDBK-E1*E2p7* cells permissive for BVDV 
infection. Moreover, the observed BVDV entry defect in MDBK-E1*E2p7* 
cells is analogous to that of CRIB cells (cells resistant to infection with 
BVDV) (60). CRIB cells are also resistant to BVDV entry and harbor 
functional CD46 on their surfaces. It was originally thought that these cells 
were deficient in LDL-R (3), a proposed BVDV entry factor, although a 
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recent study suggests that these cells do in fact express LDL-R and 
furthermore that this molecule is not required for BVDV infection (108). 
Even so, CRIB cells can be used in conjunction with MDBK-E1*E2p7* 
cells to further define a complete set of BVDV entry factors, possibly by 
cataloging differences in cell surface molecules between these BVDV-
resistant cell types and wild type MDBK cells.  
 
6.2 BVDV and HCV superinfection exclusion mechanisms 
Superinfection exclusion at the level of RNA replication 
Both BVDV and HCV-infected cells establish superinfection blocks at 
one or more steps in RNA replication. The mechanism by which existing 
BVDV and HCV RNA replication inhibits superinfecting RNA replication 
remains to be determined. One hypothesis is that exclusion might be due to 
insufficient levels of a cellular factor(s) required for virus replication. 
BVDV and HCV RNA elements or proteins could interact with limiting 
cellular factors essential for replication and sequester them during the course 
of infection, thus reducing their availability for an incoming, homologous 
virus.  
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To identify these cellular components, we could characterize cellular 
factors that up regulate BVDV or HCV replication. The observation that 
levels of replication plateau after infection or transfection of viral RNA, 
suggests that one or more cellular factors are limiting, controlling the 
amount of replication that can be supported by the host cell. Therefore, 
cellular factors, which can increase levels of viral replication, are possible 
candidates for those that are unavailable for the superinfecting virus and 
prevent the efficient establishment of its replication. One example of a 
cellular component required for HCV replication is the liver-specific 
microRNA, microRNA-122 (miR-122), which facilitates efficient HCV 
replication (94). Sequestration of miR-122 in HCV replicon-containing cells 
results in a decrease in HCV RNA replication, which can be restored if miR-
122 is ectopically expressed (94). Perhaps levels of miR-122 are reduced 
over the course of HCV replication or alternatively, miR-122 is inaccessible 
to the superinfecting virus, preventing the establishment of productive 
replication.  
Another method to identify cellular components that may be limiting 
for the superinfecting virus is to analyze cellular factors that are closely 
associated with BVDV and HCV replication complexes. This may be 
possible by tagging a component of the viral replicase complex, such as 
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NS5A, with an epitope tag, which can be pulled out from cell lysates with a 
high affinity antibody. This approach has recently been used to characterize 
proteins associated with SIN replication complexes (43, 62). Once the 
required cellular components for HCV or BVDV replication have been 
identified, cells can be examined for depletion or modulation of this factor 
during infection and whether its exogenous expression can upregulate 
replication. 
Interference at the level of RNA replication may also be related to the 
availability of subcellular sites for replication. Positive-strand RNA viruses 
replicate their RNAs in association with existing or virus-modified 
subcellular membrane organelles. Bromegrass mosaic virus (BMV), for 
example, induces spherule-like invaginations into the lumen of the ER that 
are still connected to the cytosol by a narrow channel. Negative-strand RNA 
molecules are sequestered in these compartments where they are used as 
templates for viral genome amplification (178). Likewise, flavivirus RNA 
replication occurs in a specialized membrane compartment surrounding the 
nucleus (33, 36, 37, 207, 208). HCV replication complexes are associated 
with a structure called the “membranous web” and BVDV is also known to 
extensively reorganize intracellular membranes for sites of replication (50, 
69, 194). During primary infection, these specialized areas might become 
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saturated with replication complexes, blocking access of the superinfecting 
viral RNA and preventing its entry into functional replication complexes. 
Alternatively, the availability for building blocks required to create these 
sites may become limiting. Consistent with this explanation, HCV RNA 
replication is stimulated by the increased availability of fatty acids (98), 
which may be important to maintain the integrity of the membranous web as 
a site of efficient replication. We could therefore further characterize the 
sites of BVDV and HCV replication in the cell with regard to its location, 
membrane composition, and associated host factors using a combination of 
the techniques described above.  
An additional question is what criteria regulate the establishment of a 
particular superinfection defect? Specifically, how is it that BVDV can block 
superinfecting virus at entry and replication, whereas the block in HCV-
infected and replicon cells occurs only at a post-entry step? This may be a 
consequence of replication style, protein localization, or levels of structural 
proteins. In addition, assuming that the BVDV entry block is at the 
coreceptor level, testing whether there is an intracellular interaction between 
the viral structural proteins and putative receptor/coreceptors could provide a 
potential explanation. If this is the mechanism of exclusion, it may be that 
for HCV the conformations of the nascent glycoproteins differ from those on 
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the mature virion, preventing an intracellular interaction with cellular 
receptors. Such a scenario would then preclude the establishment of an HCV 
superinfection block at the level of entry. Given the requirement for specific, 
host factors and the specialized nature of viral replication sites, it is perhaps 
not surprising that both BVDV and HCV generate blocks to superinfecting 
virus at the level of RNA replication. Using the techniques described above, 
this work will hopefully lead to the identification of the limiting factors for 
viral RNA replication and how they regulate this intricate process.  
 
Cellular alterations induced by persistent ncp BVDV infection 
Our data suggest that cellular changes or alterations within ncp BVDV 
persistently infected cells contribute to the loss of superinfection exclusion 
for cp BVDV. Superinfection exclusion was not restored by reinfection of 
the ncp BVDV persistently infected cells with the original ncp BVDV. In 
addition, ncp BVDV from persistently infected cells was capable of 
establishing superinfection exclusion in naïve MDBK cells. Persistent 
BVDV infection thus appears to induce a cellular alteration that down 
regulates ncp virus replication and allows cp BVDV superinfection to occur.  
Besides the studies discussed in Section 4.2 and 4.3, two other papers 
have examined pestivirus superinfection exclusion. Baigent et al. reported 
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that calf testis cells could be productively superinfected with cp BVDV 48 h 
after acute infection with ncp BVDV (7). NS3 and CPE became detectable 
after an additional 48 h, or 4 days post acute infection (significantly delayed 
when compared to cp BVDV infection of naïve cells).  These data are 
consistent with the observations reported here. Another earlier study was 
conducted by Mittelholzer and colleagues for CSFV (147). CSFV is 
generally noncytopathic and readily establishes persistent infections in cell 
culture. Persistently infected cultures, serially passaged more than 100 times, 
yielded cp defective interfering (DI) RNAs that spread through some of the 
cultures and killed the majority of the cells. The few surviving cells were 
still infected, but had either lost the cp DI RNA or contained an ncp CSFV 
variant that was able to “control” replication of remaining DI RNA to a level 
that was no longer cytopathic. Interestingly, virus production in the 
persistently infected CSFV cultures prior to the emergence of the cp DI 
RNAs was about 100-fold lower than after acute infection, analogous to our 
results for MDBK cells persistently infected with ncp BVDV.  Thus, the 
emergence of a packaged cp DI RNA variant, like superinfection with cp 
BVDV, was able to spread through culture, replicate to high levels and kill 
the majority of the cells.   
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Intriguing questions are raised by all of these studies. First, what are 
the cellular alterations that down regulate the replication level of the ncp 
virus after the acute phase of infection? The nature of these cellular changes 
remains unknown, but it will be interesting to see if this state requires 
continuing ncp pestivirus replication or if stable epigenetic changes have 
occurred. This could be determined by curing the persistently infected cells 
with a BVDV-specific polymerase inhibitor and then determining if these 
cells can support wild type levels of virus replication.  
Another question is how do persistently infected cells remain 
relatively resistant to superinfection by homologous ncp BVDV, but not to 
cp BVDV over the time tested? It is interesting that the same mechanism 
that excludes ncp BVDV does not apply to a superinfecting cp virus (in the 
case of our BVDV studies) or to the cp CSFV DI characterized by 
Mittelholzer et al. In persistently infected cells as opposed to acute infection, 
both cp and ncp BVDV may be able to enter the cell more efficiently, 
encountering lower levels of the E2-mediated block. At the replication level, 
however, the ncp BVDV remains blocked, whereas the cp BVDV can 
somehow enter into productive replication possibly due to fundamental 
differences in its replication mechanism. It is conceivable that due to a 
greater efficiency of replication initiation or a higher rate of replication, cp 
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BVDV escapes interaction with a negative cellular factor that is up regulated 
during persistent infection. Conversely, cp BVDV may not have the same 
requirement as ncp BVDV for a particular cellular factor that becomes down 
regulated over the course of infection. One likely candidate is the cellular 
chaperone protein Jiv. Expression of the 90 amino acid insertion of Jiv 
(Jiv90) in the cp BVDV NADL genome is sufficient for efficient cleavage at 
the NS2/3 junction. ncp BVDV, however, remains dependent on the cellular 
pool of Jiv, which becomes reduced during infection and limits the level of 
replication (111). To characterize additional cellular factors, which are 
modulated over the course of infection, one could utilize microarray analysis 
to examine the gene expression profiles of ncp BVDV acutely and 
persistently infected cells and compare them to those of cp BVDV-infected 
cells. It is also possible that the cellular alteration affects the site of ncp 
BVDV replication and that cp BVDV is more fit to utilize slightly different 
replication sites. A method to examine this hypothesis would be to compare 
the replication sites of cp and ncp BVDV, in terms of protein and membrane 
components, as well as their physical location in the cell, possibly by 
electron microscopy.  
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Role of superinfection exclusion in vivo 
The notion that cp BVDV arises from ncp BVDV by a rare RNA 
recombination event leading to fatal MD prompts the question of whether 
persistently ncp BVDV-infected cells might not exclude superinfecting cp 
BVDV in vivo. If not, how would a cp BVDV variant that arose be 
propagated? One possibility is that cp BVDV might have a different cell 
tropism than ncp BVDV.  While cp and ncp BVDV may well have different 
replication efficiencies in a given cell type, it seems unlikely that these 
variants would infect different target cells since they have identical or nearly 
identical structural proteins. Alternatively, infection may well be dynamic in 
persistently infected animals with not all susceptible target cells pre-infected 
with ncp BVDV. Our study showed a loss of superinfection exclusion in ncp 
BVDV-infected cells after 1-2 passages. This demonstrates that acutely 
infected cells that are initially refractory to superinfection may eventually 
become permissive, thus providing a reservoir of susceptible cells. This 
would give the founder virus an initial replication advantage over a 
superinfecting variant but this advantage would diminish over time. Another 
possibility is that superinfection exclusion may not be efficiently established 
in all cell types.  
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The phenomenon of HCV superinfection exclusion has potentially 
important implications for understanding HCV biology in vivo.  First, the 
efficient block for replication of the superinfecting genome would limit the 
potential for RNA recombination to cells simultaneously infected by two 
viruses or infected cells that were successfully superinfected before the 
replication block was established. This may, in part, explain the dearth of 
natural HCV recombinants that have been identified thus far despite 
numerous examples of patients harboring more than one HCV genotype (39, 
96). Second, even less-fit HCV variants generated during error-prone HCV 
replication have a chance for at least transient survival assuming that they 
could productively infect a target cell and efficiently exclude replication of 
the more fit parental virus. This could provide HCV with a larger pool of 
variants to deal with immune or other selective pressures that emerge during 
the course of infection (or treatment). The observation that superinfection 
exclusion is reversible at the cellular level suggests that interferon (24) or 
specific antiviral [(153) and this study] treatment may "cure" cells thereby 
expanding the number of hepatocytes that are permissive for replication of 
inhibitor-resistant variants. Finally, the phenomenon of superinfection 
exclusion and the fact that HCV RNA levels are regulated and plateau after 
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transfection or infection, as discussed above, suggest that there are one or 
more limiting cellular components required for HCV RNA replication.  
 
HCV JFH-1 induced cytotoxicity in CD81-expressing cells 
We observed a J6/JFH-specific cytotoxicity within CD81-expressing 
cells after prolonged J6/JFH HCVcc infection or selection of G418 resistant 
populations harboring J6/JFH replicons. This resulted in a population 
dominated by CD81low cells, rendering them nonpermissive for HCV entry. 
Notably, this was not the case for subgenomic replicons or for full-length 
Con1 or H77 replicons. One possibility to explain this genotype-specific 
difference is that high-level expression of the J6 C-NS2 region driven by the 
JFH replicase is required for CD81-dependent cytostatic or cytotoxic effects. 
Similar high levels of expression may not be achieved by the Con1 or H77 
adapted replicons. Alternatively, whatever toxic determinants lie within the 
C-NS2 region may be specific for the genotype 2a isolates tested thus far [J6 
and JFH; (221)] and not present in the corresponding genotype 1a (H77) or 
1b (Con1) proteins. However, another potentially important difference is the 
ability of J6/JFH constructs to produce infectious virus in cell culture. In 
future experiments it will be interesting to explore these possibilities by 
examining the properties of H77/JFH chimeras that are defective for virus 
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production versus those harboring adaptations that allow release of 
infectious virus [(142, 218) and M. Evans et al., in preparation].  
 Interestingly, the J6/JFH-FLneo population cured with BILN 2061 in 
the absence of G418 regained CD81 expression and became permissive for 
HCVpp entry. Several possibilities, either at the population or single cell 
level could account for restored CD81 expression. At the population level, 
CD81low cells might lose their growth advantage over surviving CD81high 
cells in the absence of J6/JFH-FLneo replication or infection. Restoration of 
CD81 expression was slow and occurred after HCV RNA reached 
background levels. This might indicate that CD81high cells have only a subtle 
growth advantage over CD81low cells in the absence of virus. This idea could 
be explored by sorting cells for CD81high or CD81low expression and 
comparing their growth rates in the absence or presence of HCV RNA. 
Alternatively, at the single cell level, slow recovery of CD81 expression 
could be due to an intrinsically slow rate of CD81 protein accumulation or 
slowly reversible epigenetic changes that down regulated CD81 expression 
and occurred due to persistent J6/JFH-FLneo replication and infection. A 
more complete understanding of the kinetics of CD81 transcription, 
translation, and protein turnover/stability may provide evidence for this 
hypothesis.  
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 Another question relates to the mechanism of cytotoxicity and the 
pathway by which the CD81high cells undergo cell death. Gene expression 
analysis of an Huh-7.5 population undergoing J6/JFH infection will assist in 
determining if specific signaling pathways, such as those involved in ER-
stress or apoptotic signaling, are activated. In addition, if Huh-7.5 cells are 
forced to over-express CD81 during J6/JFH infection, the majority of cells 
die, but some cell clones develop (M. J. Evans, personal communication). 
Characterization of the survival mechanism in these cells may provide 
insight into the cause of the cytotoxic effect in susceptible cells.  
The in vivo relevance of HCV-induced cytotoxicity and the role of the 
C-NS2 region and CD81 in this process requires further study. One might 
argue that the genotype specific differences, the high level of replication 
driven by the thus far unique non-adapted JFH-1 replicase, and the use of 
Huh-7 or Huh-7.5 hepatoma cells make it unlikely that similar effects will be 
seen in the HCV-infected liver. Certainly the generally accepted view, that 
HCV-associated liver damage is immune mediated rather than a direct 
consequence of hepatocyte infection, is consistent with this view. However, 
some instances of acute fulminant hepatitis C (54, 68, 101, 219) or rapidly 
progressive hepatitis in the post-transplant setting (30, 139) could be the 
result of HCV variants that are cytotoxic, either due to higher replication 
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levels, the production of toxic viral components, or both. In addition, the 
level of hepatocyte CD81 expression is clearly one mechanism for 
controlling HCV infection that may also influence pathogenesis. This could 
be modulated by the virus, the host-response to virus infection, or 
therapeutically. In this regard, it will be interesting to examine possible 
heterogeneity in the level of CD81 expression in HCV-infected and 
uninfected liver tissue and determine if there is a relationship between CD81 
levels, virus infection and cell death. 
 
6.3 Studies of the BVDV and HCV entry pathways 
Mechanism of HCV and BVDV activation for pH-triggered entry  
The data presented in Chapter 5 demonstrate that both BVDV and 
HCV are acid-resistant viruses that require activation for pH-triggered entry.  
Although the mechanism of this activation step remains ambiguous, the 
pathway, at least for HCV, appears to be both time- and temperature- 
dependent, given the observation that low pH can allow bound HCV virions 
to enter a cell in the presence of bafilomycin A1 after prolonged incubation 
at 37 oC. Although the effects of the elevated temperature and incubation 
time warrant further study, several scenarios can be envisioned based on 
previous work with other enveloped viruses. In the case of avian leukosis 
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virus and perhaps also for HCV, productive entry could require not only 
receptor binding but also a forming endosome, encountered only after 
incubation at 37 °C (151). However, even before receptor mediated 
endocytosis and formation of mature endosomes, HCV may require 
interactions that do not occur during binding at 4°C. Given the wealth of 
factors shown to be required for HCV entry, among them CD81, SR-BI, 
CLDN1 and GAGs, HCV may require contact with all or at least some of 
these factors prior to fusion. For example, HCV may be tethered to the cell 
initially through interactions with GAGs, then attach to the cell surface via a 
binding determinant, possibly SR-BI, as our data indicates. Productive entry 
may subsequently necessitate access to CD81 and later to CLDN1, which 
has been shown to act at a late step in HCV entry and downstream of CD81 
(53). These interactions might require lateral diffusion in the plasma 
membrane or changes at the plasma membrane that occur during endosome 
formation, either of which could be compromised by low temperature and 
decreased membrane fluidity.  
For BVDV, a time and temperature dependent activation mechanism, 
similar to HCV, could potentially occur. This event may involve interaction 
with CD46 and other coreceptors, as well as the rearrangement of disulfide 
bonds within the envelope glycoproteins. The role for disulfide bond 
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reshuffling in BVDV entry remains undetermined, at least in the context of 
my experiments presented above. However, the use of selective inhibitors of 
protein disulfide isomerases, as opposed to the relatively nonspecific action 
of DTT, may provide an alternative method to investigate the possible 
importance of disulfide bond re-organization in activation of BVDV for 
productive entry. It will also be interesting to determine if HCV undergoes 
an analogous pathway to acid sensitivity as BVDV or if these two viruses 
differ in terms of their requirements for protein disulfide isomerases, 
conformational changes within the envelope glycoproteins, or location of 
receptor interactions. 
Another question is how does an acid-resistant virion differ 
conformationally from one that is acid-sensitive and therefore, fusion 
competent? Also, at what stage in the course of their entry pathways do 
HCV and BVDV become acid-sensitive - at the cell surface, or in the 
process of internalization by receptor-mediated endocytosis? The detection 
of specific changes within the virion associated with activation could be 
used as a marker for particular stages in the virus entry, for example by 
monitoring changes in epitope exposure over time using a panel of 
glycoprotein-specific MAbs. Another method would be to bind the virus to 
bafilomycin A1-treated cells and to perform a time course of low pH pulses 
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after shifting to 37 oC in the presence of either a CD81 or CLDN1 antibody. 
It will be interesting to determine if a low pH wash at a particular time point 
during entry overcomes the requirement for one or both of these receptors, 
which have been shown to act downstream of primary binding (41, 53, 106). 
Alternatively, the blocking antibodies can be added at different time points 
after the temperature shift prior to washing with low pH. In addition, the 
virus can be incubated with a soluble form of SR-BI to determine if this 
treatment renders the virus acid-sensitive and/or increases virus binding to 
either CD81 or CLDN1. A similar protocol can also be performed with 
soluble CD81. These experiments will help delineate the kinetics of HCV 
activation and the role of particular receptors in these changes. In addition, it 
will be important to determine if the requirements for or timing of HCV 
activation in Huh-7.5 cells differ from those in polarized cells where 
CLDN1 resides in the tight junction. 
An additional intriguing question relates to the signaling events 
required for BVDV and HCV productive uptake. For BVDV, the cellular 
receptor CD46 has 2-3 spliced isoforms of its cytoplasmic tail, which may 
differ in terms of their signaling to downstream factors. We could first 
determine if signaling from CD46 is required, and if so, if a particular CD46 
isoform is needed during BVDV entry. For HCV, although the cytoplasmic 
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tail of CD81 is not required (220), SR-BI and its relative, SR-BII, have 
signaling capability that could coordinate the assembly of other entry factors 
such as CD81 and CLDN1. Future experiments should be aimed at gaining a 
better understanding of the steps leading to productive HCV entry, paying 
particular attention to interaction between the HCV glycoproteins and these 
cellular entry factors.  
 
Comparing HCVpp and HCVcc entry 
The HCVpp system has provided clues to the mechanism of HCV 
entry into cells, which can now be tested directly using HCVcc. Many of the 
observations made with HCVpp, such as receptor usage and pH-dependent 
entry, have now been confirmed in the HCVcc system. For example, the role 
of CD81 in HCV infection, previously demonstrated using HCVpp (220), is 
also important for entry of HCVcc (123, 203, 221). As I have found for 
HCVcc, HCVpp entry is also pH-dependent and sensitive to concanamycin 
A and NH4Cl (85). Interestingly, in contrast to the data presented here, Hsu 
et al. reported that HCVpp (genotype 1a, strain H77) were moderately 
susceptible to inactivation by low pH (85). The basis for this difference is 
unknown but could reflect differences in the HCV strains used in the two 
studies or the experimental systems themselves. If incorporation of HCV 
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E1E2 heterodimers into HCVpp is similar to gp120/gp41 into HIV particles 
(217), then each HCVpp may harbor less than 10 copies of functional HCV 
E1E2 heterodimers. In contrast, if HCVcc particles resemble those of the 
classical flaviviruses, which consist of 90 envelope protein dimers (110), the 
HCVcc surface may consist of tightly packed glycoprotein oligomers. One 
could imagine that such a lattice, stabilized by lateral interactions, might be 
more acid-resistant. Thus, while entry studies using HCVpp and HCVcc 
have yielded remarkably convergent results, some features may differ. It will 
also be important to compare HCVcc to HCVcc recovered from infected 
animals, so-called ex vivo HCVcc. ex vivo HCVcc retrieved from infected 
chimpanzees or uPA-SCID mice can be recultured in Huh-7.5 cells (124). 
This virus can be examined for acid-resistance, receptor usage, and pH-
dependence of entry. Entry studies using these different viruses, HCVpp, 
HCVcc, and ex vivo HCVcc, can also be extended to other cell types, 
including primary hepatocytes.  
 
6.4 Perspectives  
  These studies have described important features of BVDV and HCV 
entry and replication, provoked many additional questions, and roused new 
ideas for future research. It is clear that a better understanding of the virus 
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host interactions that are required for BVDV and HCV entry, as well as 
productive replication, may suggest new targets for therapeutic intervention. 
Future work aims to answer the questions outlined above and will no doubt 
engender additional projects as well. Moreover, as new technology becomes 
available, more sophisticated techniques can be applied to the study of 
BVDV and HCV entry. The ability to tag viral particles using a variety of 
methods and to track them in real-time using microscopy is an innovative 
and exciting approach, which provides the potential to follow the virus 
during the early events of its life cycle. These state of the art techniques can 
be combined with other approaches suggested above in an attempt to 
generate a complete picture of the cellular entry pathways of these viruses. 
With each experiment comes the opportunity to increase our understanding 
of BVDV and HCV infection and pathogenesis and to help alleviate the 
personal and economic strain imparted by these viruses on our society. 
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